<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.5.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art550.dtd?><?SourceDTD.Version 5.5.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_SYNBIO102 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Synth Syst Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">Synth Syst Biotechnol</journal-id><journal-title-group><journal-title>Synthetic and Systems Biotechnology</journal-title></journal-title-group><issn pub-type="epub">2405-805X</issn><publisher><publisher-name>KeAi Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6199817</article-id><article-id pub-id-type="publisher-id">S2405-805X(18)30060-7</article-id><article-id pub-id-type="doi">10.1016/j.synbio.2018.10.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Blossom of CRISPR technologies and applications in disease treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Huayi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Yunzi</given-names></name><email>luoyunzi@scu.edu.cn</email><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1">Department of Gastroenterology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, PR China</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. <email>luoyunzi@scu.edu.cn</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>10</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>12</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>22</day><month>10</month><year>2018</year></pub-date><volume>3</volume><issue>4</issue><fpage>217</fpage><lpage>228</lpage><history><date date-type="received"><day>1</day><month>9</month><year>2018</year></date><date date-type="rev-recd"><day>9</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder/><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Since 2013, the CRISPR-based bacterial antiviral defense systems have revolutionized the genome editing field. In addition to genome editing, CRISPR has been developed as a variety of tools for gene expression regulations, live cell chromatin imaging, base editing, epigenome editing, and nucleic acid detection. Moreover, in the context of further boosting the usability and feasibility of CRISPR systems, novel CRISPR systems and engineered CRISPR protein mutants have been explored and studied actively. With the flourish of CRISPR technologies, they have been applied in disease treatment recently, as in gene therapy, cell therapy, immunotherapy, and antimicrobial therapy. Here we present the developments of CRISPR technologies and describe the applications of these CRISPR-based technologies in disease treatment.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>CRISPR technologies</kwd><kwd>CRISPR-based tools</kwd><kwd>CRISPR-based therapy</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">At the beginning of this century, genome editing technology has been developed gradually via the exploitation of ZFNs (Zinc finger nucleases) [<xref rid="bib1" ref-type="bibr">1</xref>] and TALENs (Transcription activator-like effector nucleases) [<xref rid="bib2" ref-type="bibr">2</xref>]. However, the complexity of reconstruction of different enzymes corresponding to different targets, and the huge size of these proteins limited their applications in human disease treatment [<xref rid="bib3" ref-type="bibr">3</xref>]. After the emergence of CRISPR technology derived from the bacterial adaptive immune system, the researchers' abilities to sculpt the genome and program the gene expression have been enhanced to another level [<xref rid="bib4" ref-type="bibr">4</xref>]. The prevailing CRISPR technologies have augmented the researchers' abilities in genetic/genome engineering across a variety of life forms. Especially, the emerging CRISPR-Cas9 system has been recruited and optimized in enormous genome editing and transcription regulation applications, unprecedentedly facilitated the advancements in therapeutic applications (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Due to the simplicity of operation and huge potential to be engineered and applied in therapeutic areas, various CRISPR-based tools have been developed, such as gene editing, epigenome editing, base editing, transcriptional regulation, and nucleic acid detection. With the expansion of these tools, novel diagnosis approaches and disease treatments have been designed and carried out in practice.<fig id="fig1"><label>Fig. 1</label><caption><p>Overview of the development of the CRISPR systems and their applications.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0015">In this review, we will first state the most recent advances in the development and applications of CRISPR technologies that could be applied in disease treatment and then summarize and enumerate the applications in disease treatment with the help of these CRISPR-based tools.</p></sec><sec id="sec2"><label>2</label><title>Development of CRISPR systems</title><p id="p0020">CRISPR system was first discovered in 1987 [<xref rid="bib5" ref-type="bibr">5</xref>]. However, the wide use of CRISPR technologies has not started until 2013. In the past 5 years, CRISPR has renovated not only the molecular biology field, but also the medicine and biotechnology fields [<xref rid="bib4" ref-type="bibr">4</xref>]. After the technologies were first successfully applied in mammalian genetic modifications, scientists around the world participated positively in the development of this technology at their own expertise.</p><sec id="sec2.1"><label>2.1</label><title>The discovery of CRISPR systems</title><p id="p0025">The CRISPR systems are adaptive immune systems widely spread in bacteria and archaea. The discovery of CRISPR could be dated back to 1987, when Dr. Nakata's group [<xref rid="bib5" ref-type="bibr">5</xref>] found a special repeat sequence in <italic>Escherichia coli</italic> (<italic>E.coli)</italic> which was later named as CRISPR (clustered regularly interspaced short palindromic repeat) after two decades later in 2002 [<xref rid="bib6" ref-type="bibr">6</xref>]. At the same time, the genes located adjacent to the repeat sequences were identified as CRISPR-associated (Cas) genes. The CRISPR array and Cas proteins are the basic components necessary for the adaptive immunity process. The subsequent unraveling of the molecular details of CRISPR-Cas systems became clearer since 2007 [<xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>]. In 2012, the purified Cas9 was proved to cleave target DNA <italic>in vitro</italic> with the guidance of crRNA/tracrRNA [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib11" ref-type="bibr">11</xref>]. Later in 2013, the type II CRISPR Cas9 system showed genome editing ability in mammalian cells [<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib13" ref-type="bibr">13</xref>]. Since then, several CRISPR-Cas single effector enzymes have been characterized and engineered for use in various organisms [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>].</p><p id="p0030">CRISPR-Cas systems are divided into Class 1 and Class 2 based on major differences between the Cas proteins involved in the binding guidance and target cleavage, and further classified into six types based on the &#x0201c;signature genes&#x0201d; [<xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>]. Type I, III, and IV systems are considered as Class 1 systems based on their multi-subunit effector complexes; while the single, large, multi-domain effectors of Type II, V, and VI systems are grouped into Class 2 [<xref rid="bib16" ref-type="bibr">16</xref>]. The classification efforts are not completed as the researchers are still actively exploring other CRISPR systems and the classification needs to be refined when more information based on comparative genomic analysis, structures, and biochemical analysis of CRISPR components is gained. The most up to date classification of CRISPR-Cas systems was summarized in Koonin et al.&#x02019;s review [<xref rid="bib19" ref-type="bibr">19</xref>]. The most widely used systems were the Type II system containing Cas9 from <italic>Streptococcus pyogenes</italic> and Type V system containing Cas12a (previously called Cpf1) [<xref rid="bib20" ref-type="bibr">20</xref>] from <italic>Acidaminococcus</italic> sp (AsCas12a), <italic>Lachnospiraceae bacterium</italic> (LbCas12a) and <italic>Francisella novicida</italic> (FnCas12a).</p></sec><sec id="sec2.2"><label>2.2</label><title>The exploitation of CRISPR-based tools</title><p id="p0035">CRISPR system was first regarded as a powerful genome editing tool in eukaryotic cells in 2013 [<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib13" ref-type="bibr">13</xref>]. Soon after, numerous applications arose beyond genome editing, such as targeted gene interference (CRISPRi) and activation (CRISPRa), live cell chromatin imaging, base editing, epigenetic modulation, and nucleic acid detection (<xref rid="tbl1" ref-type="table">Table 1</xref>).<table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>The CRISPR-based tools with different effectors.</p></caption><alt-text id="alttext0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>CRISPR</th><th>Fused Effector</th><th>Example</th><th>Application</th><th>Ref.</th></tr></thead><tbody><tr><td align="left">dCas9/ddCas12a/Cas13</td><td align="left">None</td><td align="left">dCas9</td><td align="left">Down-regulation</td><td align="left">[<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib44" ref-type="bibr">44</xref>]</td></tr><tr><td align="left">dCas9/ddCas12a</td><td align="left">Transcriptional repressor</td><td align="left">dCas9-KRAB</td><td align="left">Down-regulation</td><td align="left">[<xref rid="bib41" ref-type="bibr">41</xref>]</td></tr><tr><td align="left">dCas9/ddCas12a</td><td align="left">Transcriptional activator</td><td align="left">dCas9-VP64</td><td align="left">Up-regulation</td><td align="left">[<xref rid="bib188" ref-type="bibr">188</xref>]</td></tr><tr><td align="left">dCas9</td><td align="left">Fluorescent proteins</td><td align="left">dCas9-EGFP</td><td align="left">Chromatin imaging</td><td align="left">[<xref rid="bib52" ref-type="bibr">52</xref>]</td></tr><tr><td align="left">nCas9</td><td align="left">Cytidine deaminase domain</td><td align="left">APOBEC&#x02013;XTEN&#x02013;nCas9&#x02013;UGI</td><td align="left">C&#x000b7;G to T&#x000b7;A conversion</td><td align="left">[<xref rid="bib67" ref-type="bibr">67</xref>]</td></tr><tr><td align="left">nCas9/ddCas12a</td><td align="left">Adenosine deaminase domain</td><td align="left">nCas9-ABE 7.0</td><td align="left">A&#x000b7;T to G&#x000b7;C conversion</td><td align="left">[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td align="left">dPspCas13b</td><td align="left">Adenosine deaminase domain</td><td align="left">dPspCas13a-ADAR2</td><td align="left">A to I conversion</td><td align="left">[<xref rid="bib89" ref-type="bibr">89</xref>]</td></tr><tr><td align="left">dCas9</td><td align="left">DNA methyltransferase domain</td><td align="left">dCas9-DNMT3A</td><td align="left">DNA methylation</td><td align="left">[<xref rid="bib101" ref-type="bibr">101</xref>]</td></tr><tr><td align="left">dCas9</td><td align="left">Ten-eleven translocation domain</td><td align="left">dCas9-TEF1</td><td align="left">DNA demethylation</td><td align="left">[<xref rid="bib101" ref-type="bibr">101</xref>]</td></tr><tr><td align="left">dCas9/ddCas12a</td><td align="left">Histone acetyltransferase domain</td><td align="left">dCas9-p300</td><td align="left">Histone acetylation</td><td align="left">[<xref rid="bib107" ref-type="bibr">107</xref>]</td></tr><tr><td align="left">dCas9</td><td align="left">Histone deacetylase domain</td><td align="left">dCas9-HDAC3<sup>R265p</sup></td><td align="left">Histone deacetylation</td><td align="left">[<xref rid="bib108" ref-type="bibr">108</xref>]</td></tr><tr><td align="left">nCas9</td><td align="left">DNA polymerase I domain</td><td align="left">nCas9-PolI3M</td><td align="left">Mutation in a specified window</td><td align="left">[<xref rid="bib126" ref-type="bibr">126</xref>]</td></tr></tbody></table></table-wrap></p><sec id="sec2.2.1"><label>2.2.1</label><title>Genome editing tools</title><p id="p0040">The ability to introduce desired changes into genomes at precise locations possesses tremendous value not only for molecular biology, but also for medicine and disease therapy. CRISPR systems, especially the Type II and V systems, have revolutionized the genome editing field due to its preeminent features, including higher sequence specificity, artificial guided targeting, unique adaptive nature and superior editing efficiency. As genome editing tools, CRISPR-Cas9 and CRISPR-Cas12a have been used in various organisms successfully, including mammalian cells, <italic>Saccharomyces cerevisiae</italic>, <italic>Escherichia coli</italic>, <italic>Streptomyces</italic>, <italic>Corynebacterium glutamicum</italic>, <italic>Cyanobacteria</italic>, plants and so on [<xref rid="bib21" ref-type="bibr">[21]</xref>, <xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>]. However, the further popularization and applications are limited due to their recognition mechanisms, the fidelity of editing and the size of those proteins. The CRISPR-Cas systems recognize the target genome region through searching for protospacer-adjacent motifs (PAMs) firstly. The PAMs for SpCas9 and AsCas12a/LbCas12a are restrictive in NGG and TTTN respectively [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib30" ref-type="bibr">30</xref>], and the fidelity of the CRISPR systems is not high enough. Thus they may induce unwanted off-target phenomenon [<xref rid="bib31" ref-type="bibr">31</xref>]. To solve these problems, researchers created libraries of the Cas9 and Cas12a mutants to screen for variants with higher specificity and broader PAM recognition ability, which will be discussed in part 2.3. The fidelity of genome editing could also be enhanced by using shortened sgRNAs [<xref rid="bib32" ref-type="bibr">32</xref>], the dCas9-<italic>Fok</italic>I fusion [<xref rid="bib33" ref-type="bibr">33</xref>] or the inducible transient expression strategies [<xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>]. The length of <italic>SpCas9</italic> is about 4.2&#x0202f;kb, which may hinder its application in gene therapy as the recombinant adeno-associated virus (rAAV) vectors can only hold about 4.7&#x0202f;kb generally. The &#x0201c;split-Cas9&#x0201d; which contains two parts of the Cas9 protein separately could be packed in the rAAV separately to solve this problem [<xref rid="bib37" ref-type="bibr">37</xref>]. Moreover, the delivery efficiency of the Cas9 nucleases in different cell lines can affect genome editing efficiency. A receptor-mediated delivery strategy showed increasement in editing efficiency by up to 29-fold [<xref rid="bib38" ref-type="bibr">38</xref>].</p></sec><sec id="sec2.2.2"><label>2.2.2</label><title>Gene expression tools</title><p id="p0045">Increasing efforts have been directed to re-engineer the already well-characterized Cas9 proteins. The catalytically deactivated CRISPR associate proteins (such as dCas9) with different fusion proteins are repurposed with different functions, such as genome transcriptional regulation. The dCas9 or DNase-dead Cas12a (ddCas12a) can bind the target sequence strongly with the help of guide RNA, which can interfere with transcriptional initiation or elongation via blocking RNA polymerase binding, or transcription factor binding, resulting in down-regulation of target genes [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib40" ref-type="bibr">40</xref>]. The repression of gene expression would be stronger when dCas9 or ddCas12a were fused with transcriptional repressors, such as KRAB (Kr&#x000fc;ppel-associated box) domain in mammalian cells [<xref rid="bib41" ref-type="bibr">41</xref>], SRDX in plants [<xref rid="bib42" ref-type="bibr">42</xref>] and RD1152 in yeast [<xref rid="bib43" ref-type="bibr">43</xref>]. Interestingly, some type VI RNA-guided RNA-targeting CRISPR-Cas proteins, such as <italic>Leptotrichia wadei</italic> Cas13a (LwaCas13a) and CasRx from <italic>Ruminococcus flavefacien</italic> XPD3002, can decrease the target gene expression by binding the transcripts to interfere with the RNA transcription [<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]. On the contrary, the dCas9 or ddCas12a fused with one or more transcriptional activators, such as VP16, VP64, p65AD, or the synthetic gene activators [<xref rid="bib46" ref-type="bibr">46</xref>], could up-regulate target gene expression via recruiting RNA polymerase binding [<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib43" ref-type="bibr">43</xref>]. Notably, in order to relieve the delivery pressure of CRISPR-based activator, Dr. Xie's group downsized the Cas9 variants to generate &#x0201c;mini-Cas9&#x0201d; activator by deleting conserved functional domains. The size of &#x0201c;mini-Cas9&#x0201d; can be shortened by 0.7kb&#x02013;1.2kb compared with the WT Cas9, the up-regulation abilities of the &#x0201c;mini-Cas9&#x0201d; in mammalian cells are efficient along with an optimized gRNA expression cassette [<xref rid="bib45" ref-type="bibr">45</xref>].</p></sec><sec id="sec2.2.3"><label>2.2.3</label><title>Live cell chromatin imaging tools</title><p id="p0050">Eukaryotic genomic DNA is organized three-dimensionally in cells as chromatin, which dynamically interacts with proteins and other chemicals. The information and behavior of such structures are still unclear in various cellular processes [<xref rid="bib47" ref-type="bibr">[47]</xref>, <xref rid="bib48" ref-type="bibr">[48]</xref>, <xref rid="bib49" ref-type="bibr">[49]</xref>]. Taking advantages of the live cell imaging tools, researchers can reveal the dynamic processes and explore the interactions of the mechanical factors and the signals [<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib50" ref-type="bibr">50</xref>]. The fluorescence in situ hybridization (FISH) was a major strategy for live cell imagining before 2013 [<xref rid="bib51" ref-type="bibr">51</xref>]. However, FISH had some drawbacks as it cannot be used to visualize dynamic processes in living cells [<xref rid="bib51" ref-type="bibr">51</xref>,<xref rid="bib52" ref-type="bibr">52</xref>]. The CRISPR-based live cell imaging tools emerged recently with the dCas9 fused with different fluorescent proteins [<xref rid="bib20" ref-type="bibr">20</xref>,<xref rid="bib53" ref-type="bibr">53</xref>,<xref rid="bib54" ref-type="bibr">54</xref>]. Generally, with the guidance of the optimized sgRNA, dCas9 fused with EGFP bound to the repetitive elements of the genome. After the EGFP complex gathered to these loci, the fluorescence of the EGFP would display and show robust green [<xref rid="bib52" ref-type="bibr">52</xref>]. However, the non-repetitive genomic sequences seem to be difficult to be imaged by CRISPR-based imaging tools as the fluorescence signal of a few dCas9-sgRNA complexes at the target region is not sufficient for detection [<xref rid="bib55" ref-type="bibr">55</xref>]. Researchers can add more counts of sgRNAs of the nearby loci to alleviate this problem, but this method cannot be repeated biologically easily as delivery of lots of sgRNAs is challenging and may increase the off-target rate [<xref rid="bib55" ref-type="bibr">55</xref>]. To solve this problem, researchers engineered the sgRNA scaffolds with up to 16 MS2 binding motifs which can bind to the bacteriophage MS2 coat protein (MCP). The MCPs were tagged with fluorescent proteins and thus the motifs would be labeled with fluorescence. This approach can achieve imaging of repetitive and non-repetitive genomic regions [<xref rid="bib55" ref-type="bibr">55</xref>]. It was difficult to image the different interchromosomal or intrachromosomal loci. Co-expression of dCas9 orthologs fused with different fluorescent proteins may be a good idea [<xref rid="bib56" ref-type="bibr">56</xref>]. However, imaging multiple genomic loci simultaneously is limited by the need of spectrally distinct fluorophores. Combining CRISPR-based imaging with FISH, tracking multiple genomic elements simultaneously was successful [<xref rid="bib57" ref-type="bibr">57</xref>]. Further, the multiple dynamic genomic elements imaging was achieved by the &#x0201c;track first and identify later&#x0201d; method. They first labeled and tracked chromosomal loci in live cells with the CRISPR-based imaging, then barcoded those loci by DNA sequential FISH in fixed cells [<xref rid="bib58" ref-type="bibr">58</xref>].</p></sec><sec id="sec2.2.4"><label>2.2.4</label><title>Base editing tools</title><p id="p0055">As many hereditary diseases are caused by single nucleotide mutation, the ability to perform precise genome base editing holds tremendous value in therapeutic areas. When dCas9/nCas9 or ddCas12a is fused with natural or engineered deaminase enzymes, they become base editors [<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib59" ref-type="bibr">[59]</xref>, <xref rid="bib60" ref-type="bibr">[60]</xref>, <xref rid="bib61" ref-type="bibr">[61]</xref>, <xref rid="bib62" ref-type="bibr">[62]</xref>]. The base editors can directly convert C&#x000b7;G to T&#x000b7;A or A&#x000b7;T to G&#x000b7;C without introducing double stranded DNA breaks [<xref rid="bib63" ref-type="bibr">[63]</xref>, <xref rid="bib64" ref-type="bibr">[64]</xref>, <xref rid="bib65" ref-type="bibr">[65]</xref>, <xref rid="bib66" ref-type="bibr">[66]</xref>, <xref rid="bib67" ref-type="bibr">[67]</xref>, <xref rid="bib68" ref-type="bibr">[68]</xref>]. The first example was reported in 2016 showing the C&#x000b7;G to T&#x000b7;A conversion achieved by dCas9/nCas9 fused with the cytidine deaminase enzyme named rat APOBEC1 or fused with APOBEC1 and Uracil DNA glycosylase inhibitor (UGI). The cytidine deaminase catalyzes cytosine (C) deamination and generates uracil (U) that has the base-pairing properties of thymine (T). The Cas9 nickase (nCas9) replaced the dCas9 to generate the BE3 (APOBEC&#x02013;XTEN&#x02013;nCas9&#x02013;UGI) with improved activity and accuracy [<xref rid="bib67" ref-type="bibr">67</xref>]. Nearly at the same time, the Target-AID system also achieved specific point mutation, with dCas9/nCas9 fused with the activation-induced cytidine deaminase PmCDA1 from sea lamprey and the UGI [<xref rid="bib69" ref-type="bibr">69</xref>]. Over the past few years, these base editors have been upgraded [<xref rid="bib70" ref-type="bibr">70</xref>,<xref rid="bib71" ref-type="bibr">71</xref>]. For example, the HF-BE3 was generated from protein engineering [<xref rid="bib72" ref-type="bibr">72</xref>], the BE4 and BE4-Gam were created via altering the linkers of BE3 and increasing the copies of UGI [<xref rid="bib73" ref-type="bibr">73</xref>,<xref rid="bib74" ref-type="bibr">74</xref>], the eA3A-BE3 was obtained by replacing the rAPOBEC1 with engineered human APOBEC3A (eA3A) domain of BE3 [<xref rid="bib75" ref-type="bibr">75</xref>,<xref rid="bib76" ref-type="bibr">76</xref>] and so on. Later, the editing window could be narrowed by engineering the BE3 [<xref rid="bib63" ref-type="bibr">63</xref>] and be broadened by BE-PLUS which combines the BE and the SunTag systems [<xref rid="bib77" ref-type="bibr">77</xref>]. The genome-targeting scopes of the BEs have also been broadened by replacing the dCas9/nCas9 with other CRISPR-associated proteins or the variants [<xref rid="bib63" ref-type="bibr">63</xref>,<xref rid="bib78" ref-type="bibr">78</xref>]. To deal with low efficiency caused by methylated regions or CpG contexts, researchers developed the human APOBEC3A-based BEs [<xref rid="bib79" ref-type="bibr">79</xref>]. In 2017, A&#x000b7;T to G&#x000b7;C conversion was implemented by the adenine base editors (ABEs). The ABE7.10 employing optimized bacterial adenosine deaminase tethered to nCas9 catalyzes adenosine (A) hydrolytic deamination and generates inosine (I) which is read as guanine (G) by polymerases [<xref rid="bib68" ref-type="bibr">68</xref>]. Over the past few years, researchers applied the base-editors to lots of species and organisms, such as yeast [<xref rid="bib69" ref-type="bibr">69</xref>], plants [<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib80" ref-type="bibr">[80]</xref>, <xref rid="bib81" ref-type="bibr">[81]</xref>, <xref rid="bib82" ref-type="bibr">[82]</xref>, <xref rid="bib83" ref-type="bibr">[83]</xref>], bacteria [<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib84" ref-type="bibr">84</xref>], rats [<xref rid="bib85" ref-type="bibr">85</xref>], zygotes [<xref rid="bib86" ref-type="bibr">86</xref>], embryos [<xref rid="bib87" ref-type="bibr">87</xref>,<xref rid="bib88" ref-type="bibr">88</xref>] and so on. Remarkably, an RNA targeting base editor named REPAIR (RNA Editing for Programmable A to I Replacement) can achieve A-&#x0202f;&#x0003e;&#x0202f;I editing of RNA. This base editor incorporates the catalytically inactive Cas13b from <italic>Prevotella</italic> sp. <italic>P5-125</italic> (dPspCas13b) fused with the adenosine deaminase mutant acting on RNA (ADAR2) deaminase domain (ADAR2<sub>DD</sub>) (E488Q/T375G) [<xref rid="bib89" ref-type="bibr">89</xref>], and its applications have been demonstrated in yeast [<xref rid="bib90" ref-type="bibr">90</xref>].</p></sec><sec id="sec2.2.5"><label>2.2.5</label><title>Epigenome editing tools</title><p id="p0060">The molecular mechanisms of heritable gene expression changes that cannot be attributed to changes in DNA sequence information are classified into epigenetics, while all post-translational chromatin modifications in the genome are defined as epigenome. The epigenomic features includes DNA methylation, histone modifications, chromatin variations and non-coding RNAs, which reveals unprecedented insights into gene regulation and genome organization [<xref rid="bib91" ref-type="bibr">91</xref>,<xref rid="bib92" ref-type="bibr">92</xref>]. Still, their functional roles are not fully elucidated [<xref rid="bib93" ref-type="bibr">93</xref>]. Therefore, specific epigenome mapping tools are expected to assist researchers to uncover the mysterious functions of chromatin modifications [<xref rid="bib94" ref-type="bibr">94</xref>]. With careful design and optimizations, these tools can precisely modulate gene expressions [<xref rid="bib95" ref-type="bibr">95</xref>], thus they could be potentially used for epigenetic caused disease treatment, such as glioblastoma [<xref rid="bib96" ref-type="bibr">96</xref>] and Fragile X syndrome (FXS) [<xref rid="bib97" ref-type="bibr">97</xref>]. DNA methylation and demethylation are the most widely studied phenomena of epigenome. To explore the potential of CRISPR tools in epigenome area, the dCas9 fused with the catalytic domain of distinct DNA methyltransferases (DNMTs) were designed and locus-specific DNA methylation was achieved [<xref rid="bib98" ref-type="bibr">98</xref>,<xref rid="bib99" ref-type="bibr">99</xref>]. Meanwhile, the dCas9 fused with the catalytic domain of ten-eleven translocation (TET) family enzymes achieved locus-specific DNA demethylation in mammalian cells [<xref rid="bib100" ref-type="bibr">[100]</xref>, <xref rid="bib101" ref-type="bibr">[101]</xref>, <xref rid="bib102" ref-type="bibr">[102]</xref>]. Other than DNA methylation/demethylation, histone modification is another major epigenomic features. The dCas9 fused with the KRAB domain or other protein domains could increase the tri-methylation level of histone H3 at lysine 9 (H3K9me3) specifically, finally result in target gene down-regulation [<xref rid="bib103" ref-type="bibr">103</xref>,<xref rid="bib104" ref-type="bibr">104</xref>]. Similarly, the dCas9 fused with the domain of histone demethylases, such as the catalytic domain of LSD1, resulted in a substantial local loss of the active enhancer markers H3K4me2 and H3K27ac, and finally improved the target gene expression [<xref rid="bib105" ref-type="bibr">105</xref>]. Similar to the histone methylation and demethylation processes, locus-specific histone acetylation and deacetylation can be achieved by dCas9 or ddCas12a fused with the domains of acetyltransferases and deacetylases respectively [<xref rid="bib106" ref-type="bibr">[106]</xref>, <xref rid="bib107" ref-type="bibr">[107]</xref>, <xref rid="bib108" ref-type="bibr">[108]</xref>].</p></sec><sec id="sec2.2.6"><label>2.2.6</label><title>Nucleic acid detection tools</title><p id="p0065">Rapid and precise sensing of trace amount of nucleic acids is of vital significance for clinical diagnosis and human health. The CRISPR-Cas9 system was firstly used for nucleic acid detection to discriminate different Zika viruses. The CRISPR system was combined with the RNA amplification technique known as NASBA (nucleic acid sequence-based amplification) to generate a method named NASBACC [<xref rid="bib109" ref-type="bibr">109</xref>]. In the same year, the newly discovered CRISPR system named CRISPR-C2c2 was adapted for nucleic acid detection as well. The <italic>Leptotrichia buccalis</italic> C2c2 (LbuC2c2) is an RNA-guided non-specific RNase active protein. LbuC2c2 catalyzed efficient target RNA cleavage only when such substrates could base pair with a complementary sequence in the crRNA. 0.01&#x0202f;nm target RNA can be detected distinctively by simply adding the quenched fluorescent RNA reporter and the LbuC2c2 with specific crRNA [<xref rid="bib110" ref-type="bibr">110</xref>]. Later, a method named SHERLOCK (Specific High-Sensitivity Enzymatic Reporter unLOCKing) which can discriminate nucleic acid of attomolar concentration was reported [<xref rid="bib111" ref-type="bibr">111</xref>]. In 2017, a research group developed HOLMES (one-<underline>HO</underline>ur <underline>L</underline>ow-cost <underline>M</underline>ultipurpose highly <underline>E</underline>fficient <underline>S</underline>ystem) platform for nucleic acid detection with the help of Cas12a (Patent CN 201710573752). In 2018, the HOLMESv2 which could be performed in one pot was used for nucleic acid detection with the help of Cas12b and Loop-Mediated Isothermal Amplification (LAMP) [<xref rid="bib112" ref-type="bibr">112</xref>,<xref rid="bib113" ref-type="bibr">113</xref>]. In April 2018, the <italic>Science</italic> press reported three nucleic acid detection tools with the incorporation of CRISPR tools, including DNA endonuclease-targeted CRISPR trans reporter (DETECTR) [<xref rid="bib114" ref-type="bibr">114</xref>], SHERLOCKv2 [<xref rid="bib115" ref-type="bibr">115</xref>] and heating unextracted diagnostic samples to obliterate nucleases (HUDSON) [<xref rid="bib116" ref-type="bibr">116</xref>]. DETECTR was based on the Cas12a that has target-activated, non-specific ssDNase cleavage property. It identified the HPV64 and HPV16 successfully with high sensitivity and specificity [<xref rid="bib114" ref-type="bibr">114</xref>]. SHERLOCKv2 consisting of Cas13, Cas12a, and Csm6, can achieve multiplex nucleic acid detection with tremendously improved sensitivity. The quantitative measurement of input is as low as 2 attomolar [<xref rid="bib115" ref-type="bibr">115</xref>]. The HUDSON system was designed based on SHERLOCK. The viral particles would be lysed first and the high level of ribonucleases found in bodily fluids would be inactivated with the help of heat and chemical reduction before performing the SHERLOCK steps. The advantage of HUDSON is that it is time-saving and does not require the nucleic acid extraction step [<xref rid="bib116" ref-type="bibr">116</xref>].</p></sec><sec id="sec2.2.7"><label>2.2.7</label><title>Other tools</title><p id="p0070">The CRISPR system can be redesigned to do a great deal of unimaginable work. Basically, Cas9 and Cas12a can be regarded as RNA guided DNA endonucleases. With the help of ligases or hosts, they have been used to clone large fragments [<xref rid="bib117" ref-type="bibr">[117]</xref>, <xref rid="bib118" ref-type="bibr">[118]</xref>, <xref rid="bib119" ref-type="bibr">[119]</xref>, <xref rid="bib120" ref-type="bibr">[120]</xref>]. Together with large pooled single-guide RNA (sgRNA) libraries, CRISPR-Cas proteins or fusion proteins coupled with the effectors can serve as screening tools [<xref rid="bib121" ref-type="bibr">121</xref>], such as screening cancer-related genomic ribonucleotides [<xref rid="bib122" ref-type="bibr">122</xref>], identifying fetal hemoglobin regulator [<xref rid="bib123" ref-type="bibr">123</xref>] and so on. The CRISPR-Cas system can also serve as a nucleic acid mutation toolkit [<xref rid="bib124" ref-type="bibr">124</xref>]. Taking advantages of the CRISPR system, researchers can create recording tools [<xref rid="bib125" ref-type="bibr">125</xref>] and evolutional tools with nCas9 (D10A) combined with the fidelity-reduced <italic>Escherichia coli</italic> DNA polymerase I [<xref rid="bib126" ref-type="bibr">126</xref>].</p></sec></sec><sec id="sec2.3"><label>2.3</label><title>The novel CRISPR systems</title><p id="p0075">CRISPR has been regarded as an indispensable toolkit for genetic manipulations. However, the frequently used CRISPR nucleases still have some limitations, such as the restriction of PAMs and the low fidelity. The feasible solutions to these problems include mining alternative CRISPR systems or engineering the current available CRISPR-associated nucleases to create a number of variants with specific biochemical properties such as altered PAM specificity or reduced off-target cleavage efficiency.</p><sec id="sec2.3.1"><label>2.3.1</label><title>Mining new CRISPR systems</title><p id="p0080">Apart from the first well characterized CRISPR-Cas9 system, a number of new CRISPR systems were reported from 2015 to 2017 [<xref rid="bib19" ref-type="bibr">19</xref>] (<xref rid="fig2" ref-type="fig">Fig. 2</xref>), presenting the widespread diversity of such systems. This diversity provides researchers with many variations of Cas proteins that may be explored for different applications. In 2015, Shmakov et al. discovered three distinct Class 2 CRISPR/Cas systems that were different from the Type II Cas9 [<xref rid="bib127" ref-type="bibr">127</xref>], naming as Type V-A, V-B, and V-C with the representative CRISPR-associated nucleases of Cas12a, C2c1, and C2c3, respectively [<xref rid="bib128" ref-type="bibr">128</xref>,<xref rid="bib129" ref-type="bibr">129</xref>]. In 2016, two novel CRISPR-CasX and CRISPR-CasY systems were reported, which were among the most compact systems yet identified [<xref rid="bib130" ref-type="bibr">130</xref>]. The CRISPR-associated proteins in these two systems are renamed as Cas12e and Cas12d. Another Type VI CRISPR enzymes are RNA guided RNA nucleases. There are three unique Type VI CRISPR proteins: Cas13a (C2c2), Cas13b, and Cas13c, each of which has two HEPN RNase domains [<xref rid="bib131" ref-type="bibr">131</xref>]. With the continuously published new data sets of bacterial or archaeal genomes, we believe more and more future exploration of these diverse CRISPR systems would be envisioned.<fig id="fig2"><label>Fig. 2</label><caption><p>A brief time line of key discoveries of the CRISPR systems.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec2.3.2"><label>2.3.2</label><title>Engineering of WT CRISPR/Cas proteins</title><p id="p0085">In addition to the discovery of new CRISPR systems, engineering WT enzymes could generate mutants with a variety of functions, further adding to the diversity of these enzymes. As for Cas9, one motivation of Cas9 enzyme engineering was the acquirement of diversiform PAMs. In 2014, the PI domains of different Cas9 were swapped to generate two chimeras: one was Sp-St3Cas9 (SpCas9 with the PI domain of St3Cas9) targeting the 5&#x02032;-GGGCT-3&#x02032; PAM , whereas traditional SpCas9 targeted the 5'-NGG-3'; the other one was St3-SpCas9 (St3Cas9 with the PI domain of SpCas9), targeting 5&#x02032;-GGGCG-3&#x02032; PAM, whereas traditional St3Cas9 targeted 5&#x02032;-NGGNG-3&#x02032; [<xref rid="bib29" ref-type="bibr">29</xref>]. This work not only enlarged the scope of PAM sites, but also improved the PAM specificity. In addition, the PAM-interacting motif of SpCas9 was mutagenized to create variants with different PAM recognition abilities (<xref rid="tbl2" ref-type="table">Table 2</xref>). Cas9 proteins from other species were also upgraded for targeting efficiency improvement or operational feasibility enhancement. For example, SaCas9 from <italic>Staphylococcus aureus</italic> and FnCas9 from <italic>Francisella novicida</italic>, were mutagenized with reasonable structure analysis of the gRNA-Cas9 complex. Variants that can recognize more relaxed PAMs: 5&#x02032;-NNGRRT-3&#x02032;, 5&#x02032;-NNNRRT-3&#x02032; (KRH, KKH of SaCas9) and 5&#x02032;-YG-3&#x02032; (a variant of FnCas9) were obtained [<xref rid="bib132" ref-type="bibr">132</xref>,<xref rid="bib133" ref-type="bibr">133</xref>]. Since 2015, several research groups worked on the reconstruction of SpCas9 protein, aiming not only to increase the diversity of PAM sequences, but also to improve the specificity and reduce the off-target effects. SpCas9-HF1 [<xref rid="bib134" ref-type="bibr">134</xref>], eSpCas9 [<xref rid="bib135" ref-type="bibr">135</xref>], HypaCas9 [<xref rid="bib136" ref-type="bibr">136</xref>], evoCas9 [<xref rid="bib137" ref-type="bibr">137</xref>], xCas9 3.7 [<xref rid="bib78" ref-type="bibr">78</xref>] and Sniper-Cas9 [<xref rid="bib138" ref-type="bibr">138</xref>] were generated in succession (<xref rid="tbl2" ref-type="table">Table 2</xref>). SpCas9-HF and eSpCas9 were designed according to the structure analysis of the substrate-enzyme-RNA complex. They found that 1) Disruption of SpCas9-mediated DNA contacts can alter the energetics of the complex; 2) Positive-charged groove would stabilize the non-target strand of the target DNA when it is positioned among the HNH, RuvC III, and PAM-interacting domains. Thus mutants with reduced off-target effects were obtained. HypaCas9, hyper-accurate Cas9, exhibited high genome targeting specificity without compromising on-target activity [<xref rid="bib136" ref-type="bibr">136</xref>]. The evoCas9 [<xref rid="bib137" ref-type="bibr">137</xref>] was obtained through random mutations in the REC3 domain. When screening the library of variants of SpCas9, researchers found that the specificity was improved and no off-target effect was observed. xCas9 3.7 was obtained with the help of the evolutionary methods named phage-assisted continuous evolution (PACE), and this variant not only improved the fidelity but also broadened the scope of PAM recognition [<xref rid="bib139" ref-type="bibr">139</xref>]. In 2015, another variant of SpCas9, iCas9 with higher editing efficiency was applied in the multiple-gene disruptions in <italic>Saccharomyces cerevisiae</italic> [<xref rid="bib21" ref-type="bibr">21</xref>]. Another variant, SniperCas9 with high specificity and activity was obtained by Sniper screen [<xref rid="bib138" ref-type="bibr">138</xref>]. As for Cas12a remolding, attentions have been focused on the PAM recognition diversity improvement and the ddCas12a-related tools construction. From 2017 to 2018, several groups devoted themselves to engineer Cas12a with altered PAM specificities. They obtained the RR and RVR variants of As/Lb/FnCas12a by structure analysis of the complex [<xref rid="bib140" ref-type="bibr">[140]</xref>, <xref rid="bib141" ref-type="bibr">[141]</xref>, <xref rid="bib142" ref-type="bibr">[142]</xref>].<table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>The variants of traditional Cas proteins.</p></caption><alt-text id="alttext0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Enzymes</th><th>Variants</th><th>Results</th><th>Methods</th><th>Mutated domains</th><th>ref</th></tr></thead><tbody><tr><td align="left">Sp-St3Cas9(<italic>Streptococcus thermophiles)</italic></td><td align="left">Sp-St3Cas9 (SpCas9 with the PI domain of St3Cas9)</td><td align="left">Sp-St3Cas9: 5&#x02032;-G<underline>GG</underline>CT-3&#x02032; PAM (SpCas9: NGG)</td><td rowspan="2" align="left">Swapped PI domains to generate two chimeras</td><td rowspan="2" align="left">PI</td><td rowspan="2" align="left">[<xref rid="bib29" ref-type="bibr">29</xref>]</td></tr><tr><td align="left">St3-SpCas9<italic>(Streptococcus pyogenes</italic>)</td><td align="left">St3-SpCas9 (St3Cas9 with the PI domain of SpCas9)</td><td align="left">St3-SpCas9: 5&#x02032;-G<underline>GG</underline>C<underline>G</underline>-3&#x02032; PAM (St3Cas9: NGGNG)</td></tr><tr><td align="left">iCas9 from SpCas9</td><td align="left">D147Y, P411T</td><td align="left">Improved gene disruption ability</td><td align="left">Accidentally</td><td align="left">REC1, REC3</td><td align="left">[<xref rid="bib21" ref-type="bibr">21</xref>]</td></tr><tr><td rowspan="5" align="left">Variants of SpCas9</td><td align="left">D1135E</td><td align="left">D1135E: reduced SpCas9 off-target effects</td><td rowspan="5" align="left">Random mutations in the residues of PAM-interacting motif (1097&#x02013;1368) for VQR/EQR/VRER, and based on the structures.</td><td rowspan="5" align="left">PI</td><td rowspan="5" align="left">[<xref rid="bib189" ref-type="bibr">[189]</xref>, <xref rid="bib190" ref-type="bibr">[190]</xref>, <xref rid="bib191" ref-type="bibr">[191]</xref>]</td></tr><tr><td align="left">D1135V/R1335Q/T1337R(VQR)</td><td align="left">VQR: 5&#x02032;-NGAN-3&#x02032; PAM</td></tr><tr><td align="left">D1135E/R1335Q/T1337R(EQR)</td><td align="left">EQR: 5&#x02032;-NGNG-3&#x02032; PAM</td></tr><tr><td align="left">D1135V/G1218R/R1335E/T1337R(VERE)</td><td align="left">VERE: highest activity on 5&#x02032;-NGCG-3&#x02032; PAM and minimal activity on 5&#x02032;-NGG-3&#x02032; PAM</td></tr><tr><td align="left">G1218R/N1286Q/I1331F/D1332K/R1333Q/R1335Q/T1337R(QQR1)</td><td align="left">QQR1: 5&#x02032;-TGGT-3&#x02032; or 5&#x02032;-TAAG-3&#x02032; PAMs, highly specific for 5&#x02032;-NAAG-3&#x02032; but a slower cleavage rate</td></tr><tr><td rowspan="2" align="left">Variants of SaCas9(<italic>Staphylococcus aureus</italic> Cas9)</td><td align="left">E782K/N968K/R1015H(KKH)</td><td rowspan="2" align="left">KKH KRH: 5&#x02032;-NN<underline>N</underline>RRT-3&#x02032; from 5&#x02032;-NN<underline>G</underline>RRT-3&#x02032; PAM</td><td rowspan="2" align="left">Random mutations in a region encompassing PI domain</td><td rowspan="2" align="left">Phosphate lock loop, TOPO, CTD</td><td rowspan="2" align="left">[<xref rid="bib132" ref-type="bibr">132</xref>]</td></tr><tr><td align="left">E782K/K929R/R1015H(KRH)</td></tr><tr><td align="left">Variant of FnCas9(<italic>Francisella novicida U112</italic>)</td><td align="left">E1369R/E1449H/R1556A(RHA)</td><td align="left">RHA: 5&#x02019;-YG-3&#x02032; from 5&#x02032;-NGG-3&#x02032; PAM</td><td align="left">Structure analysis of the FnCas9 and DNA/sgRNA complex</td><td align="left">WED, PI</td><td align="left">[<xref rid="bib133" ref-type="bibr">133</xref>]</td></tr><tr><td align="left">SpCas9-HF1</td><td align="left">N497A/R661A/Q695A/Q926A</td><td align="left">Enhanced specificity</td><td align="left">Structure analysis</td><td align="left">REC3,<break/>RuvC III</td><td align="left">[<xref rid="bib134" ref-type="bibr">134</xref>]</td></tr><tr><td rowspan="3" align="left">eSpCas9</td><td align="left">K855A</td><td rowspan="3" align="left">Enhanced specificity and reduced off-target rate eSpCas9(1.1): enhanced specificity</td><td rowspan="3" align="left">Structure analysis of the complex of non-target strand groove with DNA</td><td rowspan="3" align="left">HNH,<break/>RuvC III</td><td rowspan="3" align="left">[<xref rid="bib135" ref-type="bibr">135</xref>]</td></tr><tr><td align="left">eSpCas9(1.0): K810A/K1003A/R1060A</td></tr><tr><td align="left">eSpCas9(1.1): K848A/K1003A/R1060A</td></tr><tr><td align="left">HypaCas9</td><td align="left">N692A/M694A/Q695A/H698A</td><td align="left">Enhanced specificity</td><td align="left">Based on the SpCas9-HF1 and eSpCas9(1.1)</td><td align="left">REC3</td><td align="left">[<xref rid="bib136" ref-type="bibr">136</xref>]</td></tr><tr><td align="left">evoCas9</td><td align="left">M495V/Y515N/K526E/R661Q(VNEQ)</td><td align="left">Enhanced specificity, 70-fold higher fidelity of the WT</td><td align="left">Random mutations in the REC3 domain</td><td align="left">REC3</td><td align="left">[<xref rid="bib137" ref-type="bibr">137</xref>]</td></tr><tr><td align="left">xCas9</td><td align="left">xCas9 3.7: A262T/R324L/S409I/M694I/E1219V</td><td align="left">Increased PAM diversity, and improved DNA specificity</td><td align="left">The phage-assisted continuous evolution method</td><td align="left">REC2, REC3, PI</td><td align="left">[<xref rid="bib78" ref-type="bibr">78</xref>]</td></tr><tr><td align="left">Sniper-Cas9</td><td align="left">F539S/M763I/K890N</td><td align="left">High specificity without killing on-target activity</td><td align="left">Random mutagenesis</td><td align="left">REC3,<break/>RuvC II, HNH</td><td align="left">[<xref rid="bib138" ref-type="bibr">138</xref>]</td></tr><tr><td align="left">SpCas9-NG</td><td align="left">VRVRFRR: D1135V/L1111R/R1335V/A1322R/E1219F/G1218R/T1337R</td><td align="left">Recognition of relaxed NG PAMs</td><td align="left">Structure analysis</td><td align="left">PI</td><td align="left">[<xref rid="bib192" ref-type="bibr">192</xref>]</td></tr><tr><td align="left">AsCas12a(<italic>Acidaminococcus</italic> sp. <italic>BV3L6</italic>)</td><td align="left">AsCas12a.RR: S542R/K607RAsCas12a.RVR: S542R/K548V/N552R</td><td align="left">RR: TYCV; RVR; TATV PAMs, with enhanced activities <italic>in vitro</italic> and in human cells</td><td align="left">Structure analysis of the complex, selected residuals in proximity to the PAM duplex</td><td align="left">RR: WED-II, PI<break/>RVR: WED-II</td><td align="left">[<xref rid="bib141" ref-type="bibr">141</xref>]</td></tr><tr><td align="left">LbCas12a(<italic>Lachnospiraceae bacterium ND2006</italic>)</td><td align="left">LbCas12a.RR: G532R/K595R AsCas12a.RVR: G532R/K538V/Y542R</td><td align="left">RR: TYCV&#x000a0;+&#x000a0;CCCC and RVR: TATV PAMs, with enhanced activities <italic>in vitro</italic> and in human cells</td><td align="left">Sequence alignment with AsCas12a and structure analysis</td><td align="left">RR: WED-II, PI<break/>RVR: WED-II</td><td align="left">[<xref rid="bib141" ref-type="bibr">141</xref>]</td></tr><tr><td align="left">FnCas12a(<italic>Francisella tularensis novicida</italic>)</td><td align="left">FnCas12a.RR: N623R/K687RFnCas12a.RVR: N623R/K629R/N633R</td><td align="left">The highest activity of FnCas12a-RR, &#x0223c;5% at one CCCC PAM site and two TYCY PAM sites</td><td align="left">Sequence alignment with AsCas12a and LbCas12a</td><td align="left">RR: WED-II, PI<break/>RVR: WED-II</td><td align="left">[<xref rid="bib142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left">Variant of AsCas12a</td><td align="left">K949A</td><td align="left">Enhanced specificity</td><td align="left">Similar to strategies previously employed with SpCas9</td><td align="left">BH</td><td align="left">[<xref rid="bib141" ref-type="bibr">141</xref>]</td></tr></tbody></table></table-wrap></p></sec></sec></sec><sec id="sec3"><label>3</label><title>CRISPR-mediated diseases therapy</title><p id="p0090">As we stated above, CRISPR-based technologies have empowered researchers with an unprecedented toolbox that enables breakthrough discoveries and innovative methodologies. These methodologies could expand their therapeutic applications, such as the pathogen detection [<xref rid="bib143" ref-type="bibr">143</xref>], disease modeling [<xref rid="bib144" ref-type="bibr">144</xref>,<xref rid="bib145" ref-type="bibr">145</xref>], and most importantly disease therapy (<xref rid="tbl3" ref-type="table">Table 3</xref>) [<xref rid="bib146" ref-type="bibr">146</xref>,<xref rid="bib147" ref-type="bibr">147</xref>]. In this section, we would discuss the CRISPR-based technologies that have been applied in <italic>in vivo</italic> gene therapy, cell therapy, immune therapy and bacteriophage therapy (<xref rid="fig3" ref-type="fig">Fig. 3</xref>).<table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Examples of disease treatment via CRISPR-based technologies.</p></caption><alt-text id="alttext0035">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Disease</th><th>Species</th><th>Possible pathogenesis</th><th>Therapeutic Method</th><th>Results</th><th>Ref.</th></tr></thead><tbody><tr><td align="left">Hereditary tyrosinemia</td><td align="left">mouse</td><td align="left">Mutations of the fumarylacetoacetate hydrolase gene <italic>Fah</italic></td><td align="left">Delivery of the CRISPR-Cas9 system and the ssDNA donor into the mouse to correct the <italic>Fah</italic> mutants</td><td align="left">Initial expression of the wild-type FAH protein in &#x0223c;1/250 liver cells and rescued the body weight loss phenotype.</td><td align="left">[<xref rid="bib151" ref-type="bibr">151</xref>]</td></tr><tr><td align="left">Cardiovascular disease</td><td align="left">mouse</td><td align="left">Mutations in the subtilisin/kexin type 9 gene <italic>Pcsk9</italic></td><td align="left">Delivery of adenovirus expressing Cas9/sgRNA targeting the <italic>Pcsk9</italic> gene in mouse liver</td><td align="left">The mutagenesis correction rate of <italic>Pcsk9</italic> in the liver was &#x0003e;50%</td><td align="left">[<xref rid="bib152" ref-type="bibr">152</xref>]</td></tr><tr><td align="left">Duchenne muscular dystrophy (DMD)</td><td align="left">mouse</td><td align="left">Mutations in the dystrophin gene</td><td align="left">Delivery of the SpCas9 or SaCas9/sgRNA targeting the exon 23 into the <italic>mdx</italic> mouse model</td><td align="left">Excision of intervening DNA and restored the <italic>Dmd</italic> reading frame</td><td align="left">[<xref rid="bib153" ref-type="bibr">[153]</xref>, <xref rid="bib154" ref-type="bibr">[154]</xref>, <xref rid="bib155" ref-type="bibr">[155]</xref>]</td></tr><tr><td align="left">DMD</td><td align="left">mouse</td><td align="left">Mutations in the dystrophin gene</td><td align="left">Electroporation-mediated transfection of the Cas9/gRNA constructs targeting the exon 23 into the skeletal muscles of the <italic>mdx</italic> mice</td><td align="left">Excision of the mutant exon 23 of <italic>mdx</italic> the <italic>mdx</italic>&#x0202f;mice model</td><td align="left">[<xref rid="bib156" ref-type="bibr">156</xref>]</td></tr><tr><td align="left">DMD</td><td align="left">mouse</td><td align="left">Mutations in the dystrophin gene</td><td align="left">Injection of the LbCas12a mRNA, the sgRNA and the ssODN donor targeting the exon 23 into the <italic>mdx</italic> zygotes</td><td align="left">The <italic>DMD&#x0202f;</italic>mutations were corrected in the <italic>mdx</italic>&#x0202f;mice model</td><td align="left">[<xref rid="bib157" ref-type="bibr">157</xref>]</td></tr><tr><td align="left">DMD</td><td align="left">canine</td><td align="left">Mutations in the dystrophin gene</td><td align="left">Delivery of the AAV vectors carrying SpCas9/sgRNA targeting the exon 51 into the cranial tibialis muscles</td><td align="left">Dystrophin was restored to levels ranging from 3 to 90% and the muscle histology was improved</td><td align="left">[<xref rid="bib193" ref-type="bibr">193</xref>]</td></tr><tr><td align="left">Primary open-angle glaucoma (POAG)</td><td align="left">mouse</td><td align="left">Mutations in the myocilin gene</td><td align="left">Intraocular injection of the virus containing of SpCas9/sgRNA targeting the MYOC mutation (Y437H)</td><td align="left">Lower IOP and further glaucomatous damage prevention</td><td align="left">[<xref rid="bib159" ref-type="bibr">159</xref>]</td></tr><tr><td align="left">Retinal degeneration</td><td align="left">mouse</td><td align="left">Mutation in the <italic>Nrl</italic> gene</td><td align="left">Delivery of the AAVvector cayyring CRISPR-Cas9 to postmitotic photoreceptors</td><td align="left">The treatment substantially miproved rod survival and preserved cone function</td><td align="left">[<xref rid="bib160" ref-type="bibr">160</xref>]</td></tr><tr><td align="left">Hypertrophic cardiomyopathy (HCM)</td><td align="left">human embryos</td><td align="left">Mutation in the <italic>MYBPC3</italic> gene</td><td align="left">Microinjection of the recombinant Cas9 protein, sgRNA and ssODN DNA into the cytoplasm of pronuclear stage zygotes 18&#x0202f;h after fertilization</td><td align="left">The heterozygous <italic>MYBPC3</italic> mutation was corrected without evidence of off-target mutations</td><td align="left">[<xref rid="bib147" ref-type="bibr">147</xref>]</td></tr><tr><td align="left">Cardiovascular disease</td><td align="left">mouse</td><td align="left">Mutations in the subtilisin/kexin type 9 gene <italic>Pcsk9</italic></td><td align="left">Injection of the Ad vector (adenoviral vector) containing BE3 and a gRNA targeting <italic>Pcsk9</italic> codon W159 (Ad-BE3-Pcsk9)</td><td align="left">The base-editing rate was 10%&#x02013;15% and the indel rate was about 2%, leading to reduce the plasma <italic>PCSK9</italic> and cholesterol levels.</td><td align="left">[<xref rid="bib161" ref-type="bibr">161</xref>]</td></tr><tr><td align="left">Hereditary tyrosinemia</td><td align="left">mouse</td><td align="left">Mutation in the fumarylacetoacetate hydrolase gene <italic>Fah</italic></td><td align="left">Injection of the Ad vector containing BE3 and a gRNA targeting the upstream <italic>HPD</italic> enzyme Q352 (Ad-BE3-Hpd)</td><td align="left">The lethal phenotype of hereditary tyrosinemia type 1 was rescued.</td><td align="left">[<xref rid="bib161" ref-type="bibr">161</xref>]</td></tr><tr><td align="left">Phenylketonuria</td><td align="left">mouse</td><td align="left">Point mutation in the <italic>Pah</italic> gene on exon 7 (c.835&#x0202f;T&#x0202f;&#x0003e;&#x0202f;C)</td><td align="left">Injection of a dual AAV system and split nSaKKH-BE3 targeting <italic>Pah</italic><sup><italic>enu2</italic></sup> gene into the adult mice</td><td align="left">The mutant of <italic>Pah</italic><sup><italic>enu2</italic></sup> gene was corrected, the phenylalanine hydroxylase enzyme activity was restored, and the light fur phenotype was reversed in Pah<sup>enu2</sup> mice.</td><td align="left">[<xref rid="bib162" ref-type="bibr">162</xref>]</td></tr><tr><td align="left">Human genetic deafness</td><td align="left">mouse</td><td align="left">A dominant-negative missense mutation in the <italic>TMC1</italic></td><td align="left">Injection of the Cas9&#x02013;guide RNA&#x02013;lipid complexes targeting the <italic>Tmc1<sup>Bth</sup></italic> allele into the cochlea of neonatal <italic>Tmc1</italic><sup><italic>Bth/+</italic></sup> mice</td><td align="left">Higher hair cell survival rate and lower auditory brainstem response thresholds were observed</td><td align="left">[<xref rid="bib28" ref-type="bibr">28</xref>]</td></tr><tr><td align="left">Cystic Fibrosis</td><td align="left">organoids</td><td align="left">Mutation of cystic fibrosis transmembrane conductor receptor (CFTR) locus</td><td align="left">The mutant F508 del allele was corrected using the CRISPR/Cas9 mediated homologous recombination</td><td align="left">Functionality of the corrected allele in the organoid system was demonstrated</td><td align="left">[<xref rid="bib163" ref-type="bibr">163</xref>]</td></tr><tr><td align="left">&#x003b2;-thalassemia</td><td align="left">mouse</td><td align="left">Either point mutations or deletions in the &#x003b2;-globin (<italic>HBB</italic>) gene</td><td align="left">Generation of the iPSC-derived hematopoietic stem cells (HSCs) from the somatic cells of patients, correction of the mutations of <italic>HBB</italic> gene by CRISPR/Cas9 system</td><td align="left">No observations of tumor formation in the mice model after the iPSCs transplantation</td><td align="left">[<xref rid="bib166" ref-type="bibr">166</xref>]</td></tr><tr><td align="left">Microbial infection</td><td align="left">mouse</td><td align="left">Infection of bacteria with antibiotic resistance genes</td><td align="left">Delivery of the RNA-guided nuclease Cas9 targeting antibiotic resistance genes by the bacteriophage</td><td align="left">The bacteria in a mouse skin colonization model was killed successfully</td><td align="left">[<xref rid="bib169" ref-type="bibr">169</xref>]</td></tr><tr><td align="left">Tumor</td><td align="left">mouse</td><td align="left">Mutilple pathegenetic mechanisms</td><td align="left">Delivery of the CRISPR-based engineered CAR-T cells (such as PD-1 disrupted CAR-T cells) into the mice model</td><td align="left">The efficiency of the engineered CAR-T cells is higher</td><td align="left">[<xref rid="bib172" ref-type="bibr">172</xref>,<xref rid="bib174" ref-type="bibr">174</xref>,<xref rid="bib179" ref-type="bibr">179</xref>]</td></tr></tbody></table></table-wrap><fig id="fig3"><label>Fig. 3</label><caption><p>Overview of the disease treatment via CRISPR-based technologies. The CRISPR systems can be used for <italic>in vivo</italic> gene therapy though the Cas ribonucleoproteins (RNPs) or delivered by AAV. Na&#x000ef;ve T cells come from the patients and CAR T cells are activated by antibody-coated beads. The reprogramed CAR-T cells generated by knocking out the PD-1 or other receptors, were transfused back to the patients. The incorrect cells are isolated from the patients and iPSCs are generated by reprograming the fibroblasts, and corrected with the help of CRISPR-based technologies. The repaired cells were used for therapy.</p></caption><alt-text id="alttext0020">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p><sec id="sec3.1"><label>3.1</label><title><italic>In vivo</italic> gene therapy</title><p id="p0095">Gene therapy is defined as the delivery of nucleic acid into the patients for disease treatment [<xref rid="bib148" ref-type="bibr">148</xref>,<xref rid="bib149" ref-type="bibr">149</xref>]. Traditional gene therapy strategies include interfering with target gene expression, replacing the culprit genes, correcting genetic mutations and so on. With the development of CRISPR technologies, the recent advances in gene therapy intrigued our great interests [<xref rid="bib150" ref-type="bibr">150</xref>]. In 2014, the <italic>Fah</italic> mutation which causes human hereditary disease tyrosinemia was corrected in adult mice via CRISPR-Cas9. Three sgRNAs targeting the <italic>Fah</italic> (<italic>Fah1</italic>, <italic>Fah2</italic> and <italic>Fah3</italic>) were cloned into the adeno-associated virus (AAV) vector pX330, and an initial genetic correction rate of &#x0223c;1/250&#x0202f;cells was observed [<xref rid="bib151" ref-type="bibr">151</xref>]. In the same year, the CRISPR-Cas9 was successfully introduced into mice liver through adenovirus packaging and mutated the endogenous proprotein convertase subtilisin/kexin type 9 (PCSK9) gene with high efficiency. These mutations of <italic>Pcsk9</italic> reduced the low-density lipoprotein cholesterol level and protected against cardiovascular disease [<xref rid="bib152" ref-type="bibr">152</xref>]. Interestingly and persuasively, three independent reports from <italic>Science</italic> showed that the CRISPR technologies were used to treat the Duchenne muscular dystrophy (DMD) by <italic>in vivo</italic> gene therapy [<xref rid="bib153" ref-type="bibr">[153]</xref>, <xref rid="bib154" ref-type="bibr">[154]</xref>, <xref rid="bib155" ref-type="bibr">[155]</xref>]. The three groups delivered the CRISPR-Cas9 (SpCas9 or SaCas9) into the <italic>mdx</italic> mouse model of DMD through AAV vectors, and removed the mutated exon 23 from the dystrophin gene and restored dystrophin protein expression in cardiac and skeletal muscles. Improved muscle function of the DMD mice was observed. Contemporaneously, another group used the CRISPR-Cas9 to restore muscle function of the DMD mice by <italic>in vivo</italic> gene therapy successfully as well via electroporation-mediated delivery strategy [<xref rid="bib156" ref-type="bibr">156</xref>]. Unsurprisingly, CRISPR-Cas12a can also correct DMD mutations in <italic>mdx</italic> mice [<xref rid="bib157" ref-type="bibr">157</xref>]. Even more encouraging, reported on 30<sup>th</sup> August 2018 in <italic>Science</italic>, a muscular dystrophy was fixed in dog by CRISPR-based therapy [<xref rid="bib158" ref-type="bibr">158</xref>]. These studies shed light on the future applications of CRISPR-based gene editing approaches for DMD clinical therapy. In ophthalmology, CRISPR-based <italic>in vivo</italic> gene therapy again successfully lowered the intraocular pressure (IOP) of mice, which is a major risk factor of primary open-angle glaucoma (POAG) [<xref rid="bib159" ref-type="bibr">159</xref>]. The retinal degeneration in mice due to CRISPR-Cas9 mediated disruption of neural retina-specific leucine zipper protein gene (<italic>Nrl</italic> gene) could also be prevented [<xref rid="bib160" ref-type="bibr">160</xref>]. In human embryos, researchers corrected the heterozygous <italic>MYBPC3</italic> mutation in human preimplantation embryos with precise CRISPR-Cas9 system and no off-target mutation was observed [<xref rid="bib147" ref-type="bibr">147</xref>]. In 2018, the Cas9-GFP sgRNA-lipid complex was injected into the mouse model of human genetic deafness by canalostomy. The result showed that the injected mice had higher hair cell survival rates and lower auditory brainstem response thresholds than that of the control group [<xref rid="bib28" ref-type="bibr">28</xref>]. Recently, two research groups applied the base editors to gene therapy. One group injected Ad vectors (adenoviral vectors) containing spCas9-BE3 and gRNAs targeting the <italic>Pcsk9</italic> or <italic>Hpd</italic> gene separately in utero [<xref rid="bib161" ref-type="bibr">161</xref>]. Another group intravenously injected AAV-base editor systems to correct the mutation of phenylalanine hydroxylase (<italic>Phae</italic><sup><italic>nu2</italic></sup>) successfully [<xref rid="bib162" ref-type="bibr">162</xref>].</p></sec><sec id="sec3.2"><label>3.2</label><title>Cell therapy</title><p id="p0100">The easily accessible and programmable features of CRISPR-Cas system also spur a revolution in cell therapy. CRISPR technology was first applied in cell therapy in 2013 [<xref rid="bib163" ref-type="bibr">163</xref>], correcting the cystic fibrosis transmembrane conductor receptor (CFTR) locus in the cultured intestinal stem cells of cystic fibrosis (CF) patients. Then it was expanded to correct clonal cells and organoids for CFTR function restoration. Other than treating CF patients, CRISPR-Cas system has also been applied in the engineered human induced pluripotent stem cells (iPSCs) to correct disease-causing mutations, such as the &#x003b2;-thalassemia [<xref rid="bib164" ref-type="bibr">[164]</xref>, <xref rid="bib165" ref-type="bibr">[165]</xref>, <xref rid="bib166" ref-type="bibr">[166]</xref>]. The general workflow (<xref rid="fig3" ref-type="fig">Fig. 3</xref>) includes reprograming of the iPSCs from patients' fibroblasts, engineering the iPSCs to correct the defect genes by CRISPR-based systems [<xref rid="bib167" ref-type="bibr">167</xref>,<xref rid="bib168" ref-type="bibr">168</xref>], screening for the corrected cells, verifying the function restoration of the modified iPSCs, and finally transfusing the repaired cells back to the patients.</p></sec><sec id="sec3.3"><label>3.3</label><title>Antimicrobial therapy</title><p id="p0105">Antibiotic resistance has been a non-negligible risk to the world's health and global economy. Revitalizing phage therapy to treat pathogen bacterial infection has drawn the researchers' attentions. In 2014, a bacteriophage system containing CRISPR-Cas9 was reported to deal with the antibiotic resistance. The modified bacteriophage targeted the antibiotic resistance genes of <italic>Staphylococcus aureus</italic>, and then destroyed the genes and immunized avirulent <italic>Staphylococci</italic> to prevent the spread of plasmid-borne resistance genes [<xref rid="bib169" ref-type="bibr">169</xref>]. Other than killing bacteria by bacteriophage directly, they designed the phages harboring the CRISPR-Cas system to invade in the bacteria by lysogenization, which targets the specific DNAs of the bacteria such as the antibiotic resistance gene. If the bacteria contain the resistance gene, the gene will be cleaved by the CRISPR-Cas system, and the antibiotic sensitivity of the bacteria would be higher. This allows programming of lytic phages to kill only specific antibiotic-resistant bacteria [<xref rid="bib170" ref-type="bibr">170</xref>].</p></sec><sec id="sec3.4"><label>3.4</label><title>Immunotherapy</title><p id="p0110">Being a powerful tool of genome editing, CRISPR technology holds great promise as the means for immunotherapy, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy [<xref rid="bib171" ref-type="bibr">171</xref>]. T cells have the potential to target and destroy cancer cells. However, the programmed death-1 (PD-1) receptor on activated T cells can bind with the ligand PD-L1 expressed on dentritic cells (DCs) or some tumor cells, thus, decreasing the activity of T cells. To solve this problem, CRISPR-Cas9 system has been employed to reprogram the primary human T cells by destroying the function of PD-1 [<xref rid="bib172" ref-type="bibr">172</xref>]. In order to reprogram T cells, the endogenous T cell receptor (TCR) locus was replaced with a new TCR in order to recognize the cancer antigen easily via CRISPR-Cas9 [<xref rid="bib173" ref-type="bibr">173</xref>]. The engineered CAR-T cells improved the anti-tumor efficacy by ablating the genes of PD-1 via CRISPR-Cas9 system [<xref rid="bib174" ref-type="bibr">174</xref>]. Due to the drawbacks of PD-1, CAR-T cells may recognize the alloantigens of the recipient, leading to graft-versus-host disease (GVHD), and may cause immunogenicity or alloreactivity because of HLA class I (HLA-I) on the surface of allogeneic T cells [<xref rid="bib175" ref-type="bibr">175</xref>]. To eliminate these defects, multiplex genes were edited in CAR-T cells via CRISPR-Cas9, such as endogenous TCR locus (TRAC or TRBC) and &#x003b2;-2 microglobulin (B2M) [<xref rid="bib176" ref-type="bibr">176</xref>,<xref rid="bib177" ref-type="bibr">177</xref>]. The therapeutic efficacy of CAR-T cells with the lymphocyte activation gene-3 (<italic>LAG-3</italic>) deleted is higher than that of the untreated cells [<xref rid="bib178" ref-type="bibr">178</xref>]. In another case, the CAR was integrated into the TRC locus precisely under the control of endogenous regulatory elements, which can reduce tonic signaling, avert accelerated T-cell differentiation and exhaustion, and also increase the therapeutic potency of engineered T cells [<xref rid="bib179" ref-type="bibr">179</xref>]. In clinic, the immunotherapy with the modified T cells by CRISPR-Cas9 is on the way [<xref rid="bib180" ref-type="bibr">180</xref>,<xref rid="bib181" ref-type="bibr">181</xref>].</p></sec></sec><sec id="sec4"><label>4</label><title>Conclusion remarks and future prospects</title><p id="p0115">Within the last few years, stunning progress in the development of various CRISPR-based technologies has witnessed the revolutionary change in molecular biology field, particularly in mammalian model systems and human cells. Apart from the frequently used Cas9 system, alternative CRISPR-associated nuclease variants are continuing being discovered and characterized, providing potential improvements in precision, efficacy and delivery. Meanwhile, further optimization of currently well-characterized CRISPR systems also offers infinite possibilities in various applications. Still, there are some technical barriers that need to be marched over. As a generally applicable approach, CRISPR-based technologies hold great potential in therapeutic applications. In June 2016, the US approved the first CRISPR clinical trial [<xref rid="bib181" ref-type="bibr">181</xref>]. Later in October in the same year, the engineered CAR-T cells were injected into the first patient at the West China Hospital in Chengdu [<xref rid="bib182" ref-type="bibr">182</xref>]. In 2017, successful correction of the human embryos for a pathogenic gene mutation was achieved [<xref rid="bib147" ref-type="bibr">147</xref>], and more CRISPR-related clinic trials are being considered [<xref rid="bib180" ref-type="bibr">180</xref>].</p><p id="p0120">However, as the CRISPR revolution continues, social and ethical concerns over their use are also rising. Especially therapeutic applications of these powerful tools deserve greater considerations. The US Food and Drug administration (FDA) paused the CRISPR gene therapy trial in May, 2018 without giving any details [<xref rid="bib183" ref-type="bibr">183</xref>]. Without doubts, CRISPR-based therapy is still in its infant stage, with several limitations to be addressed. One of the major concerns is the off-target effect. Different Cas nucleases have been engineered to improve the targeting precision [<xref rid="bib78" ref-type="bibr">78</xref>,<xref rid="bib134" ref-type="bibr">[134]</xref>, <xref rid="bib135" ref-type="bibr">[135]</xref>, <xref rid="bib136" ref-type="bibr">[136]</xref>, <xref rid="bib137" ref-type="bibr">[137]</xref>, <xref rid="bib138" ref-type="bibr">[138]</xref>]. Another major bottle neck for CRISPR-based gene therapy is the delivery efficiency. Other than technical barriers, social and ethical concerns also draw the public attentions. One report showed that Cas9 may trigger the adaptive immune responses in humans, but currently no feasible solution has been found [<xref rid="bib184" ref-type="bibr">184</xref>]. Moreover, another report pointed out that Cas9 editing induced a p53-mediated DNA damage response, which is a phenotype common to cancer cells [<xref rid="bib185" ref-type="bibr">185</xref>], and inadvertent changes to the human germ line has also been reported [<xref rid="bib186" ref-type="bibr">186</xref>,<xref rid="bib187" ref-type="bibr">187</xref>]. The causes of these problems are not clear yet, therefore, CRISPR-based therapy still has a long way to go. All in all, as the exploitation of CRISPR continues, we believe more and more spectacular improvements and applications could be envisioned.</p></sec><sec id="sec5"><title>Conflicts of interest</title><p id="p0125">The authors have declared no conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>J.C.</given-names></name><name><surname>Holmes</surname><given-names>M.C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Guschin</surname><given-names>D.Y.</given-names></name><name><surname>Lee</surname><given-names>Y.L.</given-names></name><name><surname>Rupniewski</surname><given-names>I.</given-names></name></person-group><article-title>An improved zinc-finger nuclease architecture for highly specific genome editing</article-title><source>Nat Biotechnol</source><volume>25</volume><issue>7</issue><year>2007</year><fpage>778</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">17603475</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>J.C.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Qiao</surname><given-names>G.</given-names></name><name><surname>Barlow</surname><given-names>K.A.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>D.F.</given-names></name></person-group><article-title>A TALE nuclease architecture for efficient genome editing</article-title><source>Nat Biotechnol</source><volume>29</volume><issue>2</issue><year>2011</year><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">21179091</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>R.</given-names></name><name><surname>Lombardo</surname><given-names>A.</given-names></name><name><surname>Arens</surname><given-names>A.</given-names></name><name><surname>Miller</surname><given-names>J.C.</given-names></name><name><surname>Genovese</surname><given-names>P.</given-names></name><name><surname>Kaeppel</surname><given-names>C.</given-names></name></person-group><article-title>An unbiased genome-wide analysis of zinc-finger nuclease specificity</article-title><source>Nat Biotechnol</source><volume>29</volume><issue>9</issue><year>2011</year><fpage>816</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">21822255</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>G.J.</given-names></name><name><surname>Doudna</surname><given-names>J.A.</given-names></name></person-group><article-title>CRISPR-Cas guides the future of genetic engineering</article-title><source>Science</source><volume>361</volume><issue>6405</issue><year>2018</year><fpage>866</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">30166482</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Ishino</surname><given-names>Y.</given-names></name><name><surname>Shinagawa</surname><given-names>H.</given-names></name><name><surname>Makino</surname><given-names>K.</given-names></name><name><surname>Amemura</surname><given-names>M.</given-names></name><name><surname>Nakata</surname><given-names>A.</given-names></name></person-group><article-title>Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in <italic>Escherichia coli,</italic> and identification of the gene product</article-title><source>J Bacteriol</source><volume>169</volume><issue>12</issue><year>1987</year><fpage>5429</fpage><lpage>5433</lpage><pub-id pub-id-type="pmid">3316184</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>R.</given-names></name><name><surname>Embden</surname><given-names>JDv</given-names></name><name><surname>Gaastra</surname><given-names>W.</given-names></name><name><surname>Schouls</surname><given-names>L.M.</given-names></name></person-group><article-title>Identification of genes that are associated with DNA repeats in prokaryotes</article-title><source>Mol Microbiol</source><volume>43</volume><issue>6</issue><year>2002</year><fpage>1565</fpage><lpage>1575</lpage><pub-id pub-id-type="pmid">11952905</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Barrangou</surname><given-names>R.</given-names></name><name><surname>Fremaux</surname><given-names>C.</given-names></name><name><surname>Deveau</surname><given-names>H.</given-names></name><name><surname>Richards</surname><given-names>M.</given-names></name><name><surname>Boyaval</surname><given-names>P.</given-names></name><name><surname>Moineau</surname><given-names>S.</given-names></name></person-group><article-title>CRISPR provides acquired resistance against viruses in prokaryotes</article-title><source>Science</source><volume>315</volume><issue>5819</issue><year>2007</year><fpage>1709</fpage><lpage>1712</lpage><pub-id pub-id-type="pmid">17379808</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Garneau</surname><given-names>J.E.</given-names></name><name><surname>Dupuis</surname><given-names>M.E.</given-names></name><name><surname>Villion</surname><given-names>M.</given-names></name><name><surname>Romero</surname><given-names>D.A.</given-names></name><name><surname>Barrangou</surname><given-names>R.</given-names></name><name><surname>Boyaval</surname><given-names>P.</given-names></name></person-group><article-title>The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA</article-title><source>Nature</source><volume>468</volume><issue>7320</issue><year>2010</year><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">21048762</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Deltcheva</surname><given-names>E.</given-names></name><name><surname>Chylinski</surname><given-names>K.</given-names></name><name><surname>Sharma</surname><given-names>C.M.</given-names></name><name><surname>Gonzales</surname><given-names>K.</given-names></name><name><surname>Chao</surname><given-names>Y.</given-names></name><name><surname>Pirzada</surname><given-names>Z.A.</given-names></name></person-group><article-title>CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III</article-title><source>Nature</source><volume>471</volume><issue>7340</issue><year>2011</year><fpage>602</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">21455174</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Jinek</surname><given-names>M.</given-names></name><name><surname>Chylinski</surname><given-names>K.</given-names></name><name><surname>Fonfara</surname><given-names>I.</given-names></name><name><surname>Hauer</surname><given-names>M.</given-names></name><name><surname>Doudna</surname><given-names>J.A.</given-names></name><name><surname>Charpentier</surname><given-names>E.</given-names></name></person-group><article-title>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity</article-title><source>Science</source><volume>337</volume><issue>6096</issue><year>2012</year><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">22745249</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Gasiunas</surname><given-names>G.</given-names></name><name><surname>Barrangou</surname><given-names>R.</given-names></name><name><surname>Horvath</surname><given-names>P.</given-names></name><name><surname>Siksnys</surname><given-names>V.</given-names></name></person-group><article-title>Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria</article-title><source>Proc Natl Acad Sci U S A</source><volume>109</volume><issue>39</issue><year>2012</year><fpage>E2579</fpage><lpage>E2586</lpage><pub-id pub-id-type="pmid">22949671</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>L.</given-names></name><name><surname>Ran</surname><given-names>F.A.</given-names></name><name><surname>Cox</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Barretto</surname><given-names>R.</given-names></name><name><surname>Habib</surname><given-names>N.</given-names></name></person-group><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><issue>6121</issue><year>2013</year><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Mali</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Esvelt</surname><given-names>K.M.</given-names></name><name><surname>Aach</surname><given-names>J.</given-names></name><name><surname>Guell</surname><given-names>M.</given-names></name><name><surname>DiCarlo</surname><given-names>J.E.</given-names></name></person-group><article-title>RNA-guided human genome engineering via Cas9</article-title><source>Science</source><volume>339</volume><issue>6121</issue><year>2013</year><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">23287722</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Mougiakos</surname><given-names>I.</given-names></name><name><surname>Bosma</surname><given-names>E.F.</given-names></name><name><surname>Ganguly</surname><given-names>J.</given-names></name><name><surname>van der Oost</surname><given-names>J.</given-names></name><name><surname>van Kranenburg</surname><given-names>R.</given-names></name></person-group><article-title>Hijacking CRISPR-Cas for high-throughput bacterial metabolic engineering: advances and prospects</article-title><source>Curr Opin Biotechnol</source><volume>50</volume><year>2018</year><fpage>146</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">29414054</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Jakociunas</surname><given-names>T.</given-names></name><name><surname>Jensen</surname><given-names>M.K.</given-names></name><name><surname>Keasling</surname><given-names>J.D.</given-names></name></person-group><article-title>CRISPR/Cas9 advances engineering of microbial cell factories</article-title><source>Metab Eng</source><volume>34</volume><year>2016</year><fpage>44</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">26707540</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>K.S.</given-names></name><name><surname>Wolf</surname><given-names>Y.I.</given-names></name><name><surname>Alkhnbashi</surname><given-names>O.S.</given-names></name><name><surname>Costa</surname><given-names>F.</given-names></name><name><surname>Shah</surname><given-names>S.A.</given-names></name><name><surname>Saunders</surname><given-names>S.J.</given-names></name></person-group><article-title>An updated evolutionary classification of CRISPR&#x02013;Cas systems</article-title><source>Nat Rev Microbiol</source><volume>13</volume><issue>11</issue><year>2015</year><fpage>722</fpage><pub-id pub-id-type="pmid">26411297</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Shmakov</surname><given-names>S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Makarova</surname><given-names>K.S.</given-names></name><name><surname>Wolf</surname><given-names>Y.I.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Semenova</surname><given-names>E.</given-names></name></person-group><article-title>Discovery and functional characterization of diverse class 2 CRISPR-Cas systems</article-title><source>Mol Cell</source><volume>60</volume><issue>3</issue><year>2015</year><fpage>385</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">26593719</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Smargon</surname><given-names>A.A.</given-names></name><name><surname>Cox</surname><given-names>D.B.</given-names></name><name><surname>Pyzocha</surname><given-names>N.K.</given-names></name><name><surname>Zheng</surname><given-names>K.</given-names></name><name><surname>Slaymaker</surname><given-names>I.M.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name></person-group><article-title>Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28</article-title><source>Mol Cell</source><volume>65</volume><issue>4</issue><year>2017</year><fpage>618</fpage><lpage>630 e7</lpage><pub-id pub-id-type="pmid">28065598</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Koonin</surname><given-names>E.V.</given-names></name><name><surname>Makarova</surname><given-names>K.S.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Diversity, classification and evolution of CRISPR-Cas systems</article-title><source>Curr Opin Microbiol</source><volume>37</volume><year>2017</year><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">28605718</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Zetsche</surname><given-names>B.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Slaymaker</surname><given-names>I.M.</given-names></name><name><surname>Makarova</surname><given-names>K.S.</given-names></name><name><surname>Essletzbichler</surname><given-names>P.</given-names></name></person-group><article-title>Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system</article-title><source>Cell</source><volume>163</volume><issue>3</issue><year>2015</year><fpage>759</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">26422227</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>Z.</given-names></name><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>N.</given-names></name></person-group><article-title>Homology-integrated CRISPR-Cas (HI-CRISPR) system for one-step multigene disruption in Saccharomyces cerevisiae</article-title><source>ACS Synth Biol</source><volume>4</volume><issue>5</issue><year>2015</year><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">25207793</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Cobb</surname><given-names>R.E.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name></person-group><article-title>High-efficiency multiplex genome editing of Streptomyces species using an engineered CRISPR/Cas system</article-title><source>ACS Synth Biol</source><volume>4</volume><issue>6</issue><year>2015</year><fpage>723</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">25458909</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.L.</given-names></name><name><surname>Fujimoto</surname><given-names>N.</given-names></name><name><surname>Sasakawa</surname><given-names>N.</given-names></name><name><surname>Shirai</surname><given-names>S.</given-names></name><name><surname>Ohkame</surname><given-names>T.</given-names></name><name><surname>Sakuma</surname><given-names>T.</given-names></name></person-group><article-title>Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9</article-title><source>Stem Cell Rep</source><volume>4</volume><issue>1</issue><year>2015</year><fpage>143</fpage><lpage>154</lpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>C.R.</given-names></name><name><surname>Huang</surname><given-names>C.H.</given-names></name><name><surname>Sung</surname><given-names>L.Y.</given-names></name><name><surname>Wu</surname><given-names>M.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.C.</given-names></name></person-group><article-title>CRISPR-Cas9 for the genome engineering of cyanobacteria and succinate production</article-title><source>Metab Eng</source><volume>38</volume><year>2016</year><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">27693320</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J.S.</given-names></name><name><surname>Choi</surname><given-names>K.R.</given-names></name><name><surname>Prabowo</surname><given-names>C.P.S.</given-names></name><name><surname>Shin</surname><given-names>J.H.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Jang</surname><given-names>J.</given-names></name></person-group><article-title>CRISPR/Cas9-coupled recombineering for metabolic engineering of Corynebacterium glutamicum</article-title><source>Metab Eng</source><volume>42</volume><year>2017</year><fpage>157</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">28649005</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>K.</given-names></name></person-group><article-title>Engineering introns to express RNA guides for Cas9- and Cpf1-mediated multiplex genome editing</article-title><source>Mol Plant</source><volume>11</volume><issue>4</issue><year>2018</year><fpage>542</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">29462720</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Verwaal</surname><given-names>R.</given-names></name><name><surname>Buiting-Wiessenhaan</surname><given-names>N.</given-names></name><name><surname>Dalhuijsen</surname><given-names>S.</given-names></name><name><surname>Roubos</surname><given-names>J.A.</given-names></name></person-group><article-title>CRISPR/Cpf1 enables fast and simple genome editing of Saccharomyces cerevisiae</article-title><source>Yeast</source><volume>35</volume><issue>2</issue><year>2018</year><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">28886218</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Lamas</surname><given-names>V.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Yeh</surname><given-names>W.H.</given-names></name><name><surname>Pan</surname><given-names>B.</given-names></name></person-group><article-title>Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents</article-title><source>Nature</source><volume>553</volume><issue>7687</issue><year>2018</year><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">29258297</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Nishimasu</surname><given-names>H.</given-names></name><name><surname>Ran</surname><given-names>F.A.</given-names></name><name><surname>Hsu</surname><given-names>P.D.</given-names></name><name><surname>Konermann</surname><given-names>S.</given-names></name><name><surname>Shehata</surname><given-names>S.I.</given-names></name><name><surname>Dohmae</surname><given-names>N.</given-names></name></person-group><article-title>Crystal structure of Cas9 in complex with guide RNA and target DNA</article-title><source>Cell</source><volume>156</volume><issue>5</issue><year>2014</year><fpage>935</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">24529477</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Yamano</surname><given-names>T.</given-names></name><name><surname>Nishimasu</surname><given-names>H.</given-names></name><name><surname>Zetsche</surname><given-names>B.</given-names></name><name><surname>Hirano</surname><given-names>H.</given-names></name><name><surname>Slaymaker</surname><given-names>I.M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Crystal structure of Cpf1 in complex with guide RNA and target DNA</article-title><source>Cell</source><volume>165</volume><issue>4</issue><year>2016</year><fpage>949</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">27114038</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Foden</surname><given-names>J.A.</given-names></name><name><surname>Khayter</surname><given-names>C.</given-names></name><name><surname>Maeder</surname><given-names>M.L.</given-names></name><name><surname>Reyon</surname><given-names>D.</given-names></name><name><surname>Joung</surname><given-names>J.K.</given-names></name></person-group><article-title>High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells</article-title><source>Nat Biotechnol</source><volume>31</volume><issue>9</issue><year>2013</year><fpage>822</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">23792628</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Sander</surname><given-names>J.D.</given-names></name><name><surname>Reyon</surname><given-names>D.</given-names></name><name><surname>Cascio</surname><given-names>V.M.</given-names></name><name><surname>Joung</surname><given-names>J.K.</given-names></name></person-group><article-title>Improving CRISPR-Cas nuclease specificity using truncated guide RNAs</article-title><source>Nat Biotechnol</source><volume>32</volume><issue>3</issue><year>2014</year><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">24463574</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Guilinger</surname><given-names>J.P.</given-names></name><name><surname>Thompson</surname><given-names>D.B.</given-names></name><name><surname>Liu</surname><given-names>D.R.</given-names></name></person-group><article-title>Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification</article-title><source>Nat Biotechnol</source><volume>32</volume><issue>6</issue><year>2014</year><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">24770324</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>K.M.</given-names></name><name><surname>Pattanayak</surname><given-names>V.</given-names></name><name><surname>Thompson</surname><given-names>D.B.</given-names></name><name><surname>Zuris</surname><given-names>J.A.</given-names></name><name><surname>Liu</surname><given-names>D.R.</given-names></name></person-group><article-title>Small molecule-triggered Cas9 protein with improved genome-editing specificity</article-title><source>Nat Chem Biol</source><volume>11</volume><issue>5</issue><year>2015</year><fpage>316</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">25848930</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Kaneko</surname><given-names>T.</given-names></name><name><surname>Cheng</surname><given-names>K.</given-names></name></person-group><article-title>Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder</article-title><source>Nat Chem Biol</source><volume>12</volume><issue>11</issue><year>2016</year><fpage>959</fpage><lpage>966</lpage><pub-id pub-id-type="pmid">27642862</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>D.P.</given-names></name><name><surname>Miyaoka</surname><given-names>Y.</given-names></name><name><surname>Gilbert</surname><given-names>L.A.</given-names></name><name><surname>Mayerl</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>B.H.</given-names></name><name><surname>Weissman</surname><given-names>J.S.</given-names></name></person-group><article-title>Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity</article-title><source>Nat Commun</source><volume>7</volume><year>2016</year><fpage>12009</fpage><pub-id pub-id-type="pmid">27363581</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Truong</surname><given-names>D.J.</given-names></name><name><surname>Kuhner</surname><given-names>K.</given-names></name><name><surname>Kuhn</surname><given-names>R.</given-names></name><name><surname>Werfel</surname><given-names>S.</given-names></name><name><surname>Engelhardt</surname><given-names>S.</given-names></name><name><surname>Wurst</surname><given-names>W.</given-names></name></person-group><article-title>Development of an intein-mediated split-Cas9 system for gene therapy</article-title><source>Nucleic Acids Res</source><volume>43</volume><issue>13</issue><year>2015</year><fpage>6450</fpage><lpage>6458</lpage><pub-id pub-id-type="pmid">26082496</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Rouet</surname><given-names>R.</given-names></name><name><surname>Thuma</surname><given-names>B.A.</given-names></name><name><surname>Roy</surname><given-names>M.D.</given-names></name><name><surname>Lintner</surname><given-names>N.G.</given-names></name><name><surname>Rubitski</surname><given-names>D.M.</given-names></name><name><surname>Finley</surname><given-names>J.E.</given-names></name></person-group><article-title>Receptor-mediated delivery of CRISPR-Cas9 endonuclease for cell-type-specific gene editing</article-title><source>J Am Chem Soc</source><volume>140</volume><issue>21</issue><year>2018</year><fpage>6596</fpage><lpage>6603</lpage><pub-id pub-id-type="pmid">29668265</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>L.S.</given-names></name><name><surname>Larson</surname><given-names>M.H.</given-names></name><name><surname>Gilbert</surname><given-names>L.A.</given-names></name><name><surname>Doudna</surname><given-names>J.A.</given-names></name><name><surname>Weissman</surname><given-names>J.S.</given-names></name><name><surname>Arkin</surname><given-names>A.P.</given-names></name></person-group><article-title>Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression</article-title><source>Cell</source><volume>152</volume><issue>5</issue><year>2013</year><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">23452860</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Ran</surname><given-names>Y.</given-names></name></person-group><article-title>Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion</article-title><source>Nat Biotechnol</source><volume>35</volume><issue>5</issue><year>2017</year><fpage>438</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">28244994</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>L.A.</given-names></name><name><surname>Larson</surname><given-names>M.H.</given-names></name><name><surname>Morsut</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Brar</surname><given-names>G.A.</given-names></name><name><surname>Torres</surname><given-names>S.E.</given-names></name></person-group><article-title>CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes</article-title><source>Cell</source><volume>154</volume><issue>2</issue><year>2013</year><fpage>442</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">23849981</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Lowder</surname><given-names>L.G.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Malzahn</surname><given-names>A.A.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Voytas</surname><given-names>D.F.</given-names></name></person-group><article-title>A CRISPR-Cpf1 system for efficient genome editing and transcriptional repression in plants</article-title><source>Nat Plants</source><volume>3</volume><year>2017</year><fpage>17018</fpage><pub-id pub-id-type="pmid">28211909</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>J.</given-names></name><name><surname>HamediRad</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name></person-group><article-title>Combinatorial metabolic engineering using an orthogonal tri-functional CRISPR system</article-title><source>Nat Commun</source><volume>8</volume><issue>1</issue><year>2017</year><fpage>1688</fpage><pub-id pub-id-type="pmid">29167442</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Essletzbichler</surname><given-names>P.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name><name><surname>Belanto</surname><given-names>J.J.</given-names></name></person-group><article-title>RNA targeting with CRISPR-Cas13</article-title><source>Nature</source><volume>550</volume><issue>7675</issue><year>2017</year><fpage>280</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">28976959</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Konermann</surname><given-names>S.</given-names></name><name><surname>Lotfy</surname><given-names>P.</given-names></name><name><surname>Brideau</surname><given-names>N.J.</given-names></name><name><surname>Oki</surname><given-names>J.</given-names></name><name><surname>Shokhirev</surname><given-names>M.N.</given-names></name><name><surname>Hsu</surname><given-names>P.D.</given-names></name></person-group><article-title>Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors</article-title><source>Cell</source><volume>173</volume><issue>3</issue><year>2018</year><fpage>665</fpage><lpage>676</lpage><comment>e14</comment><pub-id pub-id-type="pmid">29551272</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Fontana</surname><given-names>J.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Carothers</surname><given-names>J.M.</given-names></name><name><surname>Zalatan</surname><given-names>J.G.</given-names></name></person-group><article-title>Synthetic CRISPR-Cas gene activators for transcriptional reprogramming in bacteria</article-title><source>Nat Commun</source><volume>9</volume><issue>1</issue><year>2018</year><fpage>2489</fpage><pub-id pub-id-type="pmid">29950558</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Nozaki</surname><given-names>T.</given-names></name><name><surname>Imai</surname><given-names>R.</given-names></name><name><surname>Tanbo</surname><given-names>M.</given-names></name><name><surname>Nagashima</surname><given-names>R.</given-names></name><name><surname>Tamura</surname><given-names>S.</given-names></name><name><surname>Tani</surname><given-names>T.</given-names></name></person-group><article-title>Dynamic organization of chromatin domains revealed by super-resolution live-cell imaging</article-title><source>Mol Cell</source><volume>67</volume><issue>2</issue><year>2017</year><fpage>282</fpage><lpage>293 e7</lpage><pub-id pub-id-type="pmid">28712725</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Gerlich</surname><given-names>D.</given-names></name><name><surname>Koch</surname><given-names>B.</given-names></name><name><surname>Dupeux</surname><given-names>F.</given-names></name><name><surname>Peters</surname><given-names>J.M.</given-names></name><name><surname>Ellenberg</surname><given-names>J.</given-names></name></person-group><article-title>Live-cell imaging reveals a stable cohesin-chromatin interaction after but not before DNA replication</article-title><source>Curr Biol</source><volume>16</volume><issue>15</issue><year>2006</year><fpage>1571</fpage><lpage>1578</lpage><pub-id pub-id-type="pmid">16890534</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shyy</surname><given-names>J.Y.</given-names></name><name><surname>Chien</surname><given-names>S.</given-names></name></person-group><article-title>Fluorescence proteins, live-cell imaging, and mechanobiology: seeing is believing</article-title><source>Annu Rev Biomed Eng</source><volume>10</volume><year>2008</year><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">18647110</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>E.</given-names></name><name><surname>Blow</surname><given-names>J.J.</given-names></name><name><surname>Tanaka</surname><given-names>T.U.</given-names></name></person-group><article-title>Live-cell imaging reveals replication of individual replicons in eukaryotic replication factories</article-title><source>Cell</source><volume>125</volume><issue>7</issue><year>2006</year><fpage>1297</fpage><lpage>1308</lpage><pub-id pub-id-type="pmid">16814716</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>S.C.</given-names></name><name><surname>Tjian</surname><given-names>R.</given-names></name><name><surname>Doudna</surname><given-names>J.A.</given-names></name></person-group><article-title>Genomes in focus: development and applications of CRISPR-Cas9 imaging technologies</article-title><source>Angew Chem Int Ed Engl</source><volume>57</volume><issue>16</issue><year>2018</year><fpage>4329</fpage><lpage>4337</lpage><pub-id pub-id-type="pmid">29080263</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Gilbert</surname><given-names>L.A.</given-names></name><name><surname>Cimini</surname><given-names>B.A.</given-names></name><name><surname>Schnitzbauer</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>G.W.</given-names></name></person-group><article-title>Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system</article-title><source>Cell</source><volume>155</volume><issue>7</issue><year>2013</year><fpage>1479</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">24360272</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>X.L.</given-names></name><name><surname>Xi</surname><given-names>H.T.</given-names></name><name><surname>Yang</surname><given-names>F.Y.</given-names></name><name><surname>Zhi</surname><given-names>X.</given-names></name><name><surname>Fu</surname><given-names>Y.H.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name></person-group><article-title>CRISPR/Cas9-AAV mediated knock-in at NRL locus in human embryonic stem cells</article-title><source>Mol Ther Nucleic Acids</source><volume>5</volume><year>2016</year></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Rocha</surname><given-names>P.P.</given-names></name><name><surname>Luo</surname><given-names>V.M.</given-names></name><name><surname>Raviram</surname><given-names>R.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Mazzoni</surname><given-names>E.O.</given-names></name></person-group><article-title>CRISPR-dCas9 and sgRNA scaffolds enable dual-colour live imaging of satellite sequences and repeat-enriched individual loci</article-title><source>Nat Commun</source><volume>7</volume><year>2016</year><fpage>11707</fpage><pub-id pub-id-type="pmid">27222091</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>P.</given-names></name><name><surname>Parlak</surname><given-names>M.</given-names></name><name><surname>Kuscu</surname><given-names>C.</given-names></name><name><surname>Bandaria</surname><given-names>J.</given-names></name><name><surname>Mir</surname><given-names>M.</given-names></name><name><surname>Szlachta</surname><given-names>K.</given-names></name></person-group><article-title>Live cell imaging of low- and non-repetitive chromosome loci using CRISPR-Cas9</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><fpage>14725</fpage><pub-id pub-id-type="pmid">28290446</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Naseri</surname><given-names>A.</given-names></name><name><surname>Reyes-Gutierrez</surname><given-names>P.</given-names></name><name><surname>Wolfe</surname><given-names>S.A.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Pederson</surname><given-names>T.</given-names></name></person-group><article-title>Multicolor CRISPR labeling of chromosomal loci in human cells</article-title><source>Proc Natl Acad Sci U S A</source><volume>112</volume><issue>10</issue><year>2015</year><fpage>3002</fpage><lpage>3007</lpage><pub-id pub-id-type="pmid">25713381</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name></person-group><article-title>Tracking multiple genomic elements using correlative CRISPR imaging and sequential DNA FISH</article-title><source>Biophys J</source><volume>112</volume><issue>6</issue><year>2017</year><fpage>1077</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">28355536</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>Y.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Harvey</surname><given-names>S.</given-names></name><name><surname>Qi</surname><given-names>L.S.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name></person-group><article-title>Multiplexed dynamic imaging of genomic loci by combined CRISPR imaging and DNA sequential FISH</article-title><source>Biophys J</source><volume>112</volume><issue>9</issue><year>2017</year><fpage>1773</fpage><lpage>1776</lpage><pub-id pub-id-type="pmid">28427715</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yin</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Chang</surname><given-names>X.</given-names></name></person-group><article-title>Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells</article-title><source>Nat Methods</source><volume>13</volume><issue>12</issue><year>2016</year><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">27723754</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>G.T.</given-names></name><name><surname>Tycko</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>D.</given-names></name><name><surname>Bassik</surname><given-names>M.C.</given-names></name></person-group><article-title>Methods and applications of CRISPR-mediated base editing in eukaryotic genomes</article-title><source>Mol Cell</source><volume>68</volume><issue>1</issue><year>2017</year><fpage>26</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">28985508</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Satomura</surname><given-names>A.</given-names></name><name><surname>Nishioka</surname><given-names>R.</given-names></name><name><surname>Mori</surname><given-names>H.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Kuroda</surname><given-names>K.</given-names></name><name><surname>Ueda</surname><given-names>M.</given-names></name></person-group><article-title>Precise genome-wide base editing by the CRISPR Nickase system in yeast</article-title><source>Sci Rep</source><volume>7</volume><issue>1</issue><year>2017</year><fpage>2095</fpage><pub-id pub-id-type="pmid">28522803</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Banno</surname><given-names>S.</given-names></name><name><surname>Nishida</surname><given-names>K.</given-names></name><name><surname>Arazoe</surname><given-names>T.</given-names></name><name><surname>Mitsunobu</surname><given-names>H.</given-names></name><name><surname>Kondo</surname><given-names>A.</given-names></name></person-group><article-title>Deaminase-mediated multiplex genome editing in Escherichia coli</article-title><source>Nat Microbiol</source><volume>3</volume><issue>4</issue><year>2018</year><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">29403014</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.B.</given-names></name><name><surname>Komor</surname><given-names>A.C.</given-names></name><name><surname>Levy</surname><given-names>J.M.</given-names></name><name><surname>Packer</surname><given-names>M.S.</given-names></name><name><surname>Zhao</surname><given-names>K.T.</given-names></name><name><surname>Liu</surname><given-names>D.R.</given-names></name></person-group><article-title>Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions</article-title><source>Nat Biotechnol</source><volume>35</volume><issue>4</issue><year>2017</year><fpage>371</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">28191901</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>R.S.</given-names></name><name><surname>Chavez</surname><given-names>A.</given-names></name><name><surname>Porter</surname><given-names>C.B.M.</given-names></name><name><surname>Hamblin</surname><given-names>M.</given-names></name><name><surname>Kaas</surname><given-names>C.S.</given-names></name><name><surname>DiCarlo</surname><given-names>J.E.</given-names></name></person-group><article-title>A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in Candida albicans</article-title><source>Nat Microbiol</source><volume>3</volume><issue>1</issue><year>2018</year><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">29062088</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>F.</given-names></name><name><surname>Kuang</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name></person-group><article-title>Highly efficient A.T to G.C base editing by Cas9n-guided tRNA adenosine deaminase in rice</article-title><source>Mol Plant</source><volume>11</volume><issue>4</issue><year>2018</year><fpage>631</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">29476918</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name></person-group><article-title>Base editing with a Cpf1-cytidine deaminase fusion</article-title><source>Nat Biotechnol</source><volume>36</volume><issue>4</issue><year>2018</year><fpage>324</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">29553573</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Komor</surname><given-names>A.C.</given-names></name><name><surname>Kim</surname><given-names>Y.B.</given-names></name><name><surname>Packer</surname><given-names>M.S.</given-names></name><name><surname>Zuris</surname><given-names>J.A.</given-names></name><name><surname>Liu</surname><given-names>D.R.</given-names></name></person-group><article-title>Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage</article-title><source>Nature</source><volume>533</volume><issue>7603</issue><year>2016</year><fpage>420</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">27096365</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Gaudelli</surname><given-names>N.M.</given-names></name><name><surname>Komor</surname><given-names>A.C.</given-names></name><name><surname>Rees</surname><given-names>H.A.</given-names></name><name><surname>Packer</surname><given-names>M.S.</given-names></name><name><surname>Badran</surname><given-names>A.H.</given-names></name><name><surname>Bryson</surname><given-names>D.I.</given-names></name></person-group><article-title>Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage</article-title><source>Nature</source><volume>551</volume><issue>7681</issue><year>2017</year><fpage>464</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">29160308</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>K.</given-names></name><name><surname>Arazoe</surname><given-names>T.</given-names></name><name><surname>Yachie</surname><given-names>N.</given-names></name><name><surname>Banno</surname><given-names>S.</given-names></name><name><surname>Kakimoto</surname><given-names>M.</given-names></name><name><surname>Tabata</surname><given-names>M.</given-names></name></person-group><article-title>Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems</article-title><source>Science</source><volume>353</volume><issue>6305</issue><year>2016</year></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Lei</surname><given-names>H.</given-names></name></person-group><article-title>Progress in the application of CRISPR: from gene to base editing</article-title><source>Med Res Rev</source><year>2018</year><fpage>1</fpage><lpage>19</lpage></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>A.</given-names></name><name><surname>Alshareef</surname><given-names>S.</given-names></name><name><surname>Mahfouz</surname><given-names>M.M.</given-names></name></person-group><article-title>CRISPR base editors: genome editing without double-stranded breaks</article-title><source>Biochem J</source><volume>475</volume><issue>11</issue><year>2018</year><fpage>1955</fpage><lpage>1964</lpage><pub-id pub-id-type="pmid">29891532</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>H.A.</given-names></name><name><surname>Komor</surname><given-names>A.C.</given-names></name><name><surname>Yeh</surname><given-names>W.H.</given-names></name><name><surname>Caetano-Lopes</surname><given-names>J.</given-names></name><name><surname>Warman</surname><given-names>M.</given-names></name><name><surname>Edge</surname><given-names>A.S.B.</given-names></name></person-group><article-title>Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><fpage>15790</fpage><pub-id pub-id-type="pmid">28585549</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Komor</surname><given-names>A.C.</given-names></name><name><surname>Zhao</surname><given-names>K.T.</given-names></name><name><surname>Packer</surname><given-names>M.S.</given-names></name><name><surname>Gaudelli</surname><given-names>N.M.</given-names></name><name><surname>Waterbury</surname><given-names>A.L.</given-names></name><name><surname>Koblan</surname><given-names>L.W.</given-names></name></person-group><article-title>Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity</article-title><source>Sci Adv</source><volume>3</volume><issue>8</issue><year>2017</year><object-id pub-id-type="publisher-id">eaao4774</object-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name></person-group><article-title>Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor</article-title><source>Cell Res</source><volume>27</volume><issue>10</issue><year>2017</year><fpage>1289</fpage><lpage>1292</lpage><pub-id pub-id-type="pmid">28849781</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Gehrke</surname><given-names>J.M.</given-names></name><name><surname>Cervantes</surname><given-names>O.</given-names></name><name><surname>Clement</surname><given-names>M.K.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name><name><surname>Bauer</surname><given-names>D.E.</given-names></name></person-group><article-title>An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities</article-title><source>Nat Biotechnol</source><volume>36</volume><issue>10</issue><year>2018</year><fpage>977</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">30059493</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Zafra</surname><given-names>M.P.</given-names></name><name><surname>Schatoff</surname><given-names>E.M.</given-names></name><name><surname>Katti</surname><given-names>A.</given-names></name><name><surname>Foronda</surname><given-names>M.</given-names></name><name><surname>Breinig</surname><given-names>M.</given-names></name><name><surname>Schweitzer</surname><given-names>A.Y.</given-names></name></person-group><article-title>Optimized base editors enable efficient editing in cells, organoids and mice</article-title><source>Nat Biotechnol</source><volume>36</volume><issue>9</issue><year>2018</year><fpage>888</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">29969439</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>BE-PLUS: a new base editing tool with broadened editing window and enhanced fidelity</article-title><source>Cell Res</source><volume>28</volume><year>2018</year><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">29875396</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.H.</given-names></name><name><surname>Miller</surname><given-names>S.M.</given-names></name><name><surname>Geurts</surname><given-names>M.H.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>N.</given-names></name></person-group><article-title>Evolved Cas9 variants with broad PAM compatibility and high DNA specificity</article-title><source>Nature</source><volume>556</volume><issue>7699</issue><year>2018</year><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">29512652</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Efficient base editing in methylated regions with a human APOBEC3A-Cas9 fusion</article-title><source>Nat Biotechnol</source><volume>36</volume><issue>10</issue><year>2018</year><fpage>946</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">30125268</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name></person-group><article-title>Generation of targeted point mutations in rice by a modified CRISPR/Cas9 system</article-title><source>Mol Plant</source><volume>10</volume><issue>3</issue><year>2017</year><fpage>526</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">27940306</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>J.K.</given-names></name></person-group><article-title>Precise editing of a target base in the rice genome using a modified CRISPR/Cas9 system</article-title><source>Mol Plant</source><volume>10</volume><issue>3</issue><year>2017</year><fpage>523</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">27932049</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Shimatani</surname><given-names>Z.</given-names></name><name><surname>Kashojiya</surname><given-names>S.</given-names></name><name><surname>Takayama</surname><given-names>M.</given-names></name><name><surname>Terada</surname><given-names>R.</given-names></name><name><surname>Arazoe</surname><given-names>T.</given-names></name><name><surname>Ishii</surname><given-names>H.</given-names></name></person-group><article-title>Targeted base editing in rice and tomato using a CRISPR-Cas9 cytidine deaminase fusion</article-title><source>Nat Biotechnol</source><volume>35</volume><issue>5</issue><year>2017</year><fpage>441</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">28346401</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>K.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>J.K.</given-names></name></person-group><article-title>Precise A.T to G.C base editing in the rice genome</article-title><source>Mol Plant</source><volume>11</volume><issue>4</issue><year>2018</year><fpage>627</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">29476916</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>L.</given-names></name><name><surname>Ni</surname><given-names>X.</given-names></name></person-group><article-title>MACBETH: multiplex automated Corynebacterium glutamicum base editing method</article-title><source>Metab Eng</source><volume>47</volume><year>2018</year><fpage>200</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">29580925</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xin</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name></person-group><article-title>Highly efficient and precise base editing by engineered dCas9-guide tRNA adenosine deaminase in rats</article-title><source>Cell Discov</source><volume>4</volume><year>2018</year><fpage>39</fpage><pub-id pub-id-type="pmid">30038797</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Effective gene editing by high-fidelity base editor 2 in mouse zygotes</article-title><source>Protein Cell</source><volume>8</volume><issue>8</issue><year>2017</year><fpage>601</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">28585179</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Ryu</surname><given-names>S.M.</given-names></name><name><surname>Kim</surname><given-names>S.T.</given-names></name><name><surname>Baek</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Lim</surname><given-names>K.</given-names></name></person-group><article-title>Highly efficient RNA-guided base editing in mouse embryos</article-title><source>Nat Biotechnol</source><volume>35</volume><issue>5</issue><year>2017</year><fpage>435</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">28244995</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>P.</given-names></name><name><surname>Ding</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Correction of beta-thalassemia mutant by base editor in human embryos</article-title><source>Protein Cell</source><volume>8</volume><issue>11</issue><year>2017</year><fpage>811</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">28942539</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>D.B.T.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Franklin</surname><given-names>B.</given-names></name><name><surname>Kellner</surname><given-names>M.J.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name></person-group><article-title>RNA editing with CRISPR-Cas13</article-title><source>Science</source><volume>358</volume><issue>6366</issue><year>2017</year><fpage>1019</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">29070703</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>H.</given-names></name></person-group><article-title>Implementation of the CRISPR-Cas13a system in fission yeast and its repurposing for precise RNA editing</article-title><source>Nucleic Acids Res</source><volume>46</volume><issue>15</issue><year>2018</year><fpage>e90</fpage><pub-id pub-id-type="pmid">29860393</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>A.D.</given-names></name><name><surname>Allis</surname><given-names>C.D.</given-names></name><name><surname>Bernstein</surname><given-names>E.</given-names></name></person-group><article-title>Epigenetics: a landscape takes shape</article-title><source>Cell</source><volume>128</volume><issue>4</issue><year>2007</year><fpage>635</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">17320500</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Jaenisch</surname><given-names>R.</given-names></name><name><surname>Bird</surname><given-names>A.</given-names></name></person-group><article-title>Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals</article-title><source>Nat Genet</source><volume>33</volume><issue>Suppl</issue><year>2003</year><fpage>245</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">12610534</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Kungulovski</surname><given-names>G.</given-names></name><name><surname>Jeltsch</surname><given-names>A.</given-names></name></person-group><article-title>Epigenome editing: state of the art, concepts, and perspectives</article-title><source>Trends Genet</source><volume>32</volume><issue>2</issue><year>2016</year><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">26732754</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Willyard</surname><given-names>C.</given-names></name></person-group><article-title>The epigenome editors: how tools such as CRISPR offer new details about epigenetics</article-title><source>Nat Med</source><volume>23</volume><issue>8</issue><year>2017</year><fpage>900</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">28777784</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Laufer</surname><given-names>B.I.</given-names></name><name><surname>Singh</surname><given-names>S.M.</given-names></name></person-group><article-title>Strategies for precision modulation of gene expression by epigenome editing: an overview</article-title><source>Epigenet Chromatin</source><volume>8</volume><year>2015</year><fpage>34</fpage></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Johnson</surname><given-names>J.</given-names></name><name><surname>St John</surname><given-names>J.C.</given-names></name></person-group><article-title>Global DNA methylation synergistically regulates the nuclear and mitochondrial genomes in glioblastoma cells</article-title><source>Nucleic Acids Res</source><volume>46</volume><issue>12</issue><year>2018</year><fpage>5977</fpage><lpage>5995</lpage><pub-id pub-id-type="pmid">29722878</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.S.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Krzisch</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Graef</surname><given-names>J.</given-names></name><name><surname>Muffat</surname><given-names>J.</given-names></name></person-group><article-title>Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene</article-title><source>Cell</source><volume>172</volume><issue>5</issue><year>2018</year><fpage>979</fpage><lpage>992 e6</lpage><pub-id pub-id-type="pmid">29456084</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>J.I.</given-names></name><name><surname>Celik</surname><given-names>H.</given-names></name><name><surname>Rois</surname><given-names>L.E.</given-names></name><name><surname>Fishberger</surname><given-names>G.</given-names></name><name><surname>Fowler</surname><given-names>T.</given-names></name><name><surname>Rees</surname><given-names>R.</given-names></name></person-group><article-title>Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation</article-title><source>Biol Open</source><volume>5</volume><issue>6</issue><year>2016</year><fpage>866</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">27170255</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Vojta</surname><given-names>A.</given-names></name><name><surname>Dobrinic</surname><given-names>P.</given-names></name><name><surname>Tadic</surname><given-names>V.</given-names></name><name><surname>Bockor</surname><given-names>L.</given-names></name><name><surname>Korac</surname><given-names>P.</given-names></name><name><surname>Julg</surname><given-names>B.</given-names></name></person-group><article-title>Repurposing the CRISPR-Cas9 system for targeted DNA methylation</article-title><source>Nucleic Acids Res</source><volume>44</volume><issue>12</issue><year>2016</year><fpage>5615</fpage><lpage>5628</lpage><pub-id pub-id-type="pmid">26969735</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>S.R.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Lubecka</surname><given-names>K.</given-names></name><name><surname>Stefanska</surname><given-names>B.</given-names></name><name><surname>Irudayaraj</surname><given-names>J.</given-names></name></person-group><article-title>CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter</article-title><source>Oncotarget</source><volume>7</volume><issue>29</issue><year>2016</year><fpage>46545</fpage><pub-id pub-id-type="pmid">27356740</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.S.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Ji</surname><given-names>X.</given-names></name><name><surname>Stelzer</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Czauderna</surname><given-names>S.</given-names></name></person-group><article-title>Editing DNA methylation in the mammalian genome</article-title><source>Cell</source><volume>167</volume><issue>1</issue><year>2016</year><fpage>233</fpage><lpage>247</lpage><comment>e17</comment><pub-id pub-id-type="pmid">27662091</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zou</surname><given-names>W.</given-names></name></person-group><article-title>A CRISPR-based approach for targeted DNA demethylation</article-title><source>Cell Discov</source><volume>2</volume><year>2016</year><fpage>16009</fpage><pub-id pub-id-type="pmid">27462456</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Thakore</surname><given-names>P.I.</given-names></name><name><surname>D'Ippolito</surname><given-names>A.M.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Safi</surname><given-names>A.</given-names></name><name><surname>Shivakumar</surname><given-names>N.K.</given-names></name><name><surname>Kabadi</surname><given-names>A.M.</given-names></name></person-group><article-title>Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements</article-title><source>Nat Methods</source><volume>12</volume><issue>12</issue><year>2015</year><fpage>1143</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">26501517</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>O'Geen</surname><given-names>H.</given-names></name><name><surname>Ren</surname><given-names>C.</given-names></name><name><surname>Nicolet</surname><given-names>C.M.</given-names></name><name><surname>Perez</surname><given-names>A.A.</given-names></name><name><surname>Halmai</surname><given-names>J.</given-names></name><name><surname>Le</surname><given-names>V.M.</given-names></name></person-group><article-title>dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression</article-title><source>Nucleic Acids Res</source><volume>45</volume><issue>17</issue><year>2017</year><fpage>9901</fpage><lpage>9916</lpage><pub-id pub-id-type="pmid">28973434</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Kearns</surname><given-names>N.A.</given-names></name><name><surname>Pham</surname><given-names>H.</given-names></name><name><surname>Tabak</surname><given-names>B.</given-names></name><name><surname>Genga</surname><given-names>R.M.</given-names></name><name><surname>Silverstein</surname><given-names>N.J.</given-names></name><name><surname>Garber</surname><given-names>M.</given-names></name></person-group><article-title>Functional annotation of native enhancers with a Cas9-histone demethylase fusion</article-title><source>Nat Methods</source><volume>12</volume><issue>5</issue><year>2015</year><fpage>401</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">25775043</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Shan</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Gene activation in human cells using CRISPR/Cpf1-p300 and CRISPR/Cpf1-SunTag systems</article-title><source>Protein Cell</source><volume>9</volume><issue>4</issue><year>2018</year><fpage>380</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">29164491</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>Hilton</surname><given-names>I.B.</given-names></name><name><surname>D'Ippolito</surname><given-names>A.M.</given-names></name><name><surname>Vockley</surname><given-names>C.M.</given-names></name><name><surname>Thakore</surname><given-names>P.I.</given-names></name><name><surname>Crawford</surname><given-names>G.E.</given-names></name><name><surname>Reddy</surname><given-names>T.E.</given-names></name></person-group><article-title>Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers</article-title><source>Nat Biotechnol</source><volume>33</volume><issue>5</issue><year>2015</year><fpage>510</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">25849900</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>D.Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.T.</given-names></name><name><surname>Lamonica</surname><given-names>J.M.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name></person-group><article-title>Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><fpage>15315</fpage><pub-id pub-id-type="pmid">28497787</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Pardee</surname><given-names>K.</given-names></name><name><surname>Green</surname><given-names>A.A.</given-names></name><name><surname>Takahashi</surname><given-names>M.K.</given-names></name><name><surname>Braff</surname><given-names>D.</given-names></name><name><surname>Lambert</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name></person-group><article-title>Rapid, low-cost detection of Zika virus using programmable biomolecular components</article-title><source>Cell</source><volume>165</volume><issue>5</issue><year>2016</year><fpage>1255</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">27160350</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>East-Seletsky</surname><given-names>A.</given-names></name><name><surname>O'Connell</surname><given-names>M.R.</given-names></name><name><surname>Knight</surname><given-names>S.C.</given-names></name><name><surname>Burstein</surname><given-names>D.</given-names></name><name><surname>Cate</surname><given-names>J.H.</given-names></name><name><surname>Tjian</surname><given-names>R.</given-names></name></person-group><article-title>Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection</article-title><source>Nature</source><volume>538</volume><issue>7624</issue><year>2016</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">27669025</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><name><surname>Essletzbichler</surname><given-names>P.</given-names></name><name><surname>Dy</surname><given-names>A.J.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name></person-group><article-title>Nucleic acid detection with CRISPR-Cas13a/C2c2</article-title><source>Science</source><volume>356</volume><issue>6336</issue><year>2017</year><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">28408723</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="book" id="sref112"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><chapter-title>CRISPR-Cas12b-assisted nucleic acid detection platform</chapter-title><year>2018</year></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.Y.</given-names></name><name><surname>Cheng</surname><given-names>Q.X.</given-names></name><name><surname>Wang</surname><given-names>J.M.</given-names></name><name><surname>Li</surname><given-names>X.Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.L.</given-names></name><name><surname>Gao</surname><given-names>S.</given-names></name></person-group><article-title>CRISPR-Cas12a-assisted nucleic acid detection</article-title><source>Cell Discov</source><volume>4</volume><year>2018</year><fpage>20</fpage><pub-id pub-id-type="pmid">29707234</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.S.</given-names></name><name><surname>Ma</surname><given-names>E.</given-names></name><name><surname>Harrington</surname><given-names>L.B.</given-names></name><name><surname>Da Costa</surname><given-names>M.</given-names></name><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Palefsky</surname><given-names>J.M.</given-names></name></person-group><article-title>CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity</article-title><source>Science</source><volume>360</volume><issue>6387</issue><year>2018</year><fpage>436</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">29449511</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Kellner</surname><given-names>M.J.</given-names></name><name><surname>Joung</surname><given-names>J.</given-names></name><name><surname>Collins</surname><given-names>J.J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6</article-title><source>Science</source><volume>360</volume><issue>6387</issue><year>2018</year><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">29449508</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Myhrvold</surname><given-names>C.</given-names></name><name><surname>Freije</surname><given-names>C.A.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Metsky</surname><given-names>H.C.</given-names></name><name><surname>Durbin</surname><given-names>A.F.</given-names></name></person-group><article-title>Field-deployable viral diagnostics using CRISPR-Cas13</article-title><source>Science</source><volume>360</volume><issue>6387</issue><year>2018</year><fpage>444</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">29700266</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.C.</given-names></name><name><surname>Larionov</surname><given-names>V.</given-names></name><name><surname>Kouprina</surname><given-names>N.</given-names></name></person-group><article-title>Highly efficient CRISPR/Cas9-mediated TAR cloning of genes and chromosomal loci from complex genomes in yeast</article-title><source>Nucleic Acids Res</source><volume>43</volume><issue>8</issue><year>2015</year><fpage>e55</fpage><lpage>e</lpage><pub-id pub-id-type="pmid">25690893</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>S.-Y.</given-names></name><name><surname>Liu</surname><given-names>J.-K.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>G.-P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>The CCTL (Cpf1-assisted Cutting and Taq DNA ligase-assisted Ligation) method for efficient editing of large DNA constructs in vitro</article-title><source>Nucleic Acids Res</source><volume>45</volume><issue>9</issue><year>2017</year><fpage>e74</fpage><lpage>e</lpage><pub-id pub-id-type="pmid">28115632</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.-Y.</given-names></name><name><surname>Zhao</surname><given-names>G.-P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>C-Brick</surname></name></person-group><article-title>A new standard for assembly of biological parts using Cpf1</article-title><source>ACS Synth Biol</source><volume>5</volume><issue>12</issue><year>2016</year><fpage>1383</fpage><lpage>1388</lpage><pub-id pub-id-type="pmid">27294364</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Jia</surname><given-names>R.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name></person-group><article-title>ExoCET: exonuclease in vitro assembly combined with RecET recombination for highly efficient direct DNA cloning from complex genomes</article-title><source>Nucleic Acids Res</source><volume>46</volume><issue>5</issue><year>2017</year><fpage>e28</fpage></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Joung</surname><given-names>J.</given-names></name><name><surname>Konermann</surname><given-names>S.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Platt</surname><given-names>R.J.</given-names></name><name><surname>Brigham</surname><given-names>M.D.</given-names></name></person-group><article-title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening</article-title><source>Nat Protoc</source><volume>12</volume><issue>4</issue><year>2017</year><fpage>828</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">28333914</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>M.</given-names></name><name><surname>Murina</surname><given-names>O.</given-names></name><name><surname>Reijns</surname><given-names>M.A.M.</given-names></name><name><surname>Agathanggelou</surname><given-names>A.</given-names></name><name><surname>Challis</surname><given-names>R.</given-names></name><name><surname>Tarnauskaite</surname><given-names>Z.</given-names></name></person-group><article-title>CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions</article-title><source>Nature</source><volume>559</volume><issue>7713</issue><year>2018</year><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">29973717</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>Grevet</surname><given-names>J.D.</given-names></name><name><surname>Lan</surname><given-names>X.</given-names></name><name><surname>Hamagami</surname><given-names>N.</given-names></name><name><surname>Edwards</surname><given-names>C.R.</given-names></name><name><surname>Sankaranarayanan</surname><given-names>L.</given-names></name><name><surname>Ji</surname><given-names>X.</given-names></name></person-group><article-title>Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells</article-title><source>Science</source><volume>361</volume><issue>6399</issue><year>2018</year><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">30026227</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Jakociunas</surname><given-names>T.</given-names></name><name><surname>Pedersen</surname><given-names>L.E.</given-names></name><name><surname>Lis</surname><given-names>A.V.</given-names></name><name><surname>Jensen</surname><given-names>M.K.</given-names></name><name><surname>Keasling</surname><given-names>J.D.</given-names></name></person-group><article-title>CasPER, a method for directed evolution in genomic contexts using mutagenesis and CRISPR/Cas9</article-title><source>Metab Eng</source><volume>48</volume><year>2018</year><fpage>288</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">29981865</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>D.R.</given-names></name></person-group><article-title>Rewritable multi-event analog recording in bacterial and mammalian cells</article-title><source>Science</source><volume>360</volume><issue>6385</issue><year>2018</year></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name><surname>Halperin</surname><given-names>S.O.</given-names></name><name><surname>Tou</surname><given-names>C.J.</given-names></name><name><surname>Wong</surname><given-names>E.B.</given-names></name><name><surname>Modavi</surname><given-names>C.</given-names></name><name><surname>Schaffer</surname><given-names>D.V.</given-names></name><name><surname>Dueber</surname><given-names>J.E.</given-names></name></person-group><article-title>CRISPR-guided DNA polymerases enable diversification of all nucleotides in a tunable window</article-title><source>Nature</source><volume>560</volume><issue>7717</issue><year>2018</year><fpage>248</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">30069054</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name><surname>Shmakov</surname><given-names>S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Makarova</surname><given-names>K.S.</given-names></name><name><surname>Wolf</surname><given-names>Y.I.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Semenova</surname><given-names>E.</given-names></name></person-group><article-title>Discovery and functional characterization of diverse class 2 CRISPR-Cas systems</article-title><source>Mol Cell</source><volume>60</volume><issue>3</issue><year>2015</year><fpage>385</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">26593719</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Shmakov</surname><given-names>S.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Makarova</surname><given-names>K.S.</given-names></name><name><surname>Wolf</surname><given-names>Y.I.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Semenova</surname><given-names>E.</given-names></name></person-group><article-title>Discovery and functional characterization of diverse class 2 CRISPR-Cas systems</article-title><source>Mol Cell</source><volume>60</volume><issue>3</issue><year>2015</year><fpage>385</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">26593719</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name><surname>East-Seletsky</surname><given-names>A.</given-names></name><name><surname>O'Connell</surname><given-names>M.R.</given-names></name><name><surname>Burstein</surname><given-names>D.</given-names></name><name><surname>Knott</surname><given-names>G.J.</given-names></name><name><surname>Doudna</surname><given-names>J.A.</given-names></name></person-group><article-title>RNA targeting by functionally orthogonal type VI-a CRISPR-Cas enzymes</article-title><source>Mol Cell</source><volume>66</volume><issue>3</issue><year>2017</year><fpage>373</fpage><lpage>383 e3</lpage><pub-id pub-id-type="pmid">28475872</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>D.</given-names></name><name><surname>Harrington</surname><given-names>L.B.</given-names></name><name><surname>Strutt</surname><given-names>S.C.</given-names></name><name><surname>Probst</surname><given-names>A.J.</given-names></name><name><surname>Anantharaman</surname><given-names>K.</given-names></name><name><surname>Thomas</surname><given-names>B.C.</given-names></name></person-group><article-title>New CRISPR&#x02013;Cas systems from uncultivated microbes</article-title><source>Nature</source><volume>542</volume><issue>7640</issue><year>2017</year><fpage>237</fpage><pub-id pub-id-type="pmid">28005056</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name><surname>Pyzocha</surname><given-names>N.K.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Diverse class 2 CRISPR-Cas effector proteins for genome engineering applications</article-title><source>ACS Chem Biol</source><volume>13</volume><issue>2</issue><year>2017</year><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">29121460</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name><surname>Kleinstiver</surname><given-names>B.P.</given-names></name><name><surname>Prew</surname><given-names>M.S.</given-names></name><name><surname>Tsai</surname><given-names>S.Q.</given-names></name><name><surname>Nguyen</surname><given-names>N.T.</given-names></name><name><surname>Topkar</surname><given-names>V.V.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name></person-group><article-title>Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition</article-title><source>Nat Biotechnol</source><volume>33</volume><issue>12</issue><year>2015</year><fpage>1293</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">26524662</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>H.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Horii</surname><given-names>T.</given-names></name><name><surname>Abudayyeh</surname><given-names>O.O.</given-names></name><name><surname>Kimura</surname><given-names>M.</given-names></name><name><surname>Hsu</surname><given-names>P.D.</given-names></name></person-group><article-title>Structure and engineering of Francisella novicida Cas9</article-title><source>Cell</source><volume>164</volume><issue>5</issue><year>2016</year><fpage>950</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">26875867</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name><surname>Kleinstiver</surname><given-names>B.P.</given-names></name><name><surname>Pattanayak</surname><given-names>V.</given-names></name><name><surname>Prew</surname><given-names>M.S.</given-names></name><name><surname>Tsai</surname><given-names>S.Q.</given-names></name><name><surname>Nguyen</surname><given-names>N.T.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name></person-group><article-title>High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects</article-title><source>Nature</source><volume>529</volume><issue>7587</issue><year>2016</year><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">26735016</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name><surname>Slaymaker</surname><given-names>I.M.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Zetsche</surname><given-names>B.</given-names></name><name><surname>Scott</surname><given-names>D.A.</given-names></name><name><surname>Yan</surname><given-names>W.X.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>Rationally engineered Cas9 nucleases with improved specificity</article-title><source>Science</source><volume>351</volume><issue>6268</issue><year>2016</year><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">26628643</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.S.</given-names></name><name><surname>Dagdas</surname><given-names>Y.S.</given-names></name><name><surname>Kleinstiver</surname><given-names>B.P.</given-names></name><name><surname>Welch</surname><given-names>M.M.</given-names></name><name><surname>Sousa</surname><given-names>A.A.</given-names></name><name><surname>Harrington</surname><given-names>L.B.</given-names></name></person-group><article-title>Enhanced proofreading governs CRISPR-Cas9 targeting accuracy</article-title><source>Nature</source><volume>550</volume><issue>7676</issue><year>2017</year><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">28931002</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name><surname>Casini</surname><given-names>A.</given-names></name><name><surname>Olivieri</surname><given-names>M.</given-names></name><name><surname>Petris</surname><given-names>G.</given-names></name><name><surname>Montagna</surname><given-names>C.</given-names></name><name><surname>Reginato</surname><given-names>G.</given-names></name><name><surname>Maule</surname><given-names>G.</given-names></name></person-group><article-title>A highly specific SpCas9 variant is identified by in vivo screening in yeast</article-title><source>Nat Biotechnol</source><volume>36</volume><issue>3</issue><year>2018</year><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">29431739</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.K.</given-names></name><name><surname>Jeong</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Jung</surname><given-names>M.</given-names></name><name><surname>Shin</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>Y.H.</given-names></name></person-group><article-title>Directed evolution of CRISPR-Cas9 to increase its specificity</article-title><source>Nat Commun</source><volume>9</volume><issue>1</issue><year>2018</year><fpage>3048</fpage><pub-id pub-id-type="pmid">30082838</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.H.</given-names></name><name><surname>Miller</surname><given-names>S.M.</given-names></name><name><surname>Geurts</surname><given-names>M.H.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>N.</given-names></name></person-group><article-title>Evolved Cas9 variants with broad PAM compatibility and high DNA specificity</article-title><source>Nature</source><volume>556</volume><issue>7699</issue><year>2018</year><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">29512652</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Cox</surname><given-names>D.B.T.</given-names></name><name><surname>Yan</surname><given-names>W.X.</given-names></name><name><surname>Manteiga</surname><given-names>J.C.</given-names></name><name><surname>Schneider</surname><given-names>M.W.</given-names></name><name><surname>Yamano</surname><given-names>T.</given-names></name></person-group><article-title>Engineered Cpf1 variants with altered PAM specificities</article-title><source>Nat Biotechnol</source><volume>35</volume><issue>8</issue><year>2017</year><fpage>789</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">28581492</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name><surname>Nishimasu</surname><given-names>H.</given-names></name><name><surname>Yamano</surname><given-names>T.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Ishitani</surname><given-names>R.</given-names></name><name><surname>Nureki</surname><given-names>O.</given-names></name></person-group><article-title>Structural basis for the altered PAM recognition by engineered CRISPR-Cpf1</article-title><source>Mol Cell</source><volume>67</volume><issue>1</issue><year>2017</year><fpage>139</fpage><lpage>147 e2</lpage><pub-id pub-id-type="pmid">28595896</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>You</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Plant genome editing using FnCpf1 and LbCpf1 nucleases at redefined and altered PAM sites</article-title><source>Mol Plant</source><volume>11</volume><issue>7</issue><year>2018</year><fpage>999</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">29567452</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name><surname>Sashital</surname><given-names>D.G.</given-names></name></person-group><article-title>Pathogen detection in the CRISPR-Cas era</article-title><source>Genome Med</source><volume>10</volume><issue>1</issue><year>2018</year><fpage>32</fpage><pub-id pub-id-type="pmid">29690921</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>R.J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Yim</surname><given-names>M.J.</given-names></name><name><surname>Swiech</surname><given-names>L.</given-names></name><name><surname>Kempton</surname><given-names>H.R.</given-names></name></person-group><article-title>CRISPR-Cas9 knockin mice for genome editing and cancer modeling</article-title><source>Cell</source><volume>159</volume><issue>2</issue><year>2014</year><fpage>440</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">25263330</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name><surname>Dow</surname><given-names>L.E.</given-names></name></person-group><article-title>Modeling disease in vivo with CRISPR/Cas9</article-title><source>Trends Mol Med</source><volume>21</volume><issue>10</issue><year>2015</year><fpage>609</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">26432018</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name><surname>Sachdeva</surname><given-names>M.</given-names></name><name><surname>Sachdeva</surname><given-names>N.</given-names></name><name><surname>Pal</surname><given-names>M.</given-names></name><name><surname>Gupta</surname><given-names>N.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name><name><surname>Majumdar</surname><given-names>M.</given-names></name></person-group><article-title>CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer</article-title><source>Cancer Gene Ther</source><volume>22</volume><issue>11</issue><year>2015</year><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">26494554</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Marti-Gutierrez</surname><given-names>N.</given-names></name><name><surname>Park</surname><given-names>S.W.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name></person-group><article-title>Correction of a pathogenic gene mutation in human embryos</article-title><source>Nature</source><volume>548</volume><issue>7668</issue><year>2017</year><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">28783728</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>R.</given-names></name></person-group><article-title>The basic science of gene therapy</article-title><source>Science</source><volume>260</volume><issue>5110</issue><year>1993</year><fpage>926</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">8493530</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name><surname>Somia</surname><given-names>N.</given-names></name><name><surname>Verma</surname><given-names>I.M.</given-names></name></person-group><article-title>Gene therapy: trials and tribulations</article-title><source>Nat Rev Genet</source><volume>1</volume><issue>2</issue><year>2000</year><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">11253666</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>F.A.</given-names></name><name><surname>Cong</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>W.X.</given-names></name><name><surname>Scott</surname><given-names>D.A.</given-names></name><name><surname>Gootenberg</surname><given-names>J.S.</given-names></name><name><surname>Kriz</surname><given-names>A.J.</given-names></name></person-group><article-title>In vivo genome editing using Staphylococcus aureus Cas9</article-title><source>Nature</source><volume>520</volume><issue>7546</issue><year>2015</year><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">25830891</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H.</given-names></name><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Bogorad</surname><given-names>R.L.</given-names></name><name><surname>Benedetti</surname><given-names>E.</given-names></name><name><surname>Grompe</surname><given-names>M.</given-names></name></person-group><article-title>Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype</article-title><source>Nat Biotechnol</source><volume>32</volume><issue>6</issue><year>2014</year><fpage>551</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">24681508</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Q.</given-names></name><name><surname>Strong</surname><given-names>A.</given-names></name><name><surname>Patel</surname><given-names>K.M.</given-names></name><name><surname>Ng</surname><given-names>S.L.</given-names></name><name><surname>Gosis</surname><given-names>B.S.</given-names></name><name><surname>Regan</surname><given-names>S.N.</given-names></name></person-group><article-title>Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing</article-title><source>Circ Res</source><volume>115</volume><issue>5</issue><year>2014</year><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">24916110</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name><surname>Long</surname><given-names>C.</given-names></name><name><surname>Amoasii</surname><given-names>L.</given-names></name><name><surname>Mireault</surname><given-names>A.A.</given-names></name><name><surname>McAnally</surname><given-names>J.R.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Sanchez-Ortiz</surname><given-names>E.</given-names></name></person-group><article-title>Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy</article-title><source>Science</source><volume>351</volume><issue>6271</issue><year>2016</year><fpage>400</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">26721683</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>C.E.</given-names></name><name><surname>Hakim</surname><given-names>C.H.</given-names></name><name><surname>Ousterout</surname><given-names>D.G.</given-names></name><name><surname>Thakore</surname><given-names>P.I.</given-names></name><name><surname>Moreb</surname><given-names>E.A.</given-names></name><name><surname>Castellanos Rivera</surname><given-names>R.M.</given-names></name></person-group><article-title>In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy</article-title><source>Science</source><volume>351</volume><issue>6271</issue><year>2016</year><fpage>403</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">26721684</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name><surname>Tabebordbar</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>K.</given-names></name><name><surname>Cheng</surname><given-names>J.K.W.</given-names></name><name><surname>Chew</surname><given-names>W.L.</given-names></name><name><surname>Widrick</surname><given-names>J.J.</given-names></name><name><surname>Yan</surname><given-names>W.X.</given-names></name></person-group><article-title>In vivo gene editing in dystrophic mouse muscle and muscle stem cells</article-title><source>Science</source><volume>351</volume><issue>6271</issue><year>2016</year><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">26721686</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Park</surname><given-names>K.H.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>El Refaey</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name></person-group><article-title>CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice</article-title><source>Mol Ther</source><volume>24</volume><issue>3</issue><year>2016</year><fpage>564</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">26449883</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Long</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>McAnally</surname><given-names>J.R.</given-names></name><name><surname>Baskin</surname><given-names>K.K.</given-names></name><name><surname>Shelton</surname><given-names>J.M.</given-names></name></person-group><article-title>CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice</article-title><source>Sci Adv</source><volume>3</volume><issue>4</issue><year>2017</year><object-id pub-id-type="publisher-id">e1602814</object-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name><surname>Amoasii</surname><given-names>L.</given-names></name><name><surname>Hildyard</surname><given-names>J.C.W.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Sanchez-Ortiz</surname><given-names>E.</given-names></name><name><surname>Mireault</surname><given-names>A.</given-names></name><name><surname>Caballero</surname><given-names>D.</given-names></name></person-group><article-title>Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy</article-title><source>Science</source><year>2018</year><object-id pub-id-type="publisher-id">eaau1549</object-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>A.</given-names></name><name><surname>Zode</surname><given-names>G.</given-names></name><name><surname>Kasetti</surname><given-names>R.B.</given-names></name><name><surname>Ran</surname><given-names>F.A.</given-names></name><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Sharma</surname><given-names>T.P.</given-names></name></person-group><article-title>CRISPR-Cas9-based treatment of myocilin-associated glaucoma</article-title><source>Proc Natl Acad Sci U S A</source><volume>114</volume><issue>42</issue><year>2017</year><fpage>11199</fpage><lpage>11204</lpage><pub-id pub-id-type="pmid">28973933</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Mookherjee</surname><given-names>S.</given-names></name><name><surname>Chaitankar</surname><given-names>V.</given-names></name><name><surname>Hiriyanna</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J.W.</given-names></name><name><surname>Brooks</surname><given-names>M.</given-names></name></person-group><article-title>Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><fpage>14716</fpage><pub-id pub-id-type="pmid">28291770</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name><surname>Rossidis</surname><given-names>A.C.</given-names></name><name><surname>Stratigis</surname><given-names>J.D.</given-names></name><name><surname>Chadwick</surname><given-names>A.C.</given-names></name><name><surname>Hartman</surname><given-names>H.A.</given-names></name><name><surname>Ahn</surname><given-names>N.J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>In utero CRISPR-mediated therapeutic editing of metabolic genes</article-title><source>Nat Med</source><volume>24</volume><issue>10</issue><year>2018</year><fpage>1513</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">30297903</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name><surname>Villiger</surname><given-names>L.</given-names></name><name><surname>Grisch-Chan</surname><given-names>H.M.</given-names></name><name><surname>Lindsay</surname><given-names>H.</given-names></name><name><surname>Ringnalda</surname><given-names>F.</given-names></name><name><surname>Pogliano</surname><given-names>C.B.</given-names></name><name><surname>Allegri</surname><given-names>G.</given-names></name></person-group><article-title>Treatment of a metabolic liver disease by in vivo genome base editing in adult mice</article-title><source>Nat Med</source><volume>24</volume><issue>10</issue><year>2018</year><fpage>1519</fpage><lpage>1525</lpage><pub-id pub-id-type="pmid">30297904</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name><surname>Schwank</surname><given-names>G.</given-names></name><name><surname>Koo</surname><given-names>B.K.</given-names></name><name><surname>Sasselli</surname><given-names>V.</given-names></name><name><surname>Dekkers</surname><given-names>J.F.</given-names></name><name><surname>Heo</surname><given-names>I.</given-names></name><name><surname>Demircan</surname><given-names>T.</given-names></name></person-group><article-title>Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients</article-title><source>Cell Stem Cell</source><volume>13</volume><issue>6</issue><year>2013</year><fpage>653</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">24315439</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>F.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>J.C.</given-names></name><name><surname>Beyer</surname><given-names>A.I.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Muench</surname><given-names>M.O.</given-names></name></person-group><article-title>Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac</article-title><source>Genome Res</source><volume>24</volume><issue>9</issue><year>2014</year><fpage>1526</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">25096406</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.Z.</given-names></name><name><surname>Wang</surname><given-names>T.T.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>B.Y.</given-names></name></person-group><article-title>Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C &#x0003e; T) mutation in beta-thalassemia-derived iPSCs</article-title><source>Sci Rep</source><volume>5</volume><year>2015</year><fpage>12065</fpage><pub-id pub-id-type="pmid">26156589</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>Z.</given-names></name><name><surname>Niu</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name><name><surname>Xian</surname><given-names>Y.</given-names></name></person-group><article-title>The combination of CRISPR/Cas9 and iPSC technologies in the gene therapy of human beta-thalassemia in mice</article-title><source>Sci Rep</source><volume>6</volume><year>2016</year><fpage>32463</fpage><pub-id pub-id-type="pmid">27581487</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Jia</surname><given-names>R.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Bian</surname><given-names>X.</given-names></name></person-group><article-title>RecET direct cloning and redalphabeta recombineering of biosynthetic gene clusters, large operons or single genes for heterologous expression</article-title><source>Nat Protoc</source><volume>11</volume><issue>7</issue><year>2016</year><fpage>1175</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">27254463</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name><surname>Weltner</surname><given-names>J.</given-names></name><name><surname>Balboa</surname><given-names>D.</given-names></name><name><surname>Katayama</surname><given-names>S.</given-names></name><name><surname>Bespalov</surname><given-names>M.</given-names></name><name><surname>Krjutskov</surname><given-names>K.</given-names></name><name><surname>Jouhilahti</surname><given-names>E.M.</given-names></name></person-group><article-title>Human pluripotent reprogramming with CRISPR activators</article-title><source>Nat Commun</source><volume>9</volume><issue>1</issue><year>2018</year><fpage>2643</fpage><pub-id pub-id-type="pmid">29980666</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name><surname>Bikard</surname><given-names>D.</given-names></name><name><surname>Euler</surname><given-names>C.W.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Nussenzweig</surname><given-names>P.M.</given-names></name><name><surname>Goldberg</surname><given-names>G.W.</given-names></name><name><surname>Duportet</surname><given-names>X.</given-names></name></person-group><article-title>Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials</article-title><source>Nat Biotechnol</source><volume>32</volume><issue>11</issue><year>2014</year><fpage>1146</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">25282355</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name><surname>Yosef</surname><given-names>I.</given-names></name><name><surname>Manor</surname><given-names>M.</given-names></name><name><surname>Kiro</surname><given-names>R.</given-names></name><name><surname>Qimron</surname><given-names>U.</given-names></name></person-group><article-title>Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria</article-title><source>Proc Natl Acad Sci U S A</source><volume>112</volume><issue>23</issue><year>2015</year><fpage>7267</fpage><lpage>7272</lpage><pub-id pub-id-type="pmid">26060300</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name><surname>Fesnak</surname><given-names>A.D.</given-names></name><name><surname>June</surname><given-names>C.H.</given-names></name><name><surname>Levine</surname><given-names>B.L.</given-names></name></person-group><article-title>Engineered T cells: the promise and challenges of cancer immunotherapy</article-title><source>Nat Rev Cancer</source><volume>16</volume><issue>9</issue><year>2016</year><fpage>566</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">27550819</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Shao</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name></person-group><article-title>CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients</article-title><source>Sci Rep</source><volume>6</volume><year>2016</year><fpage>20070</fpage><pub-id pub-id-type="pmid">26818188</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>T.L.</given-names></name><name><surname>Puig-Saus</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>R.</given-names></name><name><surname>Shifrut</surname><given-names>E.</given-names></name><name><surname>Carnevale</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>P.J.</given-names></name></person-group><article-title>Reprogramming human T cell function and specificity with non-viral genome targeting</article-title><source>Nature</source><volume>559</volume><issue>7714</issue><year>2018</year><fpage>405</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">29995861</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>L.J.</given-names></name><name><surname>Schumann</surname><given-names>K.</given-names></name><name><surname>Roybal</surname><given-names>K.T.</given-names></name><name><surname>Gate</surname><given-names>R.E.</given-names></name><name><surname>Ye</surname><given-names>C.J.</given-names></name><name><surname>Lim</surname><given-names>W.A.</given-names></name></person-group><article-title>CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells</article-title><source>Sci Rep</source><volume>7</volume><issue>1</issue><year>2017</year><fpage>737</fpage><pub-id pub-id-type="pmid">28389661</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9</article-title><source>Protein Cell</source><volume>8</volume><issue>9</issue><year>2017</year><fpage>634</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">28434148</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>June</surname><given-names>C.H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition</article-title><source>Clin Cancer Res</source><volume>23</volume><issue>9</issue><year>2017</year><fpage>2255</fpage><lpage>2266</lpage><pub-id pub-id-type="pmid">27815355</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name><surname>Komor</surname><given-names>A.C.</given-names></name><name><surname>Badran</surname><given-names>A.H.</given-names></name><name><surname>Liu</surname><given-names>D.R.</given-names></name></person-group><article-title>CRISPR-based technologies for the manipulation of eukaryotic genomes</article-title><source>Cell</source><volume>168</volume><issue>1&#x02013;2</issue><year>2017</year><fpage>20</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">27866654</pub-id></element-citation></ref><ref id="bib178"><label>178</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.H.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Lei</surname><given-names>Y.</given-names></name><name><surname>Brunetti</surname><given-names>L.</given-names></name><name><surname>Gundry</surname><given-names>M.C.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A</article-title><source>Genome Biol</source><volume>18</volume><issue>1</issue><year>2017</year><fpage>176</fpage><pub-id pub-id-type="pmid">28923089</pub-id></element-citation></ref><ref id="bib179"><label>179</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name><surname>Eyquem</surname><given-names>J.</given-names></name><name><surname>Mansilla-Soto</surname><given-names>J.</given-names></name><name><surname>Giavridis</surname><given-names>T.</given-names></name><name><surname>van der Stegen</surname><given-names>S.J.</given-names></name><name><surname>Hamieh</surname><given-names>M.</given-names></name><name><surname>Cunanan</surname><given-names>K.M.</given-names></name></person-group><article-title>Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection</article-title><source>Nature</source><volume>543</volume><issue>7643</issue><year>2017</year><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">28225754</pub-id></element-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="book" id="sref180"><person-group person-group-type="author"><name><surname>Normile</surname><given-names>D.</given-names></name></person-group><chapter-title>China sprints ahead in CRISPR therapy race</chapter-title><year>2017</year></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>S.</given-names></name></person-group><article-title>First CRISPR clinical trial gets green light from US panel</article-title><source>Nature</source><year>2016</year></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D.</given-names></name></person-group><article-title>CRISPR gene-editing tested in a person for the first time</article-title><source>Nature</source><year>2016</year></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="sref183"><article-title>CRISPR gene therapy trial on hold</article-title><source>Nat Biotechnol</source><year>2018</year></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name><surname>Charlesworth</surname><given-names>C.T.</given-names></name><name><surname>Deshpande</surname><given-names>P.S.</given-names></name><name><surname>Dever</surname><given-names>D.P.</given-names></name><name><surname>Dejene</surname><given-names>B.</given-names></name><name><surname>Gomez-Ospina</surname><given-names>N.</given-names></name><name><surname>Mantri</surname><given-names>S.</given-names></name></person-group><article-title>Identification of pre-existing adaptive immunity to Cas9 proteins in humans</article-title><source>bioRxiv</source><year>2018</year><fpage>243345</fpage></element-citation></ref><ref id="bib185"><label>185</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name><surname>Haapaniemi</surname><given-names>E.</given-names></name><name><surname>Botla</surname><given-names>S.</given-names></name><name><surname>Persson</surname><given-names>J.</given-names></name><name><surname>Schmierer</surname><given-names>B.</given-names></name><name><surname>Taipale</surname><given-names>J.</given-names></name></person-group><article-title>CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response</article-title><source>Nat Med</source><volume>24</volume><year>2018</year><fpage>927</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">29892067</pub-id></element-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name><surname>Egli</surname><given-names>D.</given-names></name><name><surname>Zuccaro</surname><given-names>M.V.</given-names></name><name><surname>Kosicki</surname><given-names>M.</given-names></name><name><surname>Church</surname><given-names>G.M.</given-names></name><name><surname>Bradley</surname><given-names>A.</given-names></name><name><surname>Jasin</surname><given-names>M.</given-names></name></person-group><article-title>Inter-homologue repair in fertilized human eggs?</article-title><source>Nature</source><volume>560</volume><issue>7717</issue><year>2018</year><fpage>E5</fpage><lpage>E7</lpage><pub-id pub-id-type="pmid">30089924</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name><surname>Adikusuma</surname><given-names>F.</given-names></name><name><surname>Piltz</surname><given-names>S.</given-names></name><name><surname>Corbett</surname><given-names>M.A.</given-names></name><name><surname>Turvey</surname><given-names>M.</given-names></name><name><surname>McColl</surname><given-names>S.R.</given-names></name><name><surname>Helbig</surname><given-names>K.J.</given-names></name></person-group><article-title>Large deletions induced by Cas9 cleavage</article-title><source>Nature</source><volume>560</volume><issue>7717</issue><year>2018</year><fpage>E8</fpage><pub-id pub-id-type="pmid">30089922</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name><surname>Mali</surname><given-names>P.</given-names></name><name><surname>Aach</surname><given-names>J.</given-names></name><name><surname>Stranges</surname><given-names>P.B.</given-names></name><name><surname>Esvelt</surname><given-names>K.M.</given-names></name><name><surname>Moosburner</surname><given-names>M.</given-names></name><name><surname>Kosuri</surname><given-names>S.</given-names></name></person-group><article-title>CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering</article-title><source>Nat Biotechnol</source><volume>31</volume><issue>9</issue><year>2013</year><fpage>833</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">23907171</pub-id></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name><surname>Kleinstiver</surname><given-names>B.P.</given-names></name><name><surname>Prew</surname><given-names>M.S.</given-names></name><name><surname>Tsai</surname><given-names>S.Q.</given-names></name><name><surname>Topkar</surname><given-names>V.V.</given-names></name><name><surname>Nguyen</surname><given-names>N.T.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name></person-group><article-title>Engineered CRISPR-Cas9 nucleases with altered PAM specificities</article-title><source>Nature</source><volume>523</volume><issue>7561</issue><year>2015</year><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">26098369</pub-id></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>C.</given-names></name><name><surname>Bargsten</surname><given-names>K.</given-names></name><name><surname>Jinek</surname><given-names>M.</given-names></name></person-group><article-title>Structural plasticity of PAM recognition by engineered variants of the RNA-guided endonuclease Cas9</article-title><source>Mol Cell</source><volume>61</volume><issue>6</issue><year>2016</year><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">26990992</pub-id></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>S.</given-names></name><name><surname>Nishimasu</surname><given-names>H.</given-names></name><name><surname>Ishitani</surname><given-names>R.</given-names></name><name><surname>Nureki</surname><given-names>O.</given-names></name></person-group><article-title>Structural basis for the altered PAM specificities of engineered CRISPR-Cas9</article-title><source>Mol Cell</source><volume>61</volume><issue>6</issue><year>2016</year><fpage>886</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">26990991</pub-id></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name><surname>Nishimasu</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Ishiguro</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Hirano</surname><given-names>S.</given-names></name><name><surname>Okazaki</surname><given-names>S.</given-names></name></person-group><article-title>Engineered CRISPR-Cas9 nuclease with expanded targeting space</article-title><source>Science</source><year>2018</year><object-id pub-id-type="publisher-id">eaas9129</object-id></element-citation></ref><ref id="bib193"><label>193</label><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name><surname>Amoasii</surname><given-names>L.</given-names></name><name><surname>Hildyard</surname><given-names>J.C.W.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Sanchez-Ortiz</surname><given-names>E.</given-names></name><name><surname>Mireault</surname><given-names>A.</given-names></name><name><surname>Caballero</surname><given-names>D.</given-names></name></person-group><article-title>Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy</article-title><source>Science</source><volume>362</volume><issue>6410</issue><year>2018</year><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">30166439</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgements</title><p>We gratefully acknowledge financial support from the Fundamental Research Funds for the central Universities to YZ. L and <funding-source id="gs1">National Natural Science Foundation of China</funding-source> (Grant No. 81502966).</p></ack><fn-group><fn id="d31e1030"><p id="ntpara0010">Peer review under responsibility of KeAi Communications Co., Ltd.</p></fn></fn-group></back></article><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Commun Biol</journal-id><journal-id journal-id-type="iso-abbrev">Commun Biol</journal-id><journal-title-group><journal-title>Communications Biology</journal-title></journal-title-group><issn pub-type="epub">2399-3642</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6208339</article-id><article-id pub-id-type="publisher-id">184</article-id><article-id pub-id-type="doi">10.1038/s42003-018-0184-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>CRISPRminer is a knowledge base for exploring CRISPR-Cas systems in microbe and phage interactions</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Fan</given-names></name><address><email>fanzhang@hit.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Shijia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ren</surname><given-names>Chunyan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Yuwei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Haibin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Yongkui</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Fengxia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Yuqiang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Kangjie</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Zhiwei</given-names></name><address><email>huangzhiwei@hit.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0193 3564</institution-id><institution-id institution-id-type="GRID">grid.19373.3f</institution-id><institution>HIT Center for Life Sciences, School of Life Science and Technology, </institution><institution>Harbin Institute of Technology, </institution></institution-wrap>150080 Harbin, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0193 3564</institution-id><institution-id institution-id-type="GRID">grid.19373.3f</institution-id><institution>School of Computer Science and Technology, </institution><institution>Harbin Institute of Technology, </institution></institution-wrap>150080 Harbin, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Division of Hematology/Oncology, Boston Children&#x02019;s Hospital, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA 02115 USA </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>1</volume><elocation-id>180</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">CRISPR-Cas systems not only play key roles in prokaryotic acquired immunity, but can also be adapted as powerful genome editing tools. Understanding the native role of CRISPR-Cas systems in providing adaptive immunity can lead to new CRISPR-based technologies. Here, we develop CRISPRminer, a knowledge base and web server to comprehensively collect and investigate the knowledge of CRISPR-Cas systems and generate instructive annotations, including CRISPR arrays and Cas protein annotation, CRISPR-Cas system classification, self-targeting events detection, microbe&#x02013;phage interaction inference, and anti-CRISPR annotation. CRISPRminer is user-friendly and freely available at <ext-link ext-link-type="uri" xlink:href="http://www.microbiome-bigdata.com/CRISPRminer">http://www.microbiome-bigdata.com/CRISPRminer</ext-link>.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">Fan Zhang et al. present CRISPRminer, a comprehensive database for exploring CRISPR-Cas systems in more than 3500 microbial species&#x000a0;and a&#x000a0;web-server for in-depth data mining.&#x000a0;CRISPRminer allows researchers to&#x000a0;predict CRISPR-Cas systems&#x000a0;and&#x000a0;investigate self-targeting CRISPRs, microbe-phage interaction networks, and anti-CRISPR features.</p></abstract><funding-group><award-group><funding-source><institution>This research was funded by the National Natural Science Foundation of China grant no. 61872117 to FZ, and Project GFEQ5750006918 supported by Natural Scientific Research Innovation Foundation in Harbin Institute of Technology.</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>This research was funded by the National Natural Science Foundation of China grant no.31422014, 31450001 and 21300605 to ZH.</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated proteins) systems are prokaryotic adaptive immune systems that are known to protect bacteria and archaea from phage infection. Understanding the native role of CRISPR-Cas systems and their programmable nature is very inspiring for adaptive immune system studies and can lead to the development of new CRISPR-based technologies.</p><p id="Par4">Bacteria and phages are engaged in an evolutionary arms race<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Bacteria utilize CRISPR-Cas adaptive immune systems for protection against phage infection<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. In turn, some phages have been found capable to evade CRISPR-Cas immunity using anti-CRISPR proteins<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. Several databases or web servers have been developed to gather information and provide useful applications to study CRISPR-Cas systems, such as CRISPRs web server (including CRISPRFinder<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, CRISPRdb<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, and CRISPRcompar<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>), CRISPRCasFinder<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, CRISPRone<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, CRISPI<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, and anti-CRISPRdb database<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. CRISPRFinder<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> and its updated version CRISPRCasFinder<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> are tools to detect CRISPR arrays and Cas gene clusters. CRISPRdb<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> focus on displaying CRISPR arrays and generating dictionaries of spacers and repeats. CRISPRcompar<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> is used to compare CRISPRs. In general, the CRISPRs web server, CRISPRCasFinder<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, CRISPI<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and CRISPRone<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, focuses on the annotation and characterization of CRISPR arrays of repeat-spacer units, and/or the Cas locus, while the anti-CRISPRdb<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> is a database of manually collected anti-CRISPR proteins and their homologs from publications. However, each of these databases only focuses on a specific field of CRISPR biology and provides limited information concerning CRISPR-Cas systems or anti-CRISPRs, without building a connection between the microbe and phage based on CRISPR-Cas immunity. Currently, with the expansion of the diversity and classification of CRISPR-Cas systems, and novel findings on microbe&#x02013;phage coevolution, the study of CRISPR-Cas systems requires all-inclusive data from multiple aspects/dimensions combined with thorough mining, yet such a comprehensive online resource or web server is still lacking.</p><p id="Par5">Here, we develop the CRISPRminer database and web server to fill this gap by comprehensively collecting and mining the knowledge underlying these systems from published observations and generating instructive annotations, and developing pipelines for CRISPR-Cas system prediction, classification, and annotation based on python scripts and a series of public tools.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Database content</title><p id="Par6">The current CRISPRminer database has integrated five categories of information that are experimentally or computationally identified to be important for CRISPR studies (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), including annotation and visualization of the CRISPR-Cas systems in 43,140 bacterial and 167 archaeal organisms from 3588 species (1279 genera), classification of the CRISPR-Cas systems into six types (21 subtypes) based on signature Cas genes and distinctive gene architectures, collection of 22,110 self-targeting events from publications and detection of 6260 putative self-targeting events in 4136 bacterial organisms, inference of putative 55,279 microbe&#x02212;phage interactions based on CRISPR-spacer sequences and 1972 relations extracted from NCBI database, and annotation of the anti-CRISPR proteins experimentally identified in published papers.<fig id="Fig1"><label>Fig. 1</label><caption><p>Five categories of information important for CRISPR studies are integrated in CRISPRminer database and the corresponding prediction services are also provided</p></caption><graphic xlink:href="42003_2018_184_Fig1_HTML" id="d29e386"/></fig></p></sec><sec id="Sec4"><title>CRISPR array and Cas protein annotation module</title><p id="Par7">By investigating completely or partially sequenced archaeal and bacterial genomes downloaded from the NCBI FTP site (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.ncbi.nlm.nih.gov/genomes/all/">ftp://ftp.ncbi.nlm.nih.gov/genomes/all/</ext-link>), we identified 91,685 CRISPR arrays in 62,176 bacterial and 167 archaeal organisms (distributed in 3588 species of 1279 genera) using PILER-CR<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, among which 43,140 organisms (including 2467 complete genomes and 262 plasmids) are detected with both the CRISPR arrays and the corresponding Cas proteins. The process for CRISPR-Cas system detection is demonstrated in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. Briefly, the PILER-CR<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> program is used with default parameters to identify CRISPR arrays, and then sequences including 15 kbp upstream and downstream of the CRISPR arrays are extracted. Open Reading Frame (ORF) annotation is performed using FragGeneScan<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. All ORFs are further annotated using RPS-BLAST against 395 profiles that represent 93 distinct Cas protein families. The CRISPR arrays lacking nearby Cas genes or Cas clusters lacking nearby CRISPRs are defined as isolated ones. The type of each CRISPR-Cas locus is determined according to the signature cas genes, such as major effector module genes including cas7, cas5, cas8, cas10, csf1, cas9, and cpf1<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. At the genus level, <italic>Mycobacterium</italic>, <italic>Escherichia</italic>, <italic>Clostridioides</italic>, and <italic>Salmonella</italic> contribute to approximately 50% of the detected CRISPR systems. At the species level, <italic>Mycobacterium tuberculosis</italic>, <italic>Escherichia coli</italic>, <italic>Clostridioides difficile</italic>, and <italic>Salmonella enterica</italic> are the dominant species. However, the enriched genus and species may be due to the largest number of strains sequenced for health-related issues, but not the actual distribution of these CRISPR-Cas systems in the microbial world.<fig id="Fig2"><label>Fig. 2</label><caption><p>The flowchart of the prediction procedure and the overview of the prediction tools and the underlying data</p></caption><graphic xlink:href="42003_2018_184_Fig2_HTML" id="d29e450"/></fig></p><p id="Par8">In the CRISPR-Cas module, users can browse the precalculated CRISPR-Cas systems through the taxonomy tree, or fuzzy search of the bacterial and archaeal description or using RefSeq accession numbers. Both global and local views are provided to visualize the detailed information. The global view provides the locations of the CRISPR regions on the genome coupled with the predicted genomic islands (GIs) using IslandViewer<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and predicted prophage regions using Prophinder<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> and PHASTER<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. The local view provides a visualization of the CRISPR arrays (shown as x10 for example, where 10 denotes the copy number of the repeats) and the Cas proteins (colored based on their functions such as acquisition, ancillary, CASCADE, crRNA maturation, and helper) with detailed information for the CRISPR array (location, repeats, and spacers) and Cas genes (locations,&#x000a0;protein sequences, HMM profiles, and type/subtype). In addition, using the &#x0201c;compare&#x0201d; tool, users can compare the CRISPR systems among the organisms belonging to the same species or genus.</p></sec><sec id="Sec5"><title>CRISPR-Cas system classification module</title><p id="Par9">The Classification module provides (sub) types annotation of the CRISPR-Cas systems based on the signature genes and distinctive gene architectures according to the most recent classification studies<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The classification scheme encompasses two classes and six types. Class 1 CRISPR-Cas systems are defined by the presence of a multi-subunit crRNA&#x02013;effector complex, including type I (I-A, I-B, I-C, I-D, I-E, I-F, and I-U subtypes) and type III (III-A, III-B, III-C, and III-U subtypes) CRISPR-Cas systems, as well as the putative new type IV<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Class 2 CRISPR-Cas systems are defined by the presence of a single subunit crRNA&#x02013;effector module, including type II (II-A, II-B, and II-C subtypes), as well as two putative new types V (V-A, V-B, V-C, and V-U subtypes) and VI (VI-A, VI-B, and VI-U subtypes)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Users can conveniently browse the bacterial organisms belonging to each (sub) type with detailed information, such as bacterial description, RefSeq ID, Genbank ID, and the Cas operon composition.</p></sec><sec id="Sec6"><title>Self-targeting module</title><p id="Par10">Self-targeting is suggested as a form of autoimmunity<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, and has been used as a genomic marker to screen CRISPR-Cas inhibitor genes in Listeria monocytogenes<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. The Self-Targeting module includes 22,110 self-targeting events collected from publications<sup><xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref></sup> and 6260 putative self-targeting events detected from 4136 CRISPR containing organisms using a similar methodology to previous reports<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Briefly, self-targeting spacers are detected using blastn (with default settings and an e-value limit of 10e&#x02212;2) against all the contigs within the same assembly except for the DNA bases within the predicted CRISPR arrays. These published and putative self-targeting events will enable the further exploration of their biological significance in CRISPR-based autoimmunity.</p></sec><sec id="Sec7"><title>Microbe&#x02212;phage interaction module</title><p id="Par11">Recent work suggests that phage&#x02212;host interactions can be inferred by analyzing CRISPR spacer sequences based on the hypothesis that hosts only incorporate spacer sequences from the phages that infect them<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. In the &#x0201c;Interaction&#x0201d; module, to infer a large-scale microbe&#x02212;phage infection network, the spacers from each microbe organism is collected and used to BLAST (blastn with parameters settings: word_size&#x02009;=&#x02009;8, e-value&#x02009;&#x0003c;&#x02009;0.01, and up to three mismatches allowed) against an integrated database of 2281 phage and archaeal virus genomes from the NCBI viral Genome Resource, the EMBL EBI phage genomes and the phagedb databases (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The interactions are grouped by their host and could be easily browsed or indexed by their host names. Additionally, information for interacting spacers and their targeting proto-spacers, as well as the phage genome content near proto-spacers, is provided. If the proto-spacer is located in a protein region, the protein annotation is also provided. Finally, each phage genome is also searched for its bacterial or archaeal host, which is annotated under the fields &#x0201c;isolate host=&#x0201d; or &#x0201c;host=&#x0201d; in its Genbank file. This analysis could help establish the link between phages and microbe, which might be an important supplement to the current understanding of natural microbial communities.</p></sec><sec id="Sec8"><title>Anti-CRISPRs annotation module</title><p id="Par12">This module contains all 23 anti-CRISPR protein families detected and validated in the CRISPR-bearing bacterial or archaeal organisms, including four from type I-E, ten from type I-F, five from type II-A, three from type II-C, and one from type I-D. Since more anti-CRISPRs are estimated to be uncovered, we searched for homologs using blastp (with e-value&#x02009;&#x0003c;&#x02009;0.01, identity&#x02009;&#x0003e;&#x02009;40%) of all validated anti-CRISPR proteins, extracted the surrounding genomic content (five proteins upstream and downstream, respectively), and determined their functions using rpsblast with an e-value cutoff of 10e&#x02212;2 against the Conserved Domain Database (CDD)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. The operons encoding anti-CRISPR proteins could be studied for further identification of conserved characteristics that are useful for anti-CRISPR prediction, such as Aca (anti-CRISPR-associated) genes with the HTH (helix-turn-helix) domain usually located downstream of the anti-CRISPRs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p></sec><sec id="Sec9"><title>Prediction module</title><p id="Par13">The Prediction module is used to annotate CRISPR-related knowledge (including CRISPR arrays and Cas clusters annotation, CRISPR-Cas systems classification, interacting phages inference, self-targeting events detection, and anti-CRISPR homolog searching) for an existing or a newly sequenced genome by directly uploading or pasting the nucleotide sequence in FASTA format. The prediction procedure underlying CRISPRminer is implemented using python scripts and a series of public tools including blastn/blastp, rpsblast, HmmScan, FragGeneScan, PILER-CR, and CRISPRCasFinder (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). At the CRISPR-Cas system annotation step, both the PILER-CR+HmmScan and&#x000a0;CRISPRCasFinder strategies&#x000a0;are supported. Briefly, in CRISPRCasFinder procedure, the CRISPR arrays are identified using CRISPRFinder, putative ORFs are identified using Prodigal v2.6.3, cas gene clusters and their (sub)type are determined using MacSyFinder. The detected CRISPR arrays coupled with nearby (within 10kbp) Cas clusters are identified as CRISPR-Cas loci according to their distances using the dynamic programming algorithm.&#x000a0;The PILER-CR+HmmScan procedure is the same as previously&#x000a0;described in CRISPR-Cas system annotation module.</p></sec><sec id="Sec10"><title>Web server</title><p id="Par14">CRISPRminer is implemented using the ThinkPHP framework and the front-end design is created using the Bootstrap framework, which is&#x000a0;a well-established tool for intuitive design. Besides, the front-end design is also created using the cross-platform JavaScript library jQuery, which is designed to simplify the client-side scripting of HTML. In addition, CRISPRminer also uses DataTable, the plugin for jQuery, to conveniently display data. CRISPRminer back-end runs on top of an Apache server, and the communication with the server is made through a Common Gateway Interface. The server works by redirecting or sending the user input to the python script for handling and displaying the results in numerical, textual, and visual output.</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p id="Par15">In summary, we comprehensively collected information about CRISPR-Cas systems and anti-CRISPRs to construct the CRISPRminer web server, seeking to accelerate our understanding of the co-evolutionary relationship between microbe and phages. As a specifically designed CRISPR knowledge database, CRISPRminer not only integrates the dispersed data but also provides a convenient way for in-depth data mining. First, we provide a Prediction module to investigate all five categories of CRISPR-related information for an existing or&#x000a0;a newly sequenced genome by uploading or pasting the sequence. Second, we provide several techniques for browsing and comparing the detected CRISPR-Cas systems in the CRISPR-Cas module. Users can look up desired bacterial and archaeal genomes through the taxonomy tree, or by a fuzzy search of the microbial description or use of the RefSeq accession number. The CRISPR systems could also be compared at different taxonomy levels (species or genus) and coupled to the annotation of genomic islands (GIs, regions of probable horizontal origin) and prophage regions. Third, by studying self-targeting spacers from all detected CRISPR arrays in currently sequenced bacterial genomes, users could further explore their biological meanings in CRISPR-based autoimmunity. Fourth, by blasting 918,168 spacers against an integrated database of 2281 phage genomes, a large-scale microbe&#x02013;phage infection network is inferred and could support further characterization of the interaction patterns and underlying processes. Finally, we incorporated experimentally validated anti-CRISPR proteins and their homologs, and annotated their surrounding gene content to facilitate anti-CRISPR discovery. This comprehensive and user-friendly CRISPRminer offers a large collection of information that could be useful to the CRISPR or microbiology community and is a much-needed tool that will facilitate research on CRISPR biology and complement other available tools for CRISPR-based applications such as genome editing. Our database will be updated regularly with newly released bacterial and archaeal genomes and provide all five categories of CRISPR-related information for these genomes automatically by utilizing the underlying prediction procedure.</p><sec id="Sec12"><title>Code availability</title><p id="Par16">The public tools used in this study can be downloaded from their official website, such as blastn/blastp and rpsblastp (<ext-link ext-link-type="uri" xlink:href="https://blast.ncbi.nlm.nih.gov/Blast.cgi">https://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>), HmmScan (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/Tools/hmmer/search/hmmscan">https://www.ebi.ac.uk/Tools/hmmer/search/hmmscan</ext-link>), PILER-CR (<ext-link ext-link-type="uri" xlink:href="https://www.drive5.com/pilercr/">https://www.drive5.com/pilercr/</ext-link>), FragGeneScan (<ext-link ext-link-type="uri" xlink:href="http://omics.informatics.indiana.edu/FragGeneScan/">http://omics.informatics.indiana.edu/FragGeneScan/</ext-link>), and CRISPRCasFinder (<ext-link ext-link-type="uri" xlink:href="https://crisprcas.i2bc.paris-saclay.fr/Home/Download">https://crisprcas.i2bc.paris-saclay.fr/Home/Download</ext-link>). CRISPRminer user manual is available at <ext-link ext-link-type="uri" xlink:href="http://www.microbiome-bigdata.com/CRISPRminer/index.php/Home/Index/help">http://www.microbiome-bigdata.com/CRISPRminer/index.php/Home/Index/help</ext-link>. The source code for CRISPRminer is available in the GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/hitzhangfan/microbiome-bigdata-Analyzer/tree/master/CRISPRminer">https://github.com/hitzhangfan/microbiome-bigdata-Analyzer/tree/master/CRISPRminer</ext-link>)</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Fan Zhang, Shijia Zhao, Chunyan Ren.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This research was funded by the National Natural Science Foundation of China grant no. 61872117 to F.Z., 31422014 and 31450001 to Z.H.; Project GFEQ5750006918 supported by Natural Scientific Research Innovation Foundation in Harbin Institute of Technology.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>F.Z. and Z.H. supervised the project. F.Z, C.R, S.Z, H.Z., and Y.L. designed the modules. S.Z., H.Z., Y.L., F.Z. Y.J., and K.Z. developed the database and web server. F.Z., C.R., and Y.Z. wrote the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Bacterial and archaeal genome sequences were downloaded from NCBI FTP site (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.ncbi.nlm.nih.gov/genomes/all/">ftp://ftp.ncbi.nlm.nih.gov/genomes/all/</ext-link>) in May 2017. 395 Cas profiles were collected from a recent study (Makarova et al., Nat. Rev. Microbiol. (2015)). Prophage regions were extracted from PHASTER (<ext-link ext-link-type="uri" xlink:href="http://phaster.ca/">http://phaster.ca/</ext-link>) and ACLAME database (<ext-link ext-link-type="uri" xlink:href="http://aclame.ulb.ac.be/Tools/Prophinder/">http://aclame.ulb.ac.be/Tools/Prophinder/</ext-link>). Genome islands were downloaded from IslandViewer 4 web server (<ext-link ext-link-type="uri" xlink:href="http://www.pathogenomics.sfu.ca/islandviewer/">http://www.pathogenomics.sfu.ca/islandviewer/</ext-link>). Phage genomes were downloaded from NCBI viral Genome Resource (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/genome/viruses/">https://www.ncbi.nlm.nih.gov/genome/viruses/</ext-link>), EMBL EBI phage genomes (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/genomes/phage.html">https://www.ebi.ac.uk/genomes/phage.html</ext-link>), and phagedb (<ext-link ext-link-type="uri" xlink:href="http://phagesdb.org/">http://phagesdb.org/</ext-link>). Besides, the datasets generated and/or analyzed during the current study could be downloaded online from the CRISPRminer website (<ext-link ext-link-type="uri" xlink:href="http://www.microbiome-bigdata.com/CRISPRminer/">http://www.microbiome-bigdata.com/CRISPRminer/</ext-link>). We confirm that all relevant data are available from the authors.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing interests</title><p>The authors declare no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>KL</given-names></name></person-group><article-title>The anti-CRISPR story: a battle for survival</article-title><source>Mol. Cell</source><year>2017</year><volume>68</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.09.002</pub-id><pub-id pub-id-type="pmid">28985512</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrangou</surname><given-names>R</given-names></name><etal/></person-group><article-title>CRISPR provides acquired resistance against viruses in prokaryotes</article-title><source>Science</source><year>2007</year><volume>315</volume><fpage>1709</fpage><lpage>1712</lpage><pub-id pub-id-type="doi">10.1126/science.1138140</pub-id><pub-id pub-id-type="pmid">17379808</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>KL</given-names></name></person-group><article-title>Phages fight back: inactivation of the CRISPR-Cas bacterial immune system by anti-CRISPR proteins</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><fpage>e1005282</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005282</pub-id><pub-id pub-id-type="pmid">26741979</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><article-title>Structural insights into the inactivation of CRISPR-Cas systems by diverse anti-CRISPR proteins</article-title><source>BMC Biol.</source><year>2018</year><volume>16</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s12915-018-0504-9</pub-id><pub-id pub-id-type="pmid">29554913</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grissa</surname><given-names>I</given-names></name><name><surname>Vergnaud</surname><given-names>G</given-names></name><name><surname>Pourcel</surname><given-names>C</given-names></name></person-group><article-title>CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats</article-title><source>Nucleic Acids Res.</source><year>2007</year><volume>35</volume><fpage>W52</fpage><lpage>W57</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm360</pub-id><pub-id pub-id-type="pmid">17537822</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grissa</surname><given-names>I</given-names></name><name><surname>Vergnaud</surname><given-names>G</given-names></name><name><surname>Pourcel</surname><given-names>C</given-names></name></person-group><article-title>The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats</article-title><source>BMC Bioinforma.</source><year>2007</year><volume>8</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-172</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grissa</surname><given-names>I</given-names></name><name><surname>Vergnaud</surname><given-names>G</given-names></name><name><surname>Pourcel</surname><given-names>C</given-names></name></person-group><article-title>CRISPRcompar: a website to compare clustered regularly interspaced short palindromic repeats</article-title><source>Nucleic Acids Res.</source><year>2008</year><volume>36</volume><fpage>W145</fpage><lpage>W148</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn228</pub-id><pub-id pub-id-type="pmid">18442988</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couvin</surname><given-names>D</given-names></name><etal/></person-group><article-title>CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced performance and integrates search for Cas proteins</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>W246</fpage><lpage>W251</lpage><pub-id pub-id-type="doi">10.1093/nar/gky425</pub-id><pub-id pub-id-type="pmid">29790974</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name></person-group><article-title>Not all predicted CRISPR-Cas systems are equal: isolated cas genes and classes of CRISPR like elements</article-title><source>BMC Bioinforma.</source><year>2017</year><volume>18</volume><fpage>92</fpage><pub-id pub-id-type="doi">10.1186/s12859-017-1512-4</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseau</surname><given-names>C</given-names></name><name><surname>Gonnet</surname><given-names>M</given-names></name><name><surname>Le Romancer</surname><given-names>M</given-names></name><name><surname>Nicolas</surname><given-names>J</given-names></name></person-group><article-title>CRISPI: a CRISPR interactive database</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>3317</fpage><lpage>3318</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp586</pub-id><pub-id pub-id-type="pmid">19846435</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C</given-names></name><etal/></person-group><article-title>Anti-CRISPRdb: a comprehensive online resource for anti-CRISPR proteins</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D393</fpage><lpage>D398</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx835</pub-id><pub-id pub-id-type="pmid">29036676</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgar</surname><given-names>RC</given-names></name></person-group><article-title>PILER-CR: fast and accurate identification of CRISPR repeats</article-title><source>BMC Bioinforma.</source><year>2007</year><volume>8</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-18</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rho</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name></person-group><article-title>FragGeneScan: predicting genes in short and error-prone reads</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><fpage>e191</fpage><pub-id pub-id-type="doi">10.1093/nar/gkq747</pub-id><pub-id pub-id-type="pmid">20805240</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Evolution and classification of the CRISPR-Cas systems</article-title><source>Nat. Rev. Microbiol.</source><year>2011</year><volume>9</volume><fpage>467</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2577</pub-id><pub-id pub-id-type="pmid">21552286</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertelli</surname><given-names>C</given-names></name><etal/></person-group><article-title>IslandViewer 4: expanded prediction of genomic islands for larger-scale datasets</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>W30</fpage><lpage>W35</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx343</pub-id><pub-id pub-id-type="pmid">28472413</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima-Mendez</surname><given-names>G</given-names></name><name><surname>Van Helden</surname><given-names>J</given-names></name><name><surname>Toussaint</surname><given-names>A</given-names></name><name><surname>Leplae</surname><given-names>R</given-names></name></person-group><article-title>Prophinder: a computational tool for prophage prediction in prokaryotic genomes</article-title><source>Bioinformatics</source><year>2008</year><volume>24</volume><fpage>863</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btn043</pub-id><pub-id pub-id-type="pmid">18238785</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arndt</surname><given-names>D</given-names></name><etal/></person-group><article-title>PHASTER: a better, faster version of the PHAST phage search tool</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>W16</fpage><lpage>W21</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw387</pub-id><pub-id pub-id-type="pmid">27141966</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>KS</given-names></name><etal/></person-group><article-title>An updated evolutionary classification of CRISPR-Cas systems</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>722</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3569</pub-id><pub-id pub-id-type="pmid">26411297</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shmakov</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diversity and evolution of class 2 CRISPR-Cas systems</article-title><source>Nat. Rev. Microbiol.</source><year>2017</year><volume>15</volume><fpage>169</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.184</pub-id><pub-id pub-id-type="pmid">28111461</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name></person-group><article-title>SnapShot: class 1 CRISPR-Cas systems</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>946</fpage><lpage>946 e941</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.018</pub-id><pub-id pub-id-type="pmid">28235204</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name></person-group><article-title>SnapShot: class 2 CRISPR-Cas systems</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>328</fpage><lpage>328 e321</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.038</pub-id><pub-id pub-id-type="pmid">28086097</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>L</given-names></name><name><surname>Wurtzel</surname><given-names>O</given-names></name><name><surname>Amitai</surname><given-names>G</given-names></name><name><surname>Sorek</surname><given-names>R</given-names></name></person-group><article-title>Self-targeting by CRISPR: gene regulation or autoimmunity?</article-title><source>Trends Genet</source><year>2010</year><volume>26</volume><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2010.05.008</pub-id><pub-id pub-id-type="pmid">20598393</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Inhibition of CRISPR-Cas9 with bacteriophage proteins</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>150</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.009</pub-id><pub-id pub-id-type="pmid">28041849</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watters</surname><given-names>Kyle E.</given-names></name><name><surname>Fellmann</surname><given-names>Christof</given-names></name><name><surname>Bai</surname><given-names>Hua B.</given-names></name><name><surname>Ren</surname><given-names>Shawn M.</given-names></name><name><surname>Doudna</surname><given-names>Jennifer A.</given-names></name></person-group><article-title>Systematic discovery of natural CRISPR-Cas12a inhibitors</article-title><source>Science</source><year>2018</year><volume>362</volume><issue>6411</issue><fpage>236</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1126/science.aau5138</pub-id><pub-id pub-id-type="pmid">30190307</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>CL</given-names></name><name><surname>Thomas</surname><given-names>BC</given-names></name><name><surname>Barrangou</surname><given-names>R</given-names></name><name><surname>Banfield</surname><given-names>JF</given-names></name></person-group><article-title>Metagenomic reconstructions of bacterial CRISPR loci constrain population histories</article-title><source>ISME J.</source><year>2016</year><volume>10</volume><fpage>858</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1038/ismej.2015.162</pub-id><pub-id pub-id-type="pmid">26394009</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchler-Bauer</surname><given-names>A</given-names></name><etal/></person-group><article-title>CDD: conserved domains and protein three-dimensional structure</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>D348</fpage><lpage>D352</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1243</pub-id><pub-id pub-id-type="pmid">23197659</pub-id></element-citation></ref></ref-list></back></article><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genome Biol</journal-id><journal-id journal-id-type="iso-abbrev">Genome Biol</journal-id><journal-title-group><journal-title>Genome Biology</journal-title></journal-title-group><issn pub-type="ppub">1474-7596</issn><issn pub-type="epub">1474-760X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6219182</article-id><article-id pub-id-type="publisher-id">1565</article-id><article-id pub-id-type="doi">10.1186/s13059-018-1565-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Highlight</subject></subj-group></article-categories><title-group><article-title>Understanding and repurposing CRISPR-mediated alternative splicing</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Jordan L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mou</surname><given-names>Haiwei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9797-8042</contrib-id><name><surname>Xue</surname><given-names>Wen</given-names></name><address><email>Wen.Xue@umassmed.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0742 0364</institution-id><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution>RNA Therapeutics Institute, University of Massachusetts Medical School, </institution></institution-wrap>Worcester, MA 01605 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0742 0364</institution-id><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution>Program in Molecular Medicine, Department of Molecular, Cell and Cancer Biology, and Li Weibo Institute for Rare Diseases Research, </institution><institution>University of Massachusetts Medical School, </institution></institution-wrap>Plantation Street, Worcester, MA 01605 USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>19</volume><elocation-id>184</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Two new studies refine our understanding of CRISPR-associated exon skipping and redefine its utility in engineering alternative splicing.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par10">The simplest iteration of CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated system 9) disrupts gene function by employing one single guide RNA (sgRNA) to localize Cas9 to make double-strand breaks (DSB) at a target genomic site. Once a DSB has been created, the cell begins to repair the DNA through non-homologous end joining (NHEJ), resulting in the insertion or deletion of a small number of nucleotides [<xref ref-type="bibr" rid="CR1">1</xref>]. Previous surveys of CRISPR/Cas9 off-target effects suggested that the technology is relatively precise, and thus positioned CRISPR/Cas9 as the preferred system for genome editing in the laboratory and potentially in the clinic. Multiple reports now suggest, however, that CRISPR/Cas9 editing results in the unintentional generation of alternatively spliced products, large genomic deletions, translocations and inversions [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par11">Here, we focus on the alternative splicing induced by CRISPR/Cas9. Several groups have reported alternative splicing following CRISPR/Cas9 editing with a sgRNA [<xref ref-type="bibr" rid="CR2">2</xref>], but the inciting event for exon skipping remains inconclusive. Two recent publications have begun to both refine our understanding of CRISPR-induced exon skipping and redefine its utility. Specifically, Li and colleagues [<xref ref-type="bibr" rid="CR6">6</xref>] set out to provide new clarity on how CRISPR-associated indels lead to exon skipping (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). Further, while alternative splicing is frequently considered an undesirable consequence of gene editing, Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] show that CRISPR cytosine to thymidine base editors (CBEs) can be repurposed for targeted splicing, adding to the repertoire of tools available for programmable genome editing (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Mechanisms of CRISPR-induced exon skipping. <bold>a</bold> From Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>], CRISPR/Cas9 induces exon skipping only with the generation of a premature termination codon (<italic>PTC</italic>) in an exon other than exon 1. <bold>b</bold> From Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>], CRISPR-SKIP repurposes the C&#x02009;&#x0003e;&#x02009;T SpCas9 Base editor, composed of the APOBEC1 cytidine deaminase, the SpCas9-D10A nickase, and the PBS1 uracil glycolase inhibitor (<italic>UGI</italic>), to mutate splice acceptor sites and thus to induce programmable exon skipping. <italic>PAM</italic>, Protospacer adjacent motif; <italic>sgRNA</italic>, single guide RNA</p></caption><graphic xlink:href="13059_2018_1565_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec2"><title>How do CRISPR/Cas9 indels induce exon skipping?</title><p id="Par12">New results from Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>] suggest that CRISPR/Cas9 induces exon skipping only after the generation of a premature termination codon (PTC). The authors demonstrate that the generation of a PTC following a Cas9-induced DNA break results in nonsense-associated alternative splicing (NAS) and the generation of alternative mRNA products.</p><p id="Par13">The researchers used 22 CRISPR/Cas9 gene edited or CBE rabbit lines. They sorted their mutated rabbit lines by the type of indel: non-frameshift, missense, PTC, and PTC in the first exon. Next, to determine whether the type of indel influences the rate of CRISPR/Cas9-induced exon skipping, they screened their 22 lines by using reverse transcriptase polymerase chain reaction (RT-PCR) to identify exon skipping events. No exon skipping was found in either the non-frameshift rabbit lines or the missense rabbit lines. In the rabbit lines with PTC mutations in exons other than exon 1, however, the researchers detected alternatively spliced mRNA. The results of work by Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>] therefore suggest that exon skipping occurs only following a PTC mutation, establishing a new rule for the prediction of when exon skipping may occur. Specifically, exon skipping is not dependent on the presence of DNA damage or an indel; rather, a CRISPR indel can only result in exon skipping if it generates a PTC in an exon other than exon 1 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>).</p></sec><sec id="Sec3"><title>Purposeful alternative splicing with CRISPR-SKIP</title><p id="Par14">While exon skipping has most often been regarded as an off-target effect that must be mitigated, previous reports have recognized the potential use of CRISPR/Cas9 alternative splicing for disease correction [<xref ref-type="bibr" rid="CR2">2</xref>]. Targetable exon exclusion strategies have already shown potential therapeutic benefit in many monogenic diseases, including Duchenne&#x02019;s muscular dystrophy, and Huntington&#x02019;s disease [<xref ref-type="bibr" rid="CR8">8</xref>]. Recent work by Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] harnesses the unique precision of CBEs to create a new biomedical tool for programmable gene splicing, termed CRISPR-SKIP [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par15">Because nearly every intron ends with a guanine, the authors hypothesized that CBEs may be used to disrupt the highly conserved splice acceptor consensus sequence for the exclusion of the following exon. Cystine to thymidine (C&#x02009;&#x0003e;&#x02009;T) CBEs have been shown previously to mutate guanine sites successfully by converting the complementary base, cystine [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. To test their hypothesis, Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] employed a C&#x02009;&#x0003e;&#x02009;T SpCas9 Base editor, composed of the APOBEC1 cytidine deaminase, the SpCas9-D10A nickase, and the PBS1 uracil glycolase inhibitor (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>).</p><p id="Par16">For simple detection of exon skipping, Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] selected exon 7 of RELA as a test locus because its length, a multiple of three, limits the likelihood that base editing would create a frameshift mutation and trigger nonsense-mediated decay. In conjunction with exon 7 of RELA, the authors also targeted the splice acceptor of exon 5 in PIK3CA. Using deep sequencing, the authors found a base-editing rate of 6.26% G&#x02009;&#x0003e;&#x02009;C in RELA and 26.38% in PI3KCA. These percentages corresponded to an exon skipping rate of 15.46% in RELA and 37.5% in PI3KCA. Surprisingly, at the exon 5 PI3KCA splice acceptor site, the authors also detected G&#x02009;&#x0003e;&#x02009;C (14.66%), G&#x02009;&#x0003e;&#x02009;T (2.58%), and a G&#x02009;&#x0003e;&#x02009;A (10.34%) modifications more than 20-nucleotides outside the CBE target range.</p><p id="Par17">Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] also compared the rate of exon skipping generated by CRISPR-SKIP to that of skipping induced by CRISPR/Cas9 following a DSB, as described by Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>]. With sgRNAs that were not targeted to the splice acceptor, CRISPR/Cas9 induced either an equivalent number of or fewer exon skipping events than CRISPR-SKIP. When the authors used the same sgRNAs targeted to the splice acceptor for both CRISPR-SKIP and CRISPR/Cas9, they found that CRISPR/Cas9 was more effective at inducing exon skipping at three of the five targets, whereas CRISPR-SKIP was more effective at the other two. Further, the authors sought to expand CRISPR-SKIP&#x02019;s utility by eliminating its dependence on the presence of an NGG protospacer adjacent motif (PAM) 12&#x02013;17&#x000a0;bp from the target cytidine. They successfully demonstrated that CBE with different Cas9 scaffolds, including SpCas9-VQR-BE3 with NGA PAM and SaCas9-KKH-BE3 with NNNRRT PAM, can induce targeted exon skipping.</p><p id="Par18">Finally, to ease the burden of identifying suitable transcripts for CRISPR-SKIP base editing, Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] developed a web-based software tool that allows researchers to identify appropriate sgRNAs for a desired target, incorporates the various CBEs and their efficiency, and generates an off-target score.</p></sec><sec id="Sec4"><title>Skipping forward</title><p id="Par19">As CRISPR/Cas9 gene editing accelerates from the bench to the clinic, understanding and perhaps exploiting the unintentional consequences, including exon skipping, translocations, inversion, and deletions, will take center stage. Two recent publications from Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>] and Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] refine our understanding of how CRISPR/Cas9 indels induce exon skipping, and further broaden the CRISPR tool-kit to include programmable exon skipping.</p><p id="Par20">Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>] sheds new light on how CRISPR/Cas9 gene inactivation inadvertently results in exon skipping. The authors&#x02019; finding that only PTC mutations induce exon skipping narrows the hunt for the inciting event of exon skipping, limiting the likelihood that DNA damage or the indel itself have causative roles. These authors suggest that their finding further supports the hypothesis of a &#x02018;nuclear scanning mechanism&#x02019; that enables the cell to identify pre-mRNAs with PTCs and shuttles these transcripts through nonsense-associated alternative splicing. We do not yet know how the cell identifies these transcripts, and why the location of the PTC determines whether the transcript undergoes nonsense-mediated decay or nonsense-associated alternative splicing. Further, the role of cis-regulatory elements, specifically exonic splicing silencers, remains elusive. In Li et al.&#x02019;s study, several missense rabbit lines had disruption of exonic regulatory elements, but only premature PTC lines resulted in exon skipping. Li et al. [<xref ref-type="bibr" rid="CR6">6</xref>] provides researchers with a new guideline to screen for the presence of alternative mRNA products following CRISPR/Cas9 editing. Specifically, it&#x02019;s advisable to sequence through your indel, and if it is a predicted PTC, run a RT-PCR to screen for the presence of alternative mRNA products.</p><p id="Par21">Although exon skipping is often viewed as an unintended consequence of CRISPR/Cas9 gene editing, Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] harnessed CBEs in CRISPR-SKIP to achieve intentional programmable alternative splicing. CRISPR-SKIP has potential broad utility in both biotechnology and the clinic. Gapinske et al. [<xref ref-type="bibr" rid="CR7">7</xref>] estimate that 118,089 out of 187,636 inner exons in protein-coding genes are targetable. CRISPR-SKIP could be harnessed as a therapeutic tool to address genetic disease by directing the expression of specific mRNA transcripts. In addition, unlike other exon skipping platforms, CRISPR-SKIP induces stable changes and thus increases the likelihood that a single treatment may be therapeutic for patients. Perhaps the most critical advantage of CRISPR-SKIP over other exon-skipping technologies, including canonical CRISPR/Cas9, is that it does not introduce high-levels of DSBs into the genome, reducing the probabilities of large deletions, translocations and inversions observed with Cas9 [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par22">The two articles highlighted here generate further questions around critical gaps in our understanding of how and when splicing occurs in CRISPR-edited systems. For example, Gapinske and colleagues [<xref ref-type="bibr" rid="CR7">7</xref>] found that they were able to edit approximately 77% of the splice acceptors that were targeted, but only 50% of subsequent exons were skipped. Missed exon skipping may be the result of cryptic splice acceptor sites, incomplete understanding of intron-exon biology, or the need for optimization of base-editing technologies.</p><p id="Par23">Taken together, these two publications provide a critical framework for understanding the mechanism and utility of CRISPR-induced exon skipping.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>Cas9</term><def><p id="Par2">CRISPR-associated system 9</p></def></def-item><def-item><term>CBE</term><def><p id="Par3">Cytosine to thymidine base editor</p></def></def-item><def-item><term>CRISPR/Cas9</term><def><p id="Par4">Clustered regularly interspersed palindromic repeats, Cas9</p></def></def-item><def-item><term>DSB</term><def><p id="Par5">Double-strand break</p></def></def-item><def-item><term>PAM</term><def><p id="Par6">Protospacer adjacent motif</p></def></def-item><def-item><term>PTC</term><def><p id="Par7">Premature termination codon</p></def></def-item><def-item><term>RT-PCR</term><def><p id="Par8">Reverse transcriptase polymerase chain reaction</p></def></def-item><def-item><term>sgRNA</term><def><p id="Par9">Single guide RNA</p></def></def-item></def-list></glossary><ack><title>Funding</title><p>This work was supported by grants from the National Institutes of Health (NIH) (DP2HL137167, P01HL131471, and UG3HL147367), the American Cancer Society (129056-RSG-16-093), UMass CCTS, Hyundai Hope on Wheels, and the Lung Cancer Research Foundation.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JLS, HM and WX wrote and approved the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar2"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Charpentier</surname><given-names>E</given-names></name></person-group><article-title>Genome editing. The new frontier of genome engineering with CRISPR-Cas9</article-title><source>Science</source><year>2014</year><volume>346</volume><fpage>1258096</fpage><pub-id pub-id-type="doi">10.1126/science.1258096</pub-id><pub-id pub-id-type="pmid">25430774</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>JL</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XO</given-names></name><etal/></person-group><article-title>CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion</article-title><source>Genome Biol</source><year>2017</year><volume>18</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/s13059-017-1237-8</pub-id><pub-id pub-id-type="pmid">28615073</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosicki</surname><given-names>M</given-names></name><name><surname>Tomberg</surname><given-names>K</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name></person-group><article-title>Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements</article-title><source>Nat Biotechnol</source><year>2018</year><volume>36</volume><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1038/nbt0918-899c</pub-id><pub-id pub-id-type="pmid">30010673</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>AI</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Colpan</surname><given-names>C</given-names></name><name><surname>Bizhanova</surname><given-names>A</given-names></name><name><surname>Akama-Garren</surname><given-names>E</given-names></name><etal/></person-group><article-title>A versatile reporter system for CRISPR-mediated chromosomal rearrangements</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><fpage>111</fpage><pub-id pub-id-type="doi">10.1186/s13059-015-0680-7</pub-id><pub-id pub-id-type="pmid">26018130</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canver</surname><given-names>MC</given-names></name><name><surname>Bauer</surname><given-names>DE</given-names></name><name><surname>Dass</surname><given-names>A</given-names></name><name><surname>Yien</surname><given-names>YY</given-names></name><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><etal/></person-group><article-title>Characterization of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>21312</fpage><lpage>21324</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.564625</pub-id><pub-id pub-id-type="pmid">24907273</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>CRISPR-induced exon skipping is dependent on premature termination codon mutations</article-title><source>Genome Biol</source><year>2018</year><volume>19</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/s13059-018-1532-z</pub-id><pub-id pub-id-type="pmid">30333044</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gapinske</surname><given-names>M</given-names></name><name><surname>Luu</surname><given-names>A</given-names></name><name><surname>Winter</surname><given-names>J</given-names></name><name><surname>Woods</surname><given-names>WS</given-names></name><name><surname>Kostan</surname><given-names>KA</given-names></name><name><surname>Shiva</surname><given-names>N</given-names></name><etal/></person-group><article-title>CRISPR-SKIP: programmable gene splicing with single base editors</article-title><source>Genome Biol</source><year>2018</year><volume>19</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/s13059-018-1482-5</pub-id><pub-id pub-id-type="pmid">30107853</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aartsma-Rus</surname><given-names>A</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name></person-group><article-title>Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications</article-title><source>RNA</source><year>2007</year><volume>13</volume><fpage>1609</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1261/rna.653607</pub-id><pub-id pub-id-type="pmid">17684229</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudelli</surname><given-names>NM</given-names></name><name><surname>Komor</surname><given-names>AC</given-names></name><name><surname>Rees</surname><given-names>HA</given-names></name><name><surname>Packer</surname><given-names>MS</given-names></name><name><surname>Badran</surname><given-names>AH</given-names></name><name><surname>Bryson</surname><given-names>DI</given-names></name><name><surname>Liu</surname><given-names>DR</given-names></name></person-group><article-title>Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage</article-title><source>Nature</source><year>2017</year><volume>551</volume><fpage>464</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/nature24644</pub-id><pub-id pub-id-type="pmid">29160308</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komor</surname><given-names>AC</given-names></name><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Packer</surname><given-names>MS</given-names></name><name><surname>Zuris</surname><given-names>JA</given-names></name><name><surname>Liu</surname><given-names>DR</given-names></name></person-group><article-title>Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage</article-title><source>Nature</source><year>2016</year><volume>533</volume><fpage>420</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/nature17946</pub-id><pub-id pub-id-type="pmid">27096365</pub-id></element-citation></ref></ref-list></back></article><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genome Biol</journal-id><journal-id journal-id-type="iso-abbrev">Genome Biol</journal-id><journal-title-group><journal-title>Genome Biology</journal-title></journal-title-group><issn pub-type="ppub">1474-7596</issn><issn pub-type="epub">1474-760X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6219166</article-id><article-id pub-id-type="publisher-id">1569</article-id><article-id pub-id-type="doi">10.1186/s13059-018-1569-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Highlight</subject></subj-group></article-categories><title-group><article-title>CRISPR/Cas9 offers a new tool for studying the role of chromatin architecture in disease pathogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dean</surname><given-names>Ann</given-names></name><address><email>anndean@helix.nih.gov</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2203 7304</institution-id><institution-id institution-id-type="GRID">grid.419635.c</institution-id><institution>Laboratory of Cellular and Developmental Biology, </institution><institution>National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, </institution></institution-wrap>Bethesda, MD 20892 USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>19</volume><elocation-id>185</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">A recent study used CRISPR/Cas9 to reveal long-range looping between disease-related genes and their regulatory elements that is mediated by the CCCTC-binding factor (CTCF) in prostate cancer.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK075033</award-id><principal-award-recipient><name><surname>Dean</surname><given-names>Ann</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par9">Extensive studies are currently devoted to understanding the three-dimensional (3D) architecture of genomes, including the formation and function of chromatin loops, topologically associated domains (TADs) and transcriptional activity-based A and B compartments. These studies provide evidence that the spatial organization of the genome is a global regulator of gene transcription. DNA looping is the fundamental architectural unit of the 3D genome and builds long-range connections and communication between genes and their regulatory enhancer elements. In addition, genome-wide association studies (GWAS) have revealed that a large fraction of disease-associated mutations or genomic rearrangements are found in non-coding rather than coding regions of the genome, providing a clue that the long range communication between genes and regulatory elements might play an important role in human disease [<xref ref-type="bibr" rid="CR1">1</xref>]. A recent article presents a systemic approach for connecting these genomic aberrations to underlying disease genes in order to understand how the GWAS-identified single nucleotide polymorphisms (SNPs) are related to disease [<xref ref-type="bibr" rid="CR2">2</xref>].</p></sec><sec id="Sec2"><title>Chromosomal looping in prostate cancer</title><p id="Par10">Enhancer-promoter looping facilitates the assembly of the transcriptional machinery at specific promoters and thus the effective initiation of transcription. Histone H3K27ac distinguishes active enhancers, which are the ones that frequently engage in looping to transcriptionally active genes, from inactive or poised enhancers. Chromosomal looping is also maintained by numerous architectural proteins and by long non-coding RNAs (lncRNAs) in addition to regulatory DNA elements. The major architectural protein CCCTC-binding factor (CTCF) is an 11 zinc-finger DNA-binding protein that associates with the cohesin complex and orchestrates long range interactions between remote enhancers and their target gene promoters to modulate gene transcription. Whether this regulation is direct or indirect and involving an insulator function is an open question.</p><p id="Par11">In this issue of <italic>Genome Biology</italic>, Guo et al. [<xref ref-type="bibr" rid="CR2">2</xref>] describe how prostate cancer (PCa) risk loci that they identified in GWAS participate in CTCF-mediated chromatin loops and function to repress the expression of the encircled genes. Strikingly, deletion of the PCa-associated CTCF loop anchors using the CRISPR/Cas9 (clustered regularly interspersed palindromic repeats/CRISPR-associated system 9) genome editing approach resulted in up to 100-fold increases in the expression of some genes within the CTCF loops. In one case, the upregulated gene, <italic>KCNN3</italic> (also called <italic>SK3</italic>), was already known to be linked to PCa biology. The CRISPR editing results suggest that <italic>KCNN3</italic> is normally held in a repressive loop by CTCF, revealing a novel mechanism underlying genetic susceptibility to PCa.</p><p id="Par12">Guo and colleagues set out to discover regulatory elements that are associated with 2181 PCa risk-associated SNPs [<xref ref-type="bibr" rid="CR2">2</xref>]. First, they required that the PCa-risk SNPs reside in open chromatin, as determined by DNase I hypersensitivity, which reduced the number of potential regulatory-function-associated SNPs to 443. They then compared these 443 SNPs to the ChIP-seq peaks for the active enhancer marker H3K27ac or insulator protein CTCF in two non-tumorigenic prostate cell populations and five prostate cancer cell lines. In this way, they identified 222 PCa-risk-associated SNPs corresponding to an H3K27ac peak and 93 corresponding to a CTCF peak, suggesting an enhancer- or insulator-like function of these SNPs in PCa.</p><p id="Par13">To ask whether the enhancer- or insulator-related SNPs were involved in the regulation of chromosomal architecture, Guo et al. [<xref ref-type="bibr" rid="CR2">2</xref>] employed in situ Hi-C to detect long-range looping interactions in normal prostate RWPE-1 cells and in the PCa cell lines C4-2B and 22Rv1. After overlap with loop anchor regions, 203 H3K27ac-associated SNPs and 85 CTCF-associated SNPs were identified as participants in chromatin loops. To delve more deeply into the functional relationships among regulatory elements, chromosome folding and the transcription landscape, the authors deleted CTCF loop anchor regions that contained PCa-risk SNPs on chromosomes 1 and 12 by CRISPR/Cas9 and performed transcriptome analysis before and after deletion. On chromosome 1, loop-encircled <italic>KCNN3</italic> expression increased almost 100-fold while other nearby genes were unaffected. On chromosome 12, <italic>KRT78</italic> was activated more than 100-fold, while the expression of some neighboring genes was modestly elevated. In contrast to these deletions, when the CTCF sites that paired with the PCa risk-associated CTCF anchor regions on the two chromosomes were deleted, there was only a modest or no influence on gene expression within the loop.</p><p id="Par14">What underlies the gene activation? Both <italic>KCNN3</italic> and <italic>KRT78</italic> are in genomic regions that are devoid of the H3K27ac mark. The authors investigated whether an enhancer element within the looped regions had become activated as assessed by H3K27ac acquisition but did not detect such a change. Instead, the result suggests that after the deletion, the genes came under the influence of a pre-existing enhancer outside the CTCF-mediated loop area that was compatible with only some of the genes that were newly available to it. As Guo et al. [<xref ref-type="bibr" rid="CR2">2</xref>] propose, loss of an &#x02018;insulator&#x02019; loop that had blocked the excluded enhancer, and the establishment of interaction between the activated genes and such an enhancer, could explain this result nicely (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Hi-C was not carried out for the deleted cells, so this idea remains speculative. Structural studies after the deletions could provide support for this idea and might also reveal what new CTCF&#x02013;CTCF associations occur that could help to explain why the deletion of one loop anchor participant was more effective than that of another in boosting <italic>KCNN3</italic> or <italic>KRT78</italic> transcription.<fig id="Fig1"><label>Fig. 1</label><caption><p>Model illustrating the chromatin architectural basis for the aberrant activation of gene expression in prostate cancer. Regions that are associated with prostate cancer risk bind CTCF and interact with each other to maintain the repression of genes within a looped region. Chromatin surrounding the gene is marked by repressive histone H3K27me3. When a prostate cancer risk-associated CTCF anchor region (red arrow becomes red triangle) is deleted by CRISPR/Cas9-based editing, the putative CTCF-mediated loop is no longer formed, and a formerly repressed gene can be accessed and aberrantly activated by an enhancer, marked by H3K27ac, that is located outside the former loop</p></caption><graphic xlink:href="13059_2018_1569_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec3"><title>Putting CRISPR to work in the 3D genome</title><p id="Par15">The 100-fold activation of <italic>KCNN3</italic> and <italic>KRT78</italic> after deletion of the two PCa-risk-associated CTCF anchor regions is especially notable in contrast to results obtained upon rapid removal of CTCF in embryonic stem cells [<xref ref-type="bibr" rid="CR3">3</xref>]. In this work, the effects on the transcriptome were generally modest and only a few genes were upregulated more than ten-fold. On the other hand, both groups concluded that those genes that are upregulated upon CTCF loss are normally repressed by CTCF indirectly. One caveat to this definitive conclusion is that, considering the size of the CTCF anchor region deletions (1&#x02013;2&#x000a0;kb) in the current work, a role for other factors bound along with CTCF cannot be excluded. To address the true function of CTCF in gene regulation, more precise CRISPR/Cas9 editing may be required.</p><p id="Par16">CRISPR/Cas9 technology is proving useful in creating precise deletions or mutations of CTCF motifs in order to determine CTCF function in cell-fate determination, gene regulation and genome topology. A nine-base pair (bp) homozygous deletion was generated by CRISPR/Cas9 editing in a core CTCF motif at a boundary in the <italic>HoxA</italic> cluster that functions to separate adjacent TADs. Abrogation of CTCF occupancy at this position resulted in the <italic>Hox</italic> genes&#x02019; becoming subject to transcriptional activation from outside their original domain [<xref ref-type="bibr" rid="CR4">4</xref>]. Consistent with Guo et al. [<xref ref-type="bibr" rid="CR2">2</xref>], CTCF functions as a regulator by long-range looping to insulate the <italic>Hox</italic> cluster&#x02019;s repressive genomic region from active chromatin and thus to maintain a low level of gene expression. In addition, a recent study showed that CRISPR-mediated disruption of CTCF-binding sites at an &#x003b1;-globin locus, subTAD, allowed the &#x003b1;-globin enhancers to activate genes on the other side of the lost boundary, which they normally cannot access [<xref ref-type="bibr" rid="CR5">5</xref>]. Another study developed a CRISPR/Cas9-based DNA-fragment in-situ-inversion technology and demonstrated that the relative orientation of CTCF-binding sites in enhancers and promoters determined the directionality of DNA looping and the regulation of gene expression [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par17">CRISPR/Cas9 has been more broadly employed to determine how 3D genome architecture is related to disease states. For example, CRISPR/Cas9 deletion of CTCF sites at the boundaries of an insulated neighborhood containing proto-oncogenes was sufficient to induce their activation in non-malignant cells [<xref ref-type="bibr" rid="CR7">7</xref>]. Importantly, recurrent focal deletions in the same regions are associated with the expression of oncogenes in T-cell acute lymphoblastic leukemia. Disruption of a CTCF-binding motif between TADs by CRISPR/Cas9 resulted in the loss of insulation and in aberrant enhancer activation of a receptor tyrosine kinase gene, <italic>PDGFRA</italic>, leading to an enhanced gliomagenesis [<xref ref-type="bibr" rid="CR8">8</xref>]. In another example, investigators used CRISPR to delete a CTCF boundary element, thereby creating topological changes, and were able to recreate a known human genetic limb malformation in a mouse model [<xref ref-type="bibr" rid="CR9">9</xref>]. A recent innovative extension of the CRISPR approach, the CRISPR-dCAS9 CLOuD9 system, which involves plant phytohormone S-(+)-abscisic acid (ABA)-induced proximity reagents to reconfigure loops between enhancers and promoters, should provide a widely applicable way to re-engineer genome conformation [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par18">Defining genome architectural mechanisms in disease-related gene regulation has great potential to illuminate the role of GWAS-identified noncoding variation in cis-regulatory elements and regulators of DNA topology. On the basis of the systematic approach described by Guo et al. [<xref ref-type="bibr" rid="CR2">2</xref>], CRISPR/Cas9 editing technology will be highly valuable in the creation of additional disease models and is likely to provide new insight into 3D architectural-based gene therapy.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>Cas9</term><def><p id="Par2">CRISPR-associated system 9</p></def></def-item><def-item><term>CRISPR</term><def><p id="Par3">Clustered regularly interspersed palindromic repeats</p></def></def-item><def-item><term>CTCF</term><def><p id="Par4">CCCTC-binding factor</p></def></def-item><def-item><term>GWAS</term><def><p id="Par5">Genome-wide association studies</p></def></def-item><def-item><term>PCa</term><def><p id="Par6">Prostate cancer</p></def></def-item><def-item><term>SNP</term><def><p id="Par7">Single nucleotide polymorphism</p></def></def-item><def-item><term>TAD</term><def><p id="Par8">Topologically associated domain</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>This work was funded by the Intramural program of the National Institute of Diabetes and Digestive and Kidney Diseases (DK075033 to AD).</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>XG and AD wrote and approved the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar2"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurano</surname><given-names>MT</given-names></name><name><surname>Humbert</surname><given-names>R</given-names></name><name><surname>Rynes</surname><given-names>E</given-names></name><name><surname>Thurman</surname><given-names>RE</given-names></name><name><surname>Haugen</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Systematic localization of common disease-associated variation in regulatory DNA</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>1190</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1126/science.1222794</pub-id><pub-id pub-id-type="pmid">22955828</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Hazelett</surname><given-names>DJ</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name><name><surname>Rhie</surname><given-names>SK</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name></person-group><article-title>CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops</article-title><source>Genome Biol</source><year>2018</year><volume>19</volume><fpage>160</fpage><pub-id pub-id-type="doi">10.1186/s13059-018-1531-0</pub-id><pub-id pub-id-type="pmid">30296942</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nora</surname><given-names>EP</given-names></name><name><surname>Goloborodko</surname><given-names>A</given-names></name><name><surname>Valton</surname><given-names>AL</given-names></name><name><surname>Gibcus</surname><given-names>JH</given-names></name><name><surname>Uebersohn</surname><given-names>A</given-names></name><name><surname>Abdennur</surname><given-names>N</given-names></name><etal/></person-group><article-title>Targeted degradation of CTCF decouples local insulation of chromosome domains from genomic compartmentalization</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>930</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.004</pub-id><pub-id pub-id-type="pmid">28525758</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narendra</surname><given-names>V</given-names></name><name><surname>Rocha</surname><given-names>PP</given-names></name><name><surname>An</surname><given-names>D</given-names></name><name><surname>Raviram</surname><given-names>R</given-names></name><name><surname>Skok</surname><given-names>JA</given-names></name><name><surname>Mazzoni</surname><given-names>EO</given-names></name><name><surname>Reinberg</surname><given-names>D</given-names></name></person-group><article-title>CTCF establishes discrete functional chromatin domains at the Hox clusters during differentiation</article-title><source>Science</source><year>2015</year><volume>347</volume><fpage>1017</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1126/science.1262088</pub-id><pub-id pub-id-type="pmid">25722416</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanssen</surname><given-names>LLP</given-names></name><name><surname>Kassouf</surname><given-names>MT</given-names></name><name><surname>Oudelaar</surname><given-names>AM</given-names></name><name><surname>Biggs</surname><given-names>D</given-names></name><name><surname>Preece</surname><given-names>C</given-names></name><name><surname>Downes</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Tissue-specific CTCF-cohesin-mediated chromatin architecture delimits enhancer interactions and function in vivo</article-title><source>Nat Cell Biol</source><year>2017</year><volume>19</volume><fpage>952</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1038/ncb3573</pub-id><pub-id pub-id-type="pmid">28737770</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Canzio</surname><given-names>D</given-names></name><name><surname>Shou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gorkin</surname><given-names>DU</given-names></name><etal/></person-group><article-title>CRISPR inversion of CTCF sites alters genome topology and enhancer/promoter function</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>900</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.038</pub-id><pub-id pub-id-type="pmid">26276636</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hnisz</surname><given-names>D</given-names></name><name><surname>Weintraub</surname><given-names>AS</given-names></name><name><surname>Day</surname><given-names>DS</given-names></name><name><surname>Valton</surname><given-names>AL</given-names></name><name><surname>Bak</surname><given-names>RO</given-names></name><name><surname>Li</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Activation of proto-oncogenes by disruption of chromosome neighborhoods</article-title><source>Science</source><year>2016</year><volume>351</volume><fpage>1454</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1126/science.aad9024</pub-id><pub-id pub-id-type="pmid">26940867</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flavahan</surname><given-names>WA</given-names></name><name><surname>Drier</surname><given-names>Y</given-names></name><name><surname>Liau</surname><given-names>BB</given-names></name><name><surname>Gillespie</surname><given-names>SM</given-names></name><name><surname>Venteicher</surname><given-names>AS</given-names></name><name><surname>Stemmer-Rachamimov</surname><given-names>AO</given-names></name><etal/></person-group><article-title>Insulator dysfunction and oncogene activation in IDH mutant gliomas</article-title><source>Nature</source><year>2016</year><volume>529</volume><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/nature16490</pub-id><pub-id pub-id-type="pmid">26700815</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupianez</surname><given-names>DG</given-names></name><name><surname>Kraft</surname><given-names>K</given-names></name><name><surname>Heinrich</surname><given-names>V</given-names></name><name><surname>Krawitz</surname><given-names>P</given-names></name><name><surname>Brancati</surname><given-names>F</given-names></name><name><surname>Klopocki</surname><given-names>E</given-names></name><etal/></person-group><article-title>Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>1012</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.004</pub-id><pub-id pub-id-type="pmid">25959774</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>SL</given-names></name><name><surname>Mariano</surname><given-names>NC</given-names></name><name><surname>Bermudez</surname><given-names>A</given-names></name><name><surname>Arruda</surname><given-names>NL</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Manipulation of nuclear architecture through CRISPR-mediated chromosomal looping</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>15993</fpage><pub-id pub-id-type="doi">10.1038/ncomms15993</pub-id><pub-id pub-id-type="pmid">28703221</pub-id></element-citation></ref></ref-list></back></article><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">mBio</journal-id><journal-id journal-id-type="iso-abbrev">MBio</journal-id><journal-id journal-id-type="hwp">mbio</journal-id><journal-id journal-id-type="pmc">mbio</journal-id><journal-id journal-id-type="publisher-id">mBio</journal-id><journal-title-group><journal-title>mBio</journal-title></journal-title-group><issn pub-type="epub">2150-7511</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6234860</article-id><article-id pub-id-type="pmid">30425154</article-id><article-id pub-id-type="publisher-id">mBio02184-18</article-id><article-id pub-id-type="doi">10.1128/mBio.02184-18</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="overline"><subject>Molecular Biology and Physiology</subject></subj-group></article-categories><title-group><article-title>Temperature, by Controlling Growth Rate, Regulates CRISPR-Cas Activity in <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content></article-title><alt-title alt-title-type="running-head">Slow Growth Promotes CRISPR Adaptation</alt-title><alt-title alt-title-type="short-authors">H&#x000f8;yland-Kroghsbo et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>H&#x000f8;yland-Kroghsbo</surname><given-names>Nina Molin</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>Katrina Arcelia</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bassler</surname><given-names>Bonnie L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><aff id="aff1"><label>a</label><addr-line>Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA</addr-line></aff><aff id="aff2"><label>b</label><addr-line>Howard Hughes Medical Institute, Chevy Chase, Maryland, USA</addr-line></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Vogel</surname><given-names>Joerg</given-names></name><role>Editor</role><aff>University of W&#x000fc;rzburg</aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Gottesman</surname><given-names>Susan</given-names></name><role>Solicited external reviewer</role><aff>NCI-NIH</aff></contrib><contrib contrib-type="reviewer"><name><surname>Marraffini</surname><given-names>Luciano</given-names></name><role>Solicited external reviewer</role><aff>Rockefeller University</aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Bonnie L. Bassler, <email>bbassler@princeton.edu</email>.</corresp><fn id="fn1" fn-type="present-address"><label>*</label><p>Present address: Katrina Arcelia Mu&#x000f1;oz, Bates College, Lewiston, Maine, USA.</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><season>Nov-Dec</season><year>2018</year></pub-date><volume>9</volume><issue>6</issue><elocation-id>e02184-18</elocation-id><history><date date-type="received"><day>2</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>9</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="mbo006184172001.pdf"/><abstract abstract-type="precis"><p><named-content content-type="genus-species">P. aeruginosa</named-content> is a soil dwelling bacterium and a plant pathogen, and it also causes life-threatening infections in humans. Thus, <named-content content-type="genus-species">P. aeruginosa</named-content> thrives in diverse environments and over a broad range of temperatures. Some <named-content content-type="genus-species">P. aeruginosa</named-content> strains rely on the CRISPR-Cas adaptive immune system as a phage defense mechanism. Our discovery that low temperatures increase CRISPR adaptation suggests that the rarely occurring but crucial naive adaptation events may take place predominantly under conditions of slow growth, e.g., during the bacterium&#x02019;s soil dwelling existence and during slow growth in biofilms.</p></abstract><abstract><title>ABSTRACT</title><p>Clustered regularly interspaced short palindromic repeat (CRISPR)-associated (CRISPR-Cas) systems are adaptive defense systems that protect bacteria and archaea from invading genetic elements. In <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content>, quorum sensing (QS) induces the CRISPR-Cas defense system at high cell density when the risk of bacteriophage infection is high. Here, we show that another cue, temperature, modulates <named-content content-type="genus-species">P. aeruginosa</named-content> CRISPR-Cas. Increased CRISPR adaptation occurs at environmental (i.e., low) temperatures compared to that at body (i.e., high) temperature. This increase is a consequence of the accumulation of CRISPR-Cas complexes, coupled with reduced <named-content content-type="genus-species">P. aeruginosa</named-content> growth rate at the lower temperature, the latter of which provides additional time prior to cell division for CRISPR-Cas to patrol the cell and successfully eliminate and/or acquire immunity to foreign DNA. Analyses of a QS mutant and synthetic QS compounds show that the QS and temperature cues act synergistically. The diversity and level of phage encountered by <named-content content-type="genus-species">P. aeruginosa</named-content> in the environment exceed that in the human body, presumably warranting increased reliance on CRISPR-Cas at environmental temperatures.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>CRISPR</kwd><kwd>phage</kwd><kwd><italic>Pseudomonas</italic></kwd><kwd>quorum sensing</kwd><kwd>growth rate</kwd></kwd-group><funding-group><award-group id="award1"><funding-source><institution-wrap><institution>Danish Council for Indepndent Research</institution></institution-wrap></funding-source><award-id>DFF-4090-00265</award-id><principal-award-recipient><name><surname>H&#x000f8;yland-Kroghsbo</surname><given-names>Nina Molin</given-names></name></principal-award-recipient></award-group><award-group id="award2"><funding-source><institution-wrap><institution>Lundbeck Fellowship</institution></institution-wrap></funding-source><award-id>R220-2016-860</award-id><principal-award-recipient><name><surname>H&#x000f8;yland-Kroghsbo</surname><given-names>Nina Molin</given-names></name></principal-award-recipient></award-group><award-group id="award3"><funding-source><institution-wrap><institution>HHS | National Institutes of Health (NIH)</institution><institution-id>https://doi.org/10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>2R37GM065859</award-id><principal-award-recipient><name><surname>Bassler</surname><given-names>Bonnie</given-names></name></principal-award-recipient></award-group><award-group id="award4"><funding-source><institution-wrap><institution>National Science Foundation (NSF)</institution><institution-id>https://doi.org/10.13039/100000001</institution-id></institution-wrap></funding-source><award-id>MCB-1713731</award-id><principal-award-recipient><name><surname>Bassler</surname><given-names>Bonnie</given-names></name></principal-award-recipient></award-group><award-group id="award5"><funding-source><institution-wrap><institution>Howard Hughes Medical Institute (HHMI)</institution><institution-id>https://doi.org/10.13039/100000011</institution-id></institution-wrap></funding-source><award-id>NA</award-id><principal-award-recipient><name><surname>Bassler</surname><given-names>Bonnie</given-names></name></principal-award-recipient></award-group><award-group id="award6"><funding-source><institution-wrap><institution>Alexander von Humboldt-Stiftung (Humboldt Foundation)</institution><institution-id>https://doi.org/10.13039/100005156</institution-id></institution-wrap></funding-source><award-id>NA</award-id><principal-award-recipient><name><surname>Bassler</surname><given-names>Bonnie</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="9" count-type="supplementary-material"/><fig-count count="5"/><table-count count="0"/><equation-count count="0"/><ref-count count="47"/><page-count count="12"/><word-count count="8647"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>November/December 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Bacteria have evolved defense systems to fend off bacteriophage viruses that prey upon them. One of these systems, the clustered regularly interspaced short palindromic repeat (CRISPR)-associated (CRISPR-Cas) system, provides acquired and heritable sequence-specific immunity against previously encountered viruses and plasmids (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). CRISPR-Cas systems generally rely on three main activities, adaptation, expression, and interference (<xref rid="B3" ref-type="bibr">3</xref>). Upon infection with a foreign genetic element, the CRISPR-Cas machinery can incorporate a short piece of foreign DNA into the genomic CRISPR array, which contains the genetic memory of prior infecting elements. The CRISPR array thereby expands in size by gaining an additional repeat and a spacer derived from the foreign DNA. This process is known as adaptation (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Next, during the expression stage, the CRISPR array is transcribed into pre-CRISPR RNAs (pre-crRNAs) that are processed into mature crRNAs, each complementary to a particular foreign DNA sequence. crRNAs guide Cas protein complexes to target complementary incoming foreign DNA, denoted protospacers (<xref rid="B6" ref-type="bibr">6</xref>). Most CRISPR-Cas systems require the presence of a short protospacer adjacent motif (PAM) to correctly identify the target DNA and distinguish it from self (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). The final stage is interference, when Cas immune surveillance complexes, guided by mature crRNAs, cleave, and thereby eliminate, complementary foreign genetic material (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Naive CRISPR adaptation to a foreign genetic element that a bacterium has not previously encountered is rare in type I CRISPR-Cas systems (<xref rid="B10" ref-type="bibr">10</xref>). However, when a crRNA has partial complementarity to a protospacer sequence, the frequency of new spacer acquisition is enhanced more than 500-fold (<xref rid="B11" ref-type="bibr">11</xref>). This process is known as primed adaptation (<xref rid="B5" ref-type="bibr">5</xref>). Primed adaptation is crucial for type I CRISPR-Cas systems to robustly fight off contemporary threats, notably when the foreign element mutates, which would otherwise allow escape from CRISPR targeting (<xref rid="B10" ref-type="bibr">10</xref>). In this same vein, CRISPR arrays possessing multiple spacers targeting the same phage reduce the chances that a phage can acquire mutations that enable it to escape detection (<xref rid="B12" ref-type="bibr">12</xref>). This arrangement, moreover, allows a larger proportion of CRISPR-Cas complexes to be loaded with crRNAs that target a particular infecting phage, providing a more favorable CRISPR-Cas complex-to-phage target ratio, again increasing the success of the defense system.</p><p>Naive adaptation requires cleavage of the newly infecting DNA, the incorporation of a short fragment as a new spacer in the CRISPR array, transcription and processing of the new crRNA, and formation of a crRNA-Cas complex to scan the genomic and foreign DNA to pinpoint the foreign DNA and target it for cleavage. These steps take time. During that time, the phage is executing its parasitic program, either lysogenizing the host, in which case adaptation would lead to host suicide, or generating numerous copies of the phage genome as the phage prepares to lyse the host cell. With respect to the phage lysis program, it could be difficult for the CRISPR-Cas machinery to keep pace (degrading phage genomes as new phage genomes are produced), possibly a contributing feature underpinning why naive adaptation is so infrequent. Indeed, in line with this argument, defective phage particles capable of infecting but not killing host bacteria have been shown to increase adaptation frequency (<xref rid="B13" ref-type="bibr">13</xref>). In this case, a defective phage injects its DNA, which can serve as a substrate for naive adaptation, in a setting in which the race between host killing and CRISPR-Cas success does not occur.</p><p>Bacteria incorporate cues, such as nutrient availability, into the regulation of CRISPR-Cas (<xref rid="B14" ref-type="bibr">14</xref><xref ref-type="bibr" rid="B15">&#x02013;</xref><xref rid="B17" ref-type="bibr">17</xref>). We previously discovered that the cue for cell population density is integrated into CRISPR-Cas regulation. Specifically, cell-cell communication, i.e., quorum sensing (QS), activates type I-F CRISPR-<italic>cas</italic> expression, CRISPR-Cas activity, and CRISPR adaptation in <named-content content-type="genus-species">P. aeruginosa</named-content> UCBPP-PA14 (here denoted PA14), enabling CRISPR-Cas function to increase in step with increasing bacterial cell density (<xref rid="B18" ref-type="bibr">18</xref>). This mechanism ensures maximum CRISPR-Cas activity when bacterial populations are at high cell density and at highest risk for phage infection and spread. Likewise, Patterson et al. showed that in <named-content content-type="genus-species">Serratia</named-content> sp. strain ATCC 39006, the QS autoinducer synthase SmaI is required for expression and activity of type I-E, I-F, and III-A CRISPR-Cas systems, as well as for adaptation of type I-E and I-F systems (<xref rid="B19" ref-type="bibr">19</xref>). Together, these results suggest that QS regulation of CRISPR-Cas may be a general phenomenon allowing bacteria to balance the risk of phage infection with the burden of producing CRISPR-Cas complexes and the risk of suicide from autoimmunity.</p><p>Here, using mutagenesis and molecular analyses, we show that another cue, low temperature, promotes CRISPR adaptation and interference in PA14. Specifically, at low temperature, CRISPR-Cas complex levels increase and growth rate decreases, each of which promotes increased adaptation. Using a QS mutant and synthetic QS compounds, we show that the temperature and QS inputs act synergistically. We hypothesize that the low temperature- and QS-mediated increases in CRISPR-Cas complex abundance elevate the number of possible adaptation/interference events. Furthermore, the reduced growth rate causes an apparent increase in CRISPR-Cas activity by providing the time required for the CRISPR-Cas machinery to carry out all of the required steps (adaptation, expression, and interference) for successful defense against a foreign invading element prior to cell division. If, simultaneously, the slow-growth conditions were unfavorable for phage propagation, it would give the CRISPR-Cas system the chance to accomplish the adaptation program prior to the cell becoming overwhelmed by replicating phage, making this mechanism particularly effective.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2.1"><title>Temperature affects CRISPR adaptation.</title><p><named-content content-type="genus-species">P. aeruginosa</named-content> is an environmental bacterium and an opportunistic human pathogen that causes nosocomial infections and chronic lung infections in patients with cystic fibrosis (CF) (<xref rid="B20" ref-type="bibr">20</xref>). PA14, the strain used in the present studies, was isolated from a burn victim. Additionally, PA14 is pathogenic in both plants and mice (<xref rid="B21" ref-type="bibr">21</xref>). PA14 has a type I-F CRISPR-Cas system, providing it with resistance to phage (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>).</p><p>Naive CRISPR adaptation to a phage that a bacterium has not encountered previously is rare in laboratory analyses of type I CRISPR-Cas systems (<xref rid="B10" ref-type="bibr">10</xref>). Adaptation requires cleavage of the foreign phage DNA, incorporation of a new spacer in the CRISPR array, transcription and processing into a mature crRNA, crRNA-guided detection of the foreign cDNA by the newly made crRNA in the Cas complex, and target cleavage by a Cas nuclease. Crucially, all of those steps must occur prior to the cell being overwhelmed by replicating phage DNA. We wondered if slowing bacterial growth could buy a bacterium more time for its CRISPR-Cas machinery to successfully adapt to and eliminate a foreign genetic element. This mechanism may be particularly relevant in the case of plasmids, which do not kill the host, and in the case of multiple phage infections of a single host cell, where the spacers acquired from one phage can be used against other invading phages. With this thought in mind, we were struck by the versatility of <named-content content-type="genus-species">P. aeruginosa</named-content> with respect to its ability to successfully reside both in the soil/plants and in mammalian hosts. These niches vary dramatically in many respects, notably for our present work, with regard to temperature and phage exposure (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). We hypothesized that slow growth, as experienced by <named-content content-type="genus-species">P. aeruginosa</named-content> in the cooler temperatures of the phage-ridden soil or during plant infection, rather than the higher temperature experienced during human infection, could provide a favorable locale for CRISPR adaptation events to occur.</p><p>To assess whether temperature influences CRISPR adaptation, we measured the ability of PA14 to adapt to the plasmid pCR2SP1 seed when grown at 37, 30, 23, and 15&#x000b0;C. The pCR2SP1 seed plasmid harbors a protospacer targeted by CRISPR2 spacer 1. The protospacer possesses a single base mutation in the 5&#x02032; seed region which fosters priming for CRISPR adaptation. During adaptation, new CRISPR spacers are incorporated at the 5&#x02032; end of a CRISPR array (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Thus, spacer number 1 becomes spacer number 2, and so on. This feature of the adaptation mechanism provides a convenient means to track adaptation events by PCR amplification of the expanding region. In our analysis, we used PCR primers flanking spacer number 1 of the CRISPR2 array. We separated the products based on size and visualized the CRISPR spacer population. In PA14, introduction of each new spacer and repeat adds 60&#x02009;bp to the existing CRISPR array. In order to have minimal CRISPR-Cas activity at the start of the experiment, cultures of PA14 were grown at 37&#x000b0;C to a low cell density and transformed with pCR2SP1 seed (<xref rid="B18" ref-type="bibr">18</xref>). Transformants were allowed to recover at 37&#x000b0;C for 1&#x02009;h and subsequently were grown on Luria-Bertani (LB) agar with gentamicin at the respective temperatures until they reached 1&#x02009;mm in diameter. Single colonies were analyzed for adaptation events by PCR. <xref ref-type="fig" rid="fig1">Figure&#x000a0;1A</xref> shows that PA14 cells grown at 37&#x000b0;C have a spacer population consisting primarily of the unadapted parent array with a minor subpopulation that gained one or two new spacers. Cas3, which cleaves DNA when bound by the Csy1&#x02013;4 complex, is required for adaptation to occur. Adaptation to the pCR2SP1 seed plasmid appears to favor the acquisition of two additional spacers rather than one or three additional spacers. Often, an adaptation ladder is observed in which each new/additional adaptation event is less frequent than the previous one; however, in the case of adaptation primed by plasmids, others have also shown adaptation patterns similar to those in <xref ref-type="fig" rid="fig1">Fig.&#x000a0;1A</xref> (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B26" ref-type="bibr">26</xref>). We sequenced the introduced spacers from 10 individual adaptation events and found that all new spacers were derived from the priming plasmid at locations within &#x0223c;1&#x02009;kb of the protospacer (data not shown). Notably, for each decrease in growth temperature to 30, 23, and 15&#x000b0;C, PA14 contains a higher proportion of adapted arrays. Quantification of these adaptation events shows that approximately 16% of the spacer population is adapted when grown at 37&#x000b0;C, and this proportion increases to 61% for PA14 grown at 15&#x000b0;C (<xref ref-type="fig" rid="fig1">Fig.&#x000a0;1B</xref>). Moreover, the fraction of arrays that acquired multiple spacers also increases with decreasing growth temperature. Arrays containing three new spacers cannot be detected in cells grown at 37&#x000b0;C, whereas approximately 8% of the cells grown at 15&#x000b0;C have acquired three spacers.</p><fig id="fig1" orientation="portrait" position="float"><label>FIG&#x000a0;1</label><caption><p>CRISPR adaptation is temperature dependent. Integration of new CRISPR spacers into the CRISPR2 locus was measured by PCR amplification of the CRISPR2 array region from single colonies of PA14 and the &#x00394;<italic>cas3</italic> mutant. Both strains harbored the CRISPR-targeted plasmid, pCR2SP1 seed, containing a seed mutation that promotes adaptation. Each adaptation event results in acquisition of a new spacer (32&#x02009;bp) and repeat (28&#x02009;bp), which is exhibited by a 60-bp increase in size of the CRISPR locus and can be visualized by gel electrophoresis. (A) Adaptation of PA14 cells carrying pCR2SP1 seed at 37, 30, 23, or 15&#x000b0;C. The &#x00394;<italic>cas3</italic> mutant is incapable of cleaving DNA bound by the Csy1&#x02013;4 complex and serves as a negative control for adaptation. Data are shown for representative colonies. (B) Quantitation of the spacer population in panel A, <italic>n</italic> = 6.</p></caption><graphic xlink:href="mbo0061841720001"/></fig><p>We envision three possible mechanisms that could underlie the increase in CRISPR adaptation that occurs at low growth temperatures, as follows: (i) the CRISPR-targeted plasmid is present at higher copy number at low temperatures than at high temperatures, fostering higher rates of priming, and hence, an increase in potential adaptation events; (ii) CRISPR-Cas complexes are more abundant at low temperatures than at high temperatures, which again would increase the chances for adaptation; and (iii) the reduced bacterial growth rate at low temperatures compared to high temperatures could provide CRISPR-Cas complexes additional time to perform all of the steps necessary to achieve immunity and hence enable higher numbers of adaptation events to occur prior to each cell division. Any combination of these three mechanisms is also possible and could contribute to the connection between low temperature and high CRISPR adaptation frequency.</p></sec><sec id="s2.2"><title>Temperature does not affect pHERD30T copy number.</title><p>First, we examined the possibility that temperature affects the relative copy number of the incoming plasmid. To do this, we measured, at different temperatures, the relative copy number of pHERD30T, the empty high-copy-number vector backbone for the pCR2SP1 seed plasmid (<xref rid="B23" ref-type="bibr">23</xref>). PA14 cells carrying pHERD30T were grown at 37, 30, 23, and 15&#x000b0;C. The relative copy number of pHERD30T was assayed by quantitative PCR (qPCR) of the total DNA using the chromosomal <italic>rpoB</italic> gene as the control. <xref ref-type="fig" rid="fig2">Figure&#x000a0;2</xref> shows that there is no effect of temperature on the relative copy number of pHERD30T.</p><fig id="fig2" orientation="portrait" position="float"><label>FIG&#x000a0;2</label><caption><p>Temperature does not affect the relative copy number of pHERD30T in PA14. PA14 harboring pHERD30T, the empty vector backbone for the pCR2SP1 seed plasmid, was grown at 37, 30, 23, and 15&#x000b0;C on LB agar supplemented with gentamicin (50&#x02009;&#x003bc;g/ml). The copy number of plasmid DNA relative to chromosomal DNA was measured by qPCR of total DNA using primers for pHERD30T and <italic>rpoB</italic>. Error bars represent standard deviation (SD) from <italic>n</italic> = 3 replicates (<italic>P</italic>&#x02009;=&#x02009;0.1752, one-way analysis of variance [ANOVA]). ns, not significant.</p></caption><graphic xlink:href="mbo0061841720002"/></fig></sec><sec id="s2.3"><title>Temperature has only a modest effect on Csy4 abundance.</title><p>We examined the second possibility, that the level of the CRIPSR-Cas machinery present in cells is affected by temperature. We reasoned that temperature could affect the transcription, translation, and/or stability of Cas proteins. No matter which mechanism, the outcome would be a change in the cellular concentration of CRISPR-Cas complexes. Thus, we assessed the relative abundances of CRISPR-Cas complexes at the different temperatures using Csy4-3&#x000d7;FLAG as the proxy. Csy4 is a component of the Csy1&#x02013;4-crRNA CRISPR-Cas complex that binds to and targets foreign DNA for cleavage (<xref rid="B22" ref-type="bibr">22</xref>). A cross-streak assay was performed to verify that CRISPR-Cas-dependent resistance to the CRISPR-targeted phage DMS3m<sup>vir</sup> was not affected by fusion of the 3&#x000d7;FLAG tag to Csy4 (see <xref ref-type="supplementary-material" rid="figS1">Fig.&#x000a0;S1</xref> in the supplemental material). In contrast to a &#x00394;CRISPR &#x00394;<italic>cas</italic> mutant strain lacking both CRISPR arrays, <italic>cas1</italic>, <italic>cas3</italic>, and <italic>csy1</italic>&#x02013;<italic>4</italic> and which succumbed to DMS3m<sup>vir</sup> phage infection, the PA14 strain carrying <italic>csy4-3&#x000d7;flag</italic> was resistant, suggesting that the Csy4-3&#x000d7;FLAG protein is functional.</p><supplementary-material content-type="local-data" id="figS1"><object-id pub-id-type="doi">10.1128/mBio.02184-18.1</object-id><label>FIG&#x000a0;S1</label><p>The 3&#x000d7;FLAG-tagged Csy4 protein is functional. WT PA14, <italic>csy4-3&#x000d7;flag</italic> mutant, and &#x00394;CRISPR &#x00394;<italic>cas</italic> mutant strains were streaked (left to right) across the virulent phage DMS3m<sup>vir</sup> (indicated by the vertical dotted line). DMS3m<sup>vir</sup> is targeted by PA14 CRISPR2 spacer 1. A functional CRISPR-Cas apparatus protects PA14 cells against this phage (<xref rid="B23" ref-type="bibr">23</xref>). Download <inline-supplementary-material id="fS1" mimetype="image" mime-subtype="tiff" xlink:href="mbo006184172sf1.tif" content-type="local-data">FIG&#x000a0;S1, TIF file, 0.1 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material><p>To test whether growth temperature affects Csy4 levels, we grew PA14 at 37, 30, 23, and 15&#x000b0;C and measured the relative abundance of Csy4 by Western blotting. <xref ref-type="fig" rid="fig3">Figure&#x000a0;3</xref> shows that relative to a control protein, RpoB, Csy4-3&#x000d7;FLAG levels increase slightly with decreasing temperature. Quantitation shows that there is 1.2- to 1.4-fold more Csy4-3&#x000d7;FLAG present at temperatures below 37&#x000b0;C (<xref ref-type="fig" rid="fig3">Fig.&#x000a0;3</xref>). To address the possibility that temperature affects Csy4-3&#x000d7;FLAG stability, in our assay, we grew WT PA14 carrying Csy4-3&#x000d7;FLAG at 23&#x000b0;C to an optical density at 600 nm (OD<sub>600</sub>) of 1. We treated the culture with gentamicin to arrest protein synthesis, divided the culture into two aliquots, and incubated one aliquot at 23&#x000b0;C and the other at 37&#x000b0;C for two more hours. Csy4 levels remained constant at both temperatures (<xref ref-type="supplementary-material" rid="figS2">Fig.&#x000a0;S2</xref>). Using this assay, we cannot, however, exclude the possibility that there may be temperature-dependent differences in the stability of CRISPR-Cas complexes, which could contribute to the temperature-dependent regulation of CRISPR-mediated adaptation. We suggest that the enhanced CRIPSR-mediated adaptation that occurs at low temperatures (<xref ref-type="fig" rid="fig1">Fig.&#x000a0;1</xref>) can be explained by differences in the abundance of CRISPR-Cas machinery alone or, perhaps, in combination with slow growth, as investigated in the next section.</p><fig id="fig3" orientation="portrait" position="float"><label>FIG&#x000a0;3</label><caption><p>Csy4 levels are modestly upregulated at low temperatures. Western blot of PA14 Csy4-3&#x000d7;FLAG grown at 37, 30, 23, and 15&#x000b0;C. Top, abundance of RpoB, which was used as the endogenous control. Bottom, abundance of Csy4-3&#x000d7;FLAG. Quantitation of the relative abundance of Csy4-3&#x000d7;FLAG normalized to RpoB is shown below the blot. The data are representative of &#x0003e;3 independent experiments.</p></caption><graphic xlink:href="mbo0061841720003"/></fig><supplementary-material content-type="local-data" id="figS2"><object-id pub-id-type="doi">10.1128/mBio.02184-18.2</object-id><label>FIG&#x000a0;S2</label><p>Csy4-3&#x000d7;FLAG stability at 37&#x000b0;C and 23&#x000b0;C. Western blot of PA14 Csy4-3&#x000d7;FLAG. Cultures were grown to an OD<sub>600</sub> of 1 at 23&#x000b0;C, gentamicin was added to arrest protein synthesis, and the cultures were divided into two aliquots, where one was incubated at 37&#x000b0;C and the other at 23&#x000b0;C. Samples were taken at 0, 30, 60, and 120 min after the addition of gentamicin. Top, abundance of RpoB, which was used as the endogenous control. Bottom, abundance of Csy4-3&#x000d7;FLAG. Download <inline-supplementary-material id="fS2" mimetype="image" mime-subtype="tiff" xlink:href="mbo006184172sf2.tif" content-type="local-data">FIG&#x000a0;S2, TIF file, 0.1 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material></sec><sec id="s2.4"><title>Growth rate affects CRISPR-Cas activity.</title><p>We examined the final possibility, that growth rate contributes to the temperature-dependent effects we observe on CRISPR adaptation in PA14. For this analysis, we assayed the elimination of a plasmid rather than a phage because temperature affects CRISPR-Cas-independent phage-host interactions, including phage adsorption rates, plaquing efficiency, the lysis-versus-lysogeny switch, and the activity of restriction modification antiphage defenses (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B27" ref-type="bibr">27</xref><xref ref-type="bibr" rid="B28">&#x02013;</xref><xref rid="B30" ref-type="bibr">30</xref>). Indeed, as one example of these complexities, we show in <xref ref-type="supplementary-material" rid="figS3">Fig.&#x000a0;S3</xref> that the rate of JBD44a phage adsorption to PA14 is increased at 23&#x000b0;C compared to 37&#x000b0;C, irrespective of the presence/absence of CRISPR-Cas. This temperature-mediated effect on adsorption may be explained by increased long-chain O-antigen decoration of the cell surface that occurs at low temperatures. These O-antigen moieties play phage receptor roles (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>).</p><supplementary-material content-type="local-data" id="figS3"><object-id pub-id-type="doi">10.1128/mBio.02184-18.3</object-id><label>FIG&#x000a0;S3</label><p>Temperature affects phage adsorption independently of CRISPR-Cas. WT PA14, a &#x00394;CRISPR &#x00394;<italic>cas</italic> mutant, and a WT resistant (WT<sup>r</sup>) strain carrying a CRISPR spacer targeting JBD44a were grown to an OD<sub>600</sub> of 1 at 37&#x000b0;C (A) or 23&#x000b0;C (B) and infected with phage JBD44a at a multiplicity of infection (MOI) of 30. PFU were quantified over time. SD represents 3 replicates. Cells grown at 23&#x000b0;C adsorb phage at a higher rate than those grown at 37&#x000b0;C. Download <inline-supplementary-material id="fS3" mimetype="image" mime-subtype="tiff" xlink:href="mbo006184172sf3.tif" content-type="local-data">FIG&#x000a0;S3, TIF file, 0.01 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material><p>To measure the influence of growth rate on the ability of CRISPR-Cas to eradicate a foreign genetic element, we assayed CRISPR-Cas effectiveness in eliminating the CRISPR-targeted plasmid called pCR2SP1 (<xref rid="B23" ref-type="bibr">23</xref>) when PA14 was grown at different rates. This pHERD30T-derived plasmid contains a protospacer targeted by CRISPR2 spacer 1 flanked by a PAM sequence that is required for CRISPR interference (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>To control bacterial growth rate, we varied aeration levels by shaking the cultures at either 250 rpm or at 150 rpm. We note that we did not use minimal versus rich growth medium to control growth rate because, as noted above, nutrient availability affects the activity of CRISPR-Cas systems in multiple bacteria, including PA14 (<xref rid="B14" ref-type="bibr">14</xref><xref ref-type="bibr" rid="B15">&#x02013;</xref><xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Rather, we grew the rapidly/slowly shaken samples for different times to enable the cultures to achieve the same final cell density (<xref ref-type="supplementary-material" rid="figS4">Fig.&#x000a0;S4</xref>). We quantified the percentages of the control plasmid pHERD30T and the CRISPR-targeted plasmid pCR2SP1 present in the cells at the beginning of the experiment and assessed their retention after rapid or slow growth at 37&#x000b0;C to an OD<sub>600</sub> of 1. In spite of CRISPR targeting of pCR2SP1, after rapid growth, 22% of the plasmids were retained compared to time zero. In contrast, following slow growth, only 0.03% of the plasmids were retained. Thus, CRISPR-Cas interference was &#x0003e;600-fold more effective during slow growth than during rapid growth (<xref ref-type="fig" rid="fig4">Fig.&#x000a0;4A</xref>). Upon extended growth of the rapidly growing culture, the effectiveness of CRISPR-Cas interference increased to levels similar to those of the slowly growing culture (<xref ref-type="supplementary-material" rid="figS5">Fig.&#x000a0;S5</xref>). The pCR2SP1 plasmid carries a protospacer with perfect CRISPR targeting; however, it may also prime adaptation, which in turn would further increase the frequency of CRISPR targeting and subsequent plasmid curing. In order to address the possibility of priming from the protospacer contributing to the plasmid curing measured in <xref ref-type="fig" rid="fig4">Fig.&#x000a0;4A</xref>, we quantified the population-wide level of adaptation at both the beginning and the end of the experiment. <xref ref-type="fig" rid="fig4">Figure&#x000a0;4B</xref> shows that no increase in adaptation frequency occurred during the experiment. Hence, the plasmid curing observed in <xref ref-type="fig" rid="fig4">Fig.&#x000a0;4A</xref> can be attributed to CRISPR targeting of the pCR2SP1 plasmid. To determine whether growth rate affects Csy4 levels, we assessed Csy4-3&#x000d7;FLAG amounts following growth at 37&#x000b0; with shaking at 150 rpm and 250 rpm to an OD<sub>600</sub> of 1. <xref ref-type="fig" rid="fig4">Figure&#x000a0;4C</xref> shows that growth rate does not affect the abundance of Csy4-3&#x000d7;FLAG.</p><fig id="fig4" orientation="portrait" position="float"><label>FIG&#x000a0;4</label><caption><p>Growth rate affects CRISPR-Cas activity. (A) Retention of the control parent plasmid pHERD30T (black) and the CRISPR-targeted plasmid pCR2SP1 (gray) in PA14 grown at 37&#x000b0;C to an OD<sub>600</sub> of 1 with aeration at 250 rpm (denoted rapid growth) or 150 rpm (denoted slow growth). One hundred percent denotes no plasmid loss. SD represents 3 replicates. (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, Student&#x02019;s <italic>t</italic> test). (B) Adaptation of PA14 cells carrying pCR2SP1 grown as in panel A at T&#x02009;=&#x02009;0 and at the end of the experiment, at OD<sub>600</sub> of 1. (C) Western blot of PA14 Csy4-3&#x000d7;FLAG grown as in panel A to an OD<sub>600</sub> of 1. Top, abundance of RpoB, which was used as the endogenous control. Bottom, abundance of Csy4-3&#x000d7;FLAG. Quantitation of the relative abundance of Csy4-3&#x000d7;FLAG normalized to RpoB is shown below the blot.</p></caption><graphic xlink:href="mbo0061841720004"/></fig><supplementary-material content-type="local-data" id="figS4"><object-id pub-id-type="doi">10.1128/mBio.02184-18.4</object-id><label>FIG&#x000a0;S4</label><p>Growth curves for PA14 grown at 150 rpm (slow) and 250 rpm (rapid). Colonies of PA14 carrying the pHERD30T plasmid were inoculated in LB broth and grown at 37&#x000b0;C with rapid (250 rpm) or slow (150 rpm) shaking. Growth was measured as the OD<sub>600</sub>. The doubling time of PA14 during rapid exponential growth is 32.6 min (<italic>R</italic><sup>2</sup> = 0.9996). During slow exponential growth, between an OD<sub>600</sub> of 0.025 and 0.2, the doubling time is 61.4 min (<italic>R</italic><sup>2</sup> = 0.9791), and between OD<sub>600</sub> of 0.2 and 0.7, the doubling time is 185.3 min (<italic>R</italic><sup>2</sup> = 0.9546). <italic>n</italic>&#x02009;=&#x02009;3. Download <inline-supplementary-material id="fS4" mimetype="image" mime-subtype="tiff" xlink:href="mbo006184172sf4.tif" content-type="local-data">FIG&#x000a0;S4, TIF file, 0.01 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material><supplementary-material content-type="local-data" id="figS5"><object-id pub-id-type="doi">10.1128/mBio.02184-18.5</object-id><label>FIG&#x000a0;S5</label><p>Plasmid loss after extended growth. The data in this figure extend the analyses shown in <xref ref-type="fig" rid="fig4">Fig.&#x000a0;4A</xref>. In <xref ref-type="fig" rid="fig4">Fig.&#x000a0;4A</xref>, cultures of PA14 carrying pCR2SP1 were grown at 37&#x000b0;C with shaking at 150 rpm (slow growth) or 250 rpm (rapid growth) until each culture reached an OD<sub>600</sub> of 1. Here, we show data for cultures grown at 250 rpm for an extended time, a time equal to that required for the cultures grown at 150 rpm to reach OD<sub>600</sub> of 1. The data show that increased growth time at 250 rpm, which enables the culture to enter stationary phase, causes increased loss of both the untargeted pHERD30T plasmid and the CRISPR-targeted pCR2SP1 plasmid. Download <inline-supplementary-material id="fS5" mimetype="image" mime-subtype="tiff" xlink:href="mbo006184172sf5.tif" content-type="local-data">FIG&#x000a0;S5, TIF file, 0.05 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material></sec><sec id="s2.5"><title>Quorum sensing acts synergistically with temperature to regulate CRISPR-Cas-mediated adaptation.</title><p>QS regulates CRISPR-Cas (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). QS relies on the production, release, and group-wide detection of diffusible signaling molecules called autoinducers (AIs), and the process allows bacteria to collectively control genes required for group behaviors (<xref rid="B34" ref-type="bibr">34</xref>). The major PA14 QS circuit consists of two AI-receptor pairs called LasI/R and RhlI/R. LasI produces the AI 3-oxo-C<sub>12</sub>-homoserine lactone (3OC<sub>12</sub>-HSL), which activates the receptor LasR. LasR activates expression of many genes, including those encoding the second QS system, <italic>rhlI</italic> and <italic>rhlR</italic> (<xref rid="B35" ref-type="bibr">35</xref><xref ref-type="bibr" rid="B36">&#x02013;</xref><xref rid="B38" ref-type="bibr">38</xref>). RhlI synthesizes the AI C<sub>4</sub>-homoserine lactone (C<sub>4</sub>-HSL) that, when bound to RhlR, activates a second wave of QS genes (<xref rid="B36" ref-type="bibr">36</xref>).</p><p>We previously showed that in PA14, <italic>cas3</italic> expression is activated at high cell density, a hallmark of a QS-regulated trait. Moreover, a PA14 mutant lacking both QS AI synthase genes (&#x00394;<italic>lasI</italic> and &#x00394;<italic>rhlI</italic>) exhibited reduced CRISPR-Cas expression, interference, and adaptation compared to WT PA14. Complementation of the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant via exogenous supplementation with the 3OC<sub>12</sub>-HSL and C<sub>4</sub>-HSL AIs restored CRISPR-Cas function to WT levels (<xref rid="B18" ref-type="bibr">18</xref>). We wondered whether the temperature and QS cues function independently or synergistically to regulate CRISPR-Cas. To assess if QS influences temperature-dependent CRISPR adaptation, we used an adaptation assay similar to that shown in <xref ref-type="fig" rid="fig1">Fig.&#x000a0;1</xref>. In this case, we assayed CRISPR-Cas-mediated adaptation to the pCR2SP1 seed plasmid in a PA14 &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant that lacks the ability to produce the two QS AIs. Colonies were grown in the absence and presence of 2&#x02009;&#x003bc;M 3OC<sub>12</sub>-HSL plus 10&#x02009;&#x003bc;M C<sub>4</sub>-HSL. Compared to the untreated &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant strain, supplementation with AIs increased the frequency of CRISPR adaptation (<xref ref-type="fig" rid="fig5">Fig.&#x000a0;5</xref>). The effect of AIs on adaptation frequency was more pronounced at 30&#x000b0;C and 23&#x000b0;C than at 37&#x000b0;C, suggesting that QS and lower temperatures synergistically enhance CRISPR-Cas-mediated adaptation. At 15&#x000b0;C, however, there was no effect of AI supplementation on CRISPR-Cas-directed adaptation frequency, suggesting that at the lowest temperature we tested, temperature alone is sufficient to promote the maximum operating capacity of the CRISPR-Cas system. To examine the role of QS in the temperature-dependent production of Csy4, we measured Csy4-3&#x000d7;FLAG levels in the WT and in the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant strain grown at 37, 30, 23, and 15&#x000b0;C. Because RpoB production is altered in the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant strain relative to WT PA14, we used GroEL as the internal control for this experiment. <xref ref-type="supplementary-material" rid="figS6">Figure&#x000a0;S6A</xref> shows that at all temperatures tested, levels of Csy4-3&#x000d7;FLAG are higher in the WT strain than in the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant strain. Additionally, reducing the temperature promotes increases in Csy4-3&#x000d7;FLAG levels, and this effect is more pronounced in the WT strain than in the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant strain. In agreement with the QS and temperature-dependent findings regarding the regulation of Csy4-3&#x000d7;FLAG, interference is more effective in the WT strain than in the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant strain when grown rapidly or slowly (<xref ref-type="supplementary-material" rid="figS6">Fig.&#x000a0;S6B</xref>, right).</p><fig id="fig5" orientation="portrait" position="float"><label>FIG&#x000a0;5</label><caption><p>QS and low temperature act synergistically to enhance CRISPR-Cas-mediated adaptation. PCR amplification of the CRISPR2 array and visualization by gel electrophoresis, as in <xref ref-type="fig" rid="fig1">Fig.&#x000a0;1</xref>. The PA14 &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant does not produce 3OC<sub>12</sub>-HSL or C<sub>4</sub>-HSL. 3OC<sub>12</sub>-HSL and C<sub>4</sub>-HSL (designated AI) were supplied at saturating concentrations (2&#x02009;&#x003bc;M and 10&#x02009;&#x003bc;M, respectively), as denoted. The data are representative of &#x0003e;3 independent experiments.</p></caption><graphic xlink:href="mbo0061841720005"/></fig><supplementary-material content-type="local-data" id="figS6"><object-id pub-id-type="doi">10.1128/mBio.02184-18.6</object-id><label>FIG&#x000a0;S6</label><p>The effect of QS on temperature-dependent Csy4 regulation and growth rate regulation of CRISPR-Cas activity. (A) Western blot of PA14 Csy4-3&#x000d7;FLAG grown at 37, 30, 23, and 15&#x000b0;C. Top, abundance of GroEL, which was used as the endogenous control. Bottom, abundance of Csy4-3&#x000d7;FLAG. Quantitation of the relative abundance of Csy4-3&#x000d7;FLAG normalized to GroEL is shown below the blot. (B) Retention of the control parent plasmid pHERD30T (left) and the CRISPR-targeted plasmid pCR2SP1 (right) in WT PA14 and the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant strain grown at 37&#x000b0;C to an OD<sub>600</sub> of 1 with aeration at 250 rpm (denoted rapid growth) or 150 rpm (denoted slow growth). One hundred percent denotes no plasmid loss. SD represents 3 replicates. (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 for pCR2SP1, Student&#x02019;s <italic>t</italic> test). Download <inline-supplementary-material id="fS6" mimetype="image" mime-subtype="tiff" xlink:href="mbo006184172sf6.tif" content-type="local-data">FIG&#x000a0;S6, TIF file, 0.2 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material><p>Li et al. reported that in PA14, CRISPR-Cas degrades <italic>lasR</italic> mRNA, which in turn affects QS-controlled virulence in a mouse model of infection (<xref rid="B39" ref-type="bibr">39</xref>). Therefore, the possibility existed that temperature control of CRISPR-Cas activity could affect LasR receptor levels, resulting in a regulatory feedback loop that contributes to the effects we observe. We could not, however, replicate the findings by Li et al. Specifically, reverse transcription-quantitative PCR (qRT-PCR) of <italic>lasR</italic> in the PA14 WT and &#x00394;CRISPR &#x00394;<italic>cas</italic> mutant strains showed no differences under any of our experimental conditions (<xref ref-type="supplementary-material" rid="figS7">Fig.&#x000a0;S7A</xref>). We also tested the relative levels of <italic>lasB</italic>, encoding elastase, which is under the direct control of LasR (<xref ref-type="supplementary-material" rid="figS7">Fig.&#x000a0;S7B</xref>). Again, there was no effect of CRISPR-Cas on expression of this QS-regulated gene under any condition we tested.</p><supplementary-material content-type="local-data" id="figS7"><object-id pub-id-type="doi">10.1128/mBio.02184-18.7</object-id><label>FIG&#x000a0;S7</label><p>CRISPR-Cas does not regulate <italic>lasR</italic> or <italic>lasB</italic>. (A) Relative <italic>lasR</italic> mRNA levels normalized to 5S RNA were measured by qRT-PCR in PA14 and in the isogenic &#x00394;CRISPR &#x00394;<italic>cas</italic> mutant strain under different QS states (OD<sub>600</sub>, 1 and 2). (B) As in panel A, showing <italic>lasB</italic> mRNA, encoding the virulence factor elastase, the transcription of which is activated by LasR. Error bars represent SD from <italic>n</italic>&#x02009;=&#x02009;3 replicates. (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, Student&#x02019;s <italic>t</italic> test). Unlike the results obtained by Li et al. (<xref rid="B39" ref-type="bibr">39</xref>), under our experimental conditions, CRISPR-Cas neither affects the relative levels of <italic>lasR</italic> mRNA nor LasR-regulated <italic>lasB</italic> mRNA levels. Download <inline-supplementary-material id="fS7" mimetype="image" mime-subtype="tiff" xlink:href="mbo006184172sf7.tif" content-type="local-data">FIG&#x000a0;S7, TIF file, 0.02 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>Here, we discover that temperature is an environmental regulator of CRISPR-Cas interference and adaptation, i.e., target cleavage and acquisition of new immunity spacers, respectively, in <named-content content-type="genus-species">P. aeruginosa</named-content> PA14. Specifically, CRISPR adaptation increases with decreasing temperature. The underlying mechanism appears to rely minimally on an increased abundance of CRISPR-Cas components, but rather primarily on slow growth itself, presumably buying time for the CRISPR-Cas machinery to successfully destroy/adapt to foreign DNA. Given that growth rate and temperature are often connected, this phenomenon could be relevant in other bacteria that harbor CRISPR-Cas systems.</p><p><named-content content-type="genus-species">P. aeruginosa</named-content> is a soil-dwelling organism that is also an opportunistic human pathogen. Phage abundance and diversity are high in ecosystems, such as soil, whereas they are particularly limited in the human lung, a major habitat for infectious <named-content content-type="genus-species">P. aeruginosa</named-content>, most notably in CF sufferers (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Our finding that higher CRISPR-Cas activity occurs at lower temperatures correlates with the increased threat of potential foreign parasitic elements in soil (generally at low temperatures) compared to during human infection (generally at 37&#x000b0;C). Thus, we predict that bacteria are better equipped to defend themselves against phage attacks and to adapt to mutating phage in the environment than in the human body; however, one consequence is that bacteria may be vulnerable to a higher incidence of autoimmunity in the environment. We recognize that <named-content content-type="genus-species">P. aeruginosa</named-content> causes biofilm infections, in which the bacteria exhibit slow growth (<xref rid="B40" ref-type="bibr">40</xref>), and that not all <named-content content-type="genus-species">P. aeruginosa</named-content> infections in humans are under 37&#x000b0;C conditions. We anticipate that CRISPR-Cas may be more active in <named-content content-type="genus-species">P. aeruginosa</named-content> biofilm infections and in superficial wound infections than during bacteremia, which would presumably involve planktonic cells at 37&#x000b0;C. Our discovery that low temperatures increase CRISPR adaptation in <named-content content-type="genus-species">P. aeruginosa</named-content> suggests that the rarely occurring but crucial naive adaptation events may take place predominantly during the bacterium&#x02019;s soil dwelling existence and during slow growth in biofilms.</p><p>Another environmental regulator of CRISPR-Cas in <named-content content-type="genus-species">P. aeruginosa</named-content> PA14 is QS. We previously showed that QS, via the two main synthases LasI and RhlI, activates CRISPR-Cas expression, interference, and adaptation (<xref rid="B18" ref-type="bibr">18</xref>). Interestingly, in <named-content content-type="genus-species">P. aeruginosa</named-content> PAO1, QS is temperature dependent due to the presence of conserved thermosensing RNA &#x0201c;thermometers&#x0201d; that reside in the 5&#x02032; untranslated regions (UTRs) of <italic>lasI</italic> and <italic>rhlAB-R</italic>, the latter of which controls the expression of <italic>rhlR</italic>. Thermoregulation of <italic>lasI</italic> and <italic>rhlR</italic> increases their expression at 37&#x000b0;C compared to 30&#x000b0;C, and consequently, causes increased production of QS-regulated virulence factors (<xref rid="B41" ref-type="bibr">41</xref>). Given that, in PAO1, QS regulators and QS-controlled traits are more highly expressed at 37&#x000b0;C than at lower temperatures, one would expect CRISPR-Cas activity to be maximal at 37&#x000b0;C, since we found that QS activates CRISPR-Cas (<xref rid="B18" ref-type="bibr">18</xref>). Nonetheless, we do not find this to be the case, at least for PA14. CRISPR-Cas is more active at low temperatures than at high temperatures, and Csy4 is 20 to 40% more abundant at low temperatures than at high temperatures. To reconcile these findings, we posit that although the Csy4-3&#x000d7;FLAG protein displays equal stability for up to 2 h at 37&#x000b0;C and 23&#x000b0;C, CRISPR-Cas complexes may be more stable at lower temperatures than at higher temperatures, which yields increased levels of assembled CRISPR-Cas complexes, and thus, CRISPR-Cas activity, at low temperatures. Additionally, low temperatures may favor more rapid and tighter annealing of crRNA to its target and thereby enhance interference and adaptation.</p><p>Other reports show correlations between slow growth and CRISPR adaptation. For example, in nutrient-poor medium, PA14 primarily acquires CRISPR-based immunity to the phage DMS3<sup>vir</sup> as opposed to during growth in nutrient-rich medium, which, in contrast, promotes the accumulation of phage receptor mutations (<xref rid="B17" ref-type="bibr">17</xref>). We hypothesize that, under poor growth conditions, increased CRISPR-based adaptation is mediated in part by the lower growth rate of the bacteria than that under ideal growth conditions, again providing the bacteria crucial time to adapt. In the same vein, Amlinger et al. discovered that naive adaptation occurs with the highest frequency in late-exponential phase in liquid cultures of <named-content content-type="genus-species">Escherichia coli</named-content> overproducing CRISPR-Cas (<xref rid="B42" ref-type="bibr">42</xref>). One can imagine that CRISPR-<italic>cas</italic> expression was maintained at a relatively constant level in this experiment due to the use of a synthetic promoter. Thus, maximal adaptation in late-exponential phase could be due to the declining growth rate, in agreement with our findings (<xref ref-type="fig" rid="fig4">Fig.&#x000a0;4</xref>).</p><p>Our results showing that slow growth increases the frequency of CRISPR-Cas-mediated plasmid loss suggests that biofilms, which exhibit particularly slow growth in their cores (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B43" ref-type="bibr">43</xref>), may exhibit exceptionally high CRISPR-Cas activity compared to exponentially growing planktonic cells. High CRISPR-Cas activity in slowly growing cells offers the exciting possibility that transiently growth-arrested antibiotic-tolerant persister subpopulations (<xref rid="B44" ref-type="bibr">44</xref>) could be natural reservoirs of cells that are primed for CRISPR adaptation. A phage, upon infecting a persister cell, has its lytic cycle arrested until the host cell resumes growth (<xref rid="B45" ref-type="bibr">45</xref>). If CRISPR-Cas is active in persister cells, the persistent stage would afford the host cell ample time for adaptation, possibly providing the cell a means to more efficiently eliminate additional phages that have also infected the cell. Moreover, after resuming growth, the adapted cell would be prepared to fend off infecting phages coming from neighboring cells. Indeed, persistence, which is induced at high cell density when cells are at highest risk of phage infection, may be a form of phage defense. QS increases persister formation in PA14 and PAO1 (<xref rid="B46" ref-type="bibr">46</xref>). Thus, QS inhibitors may reduce the fraction of persister cells present, which would (i) allow antibiotics to kill pathogenic bacteria more effectively and (ii) minimize the population of cells that could be particularly prone to acquiring CRISPR-based immunity toward phage therapies. We envision that antibacterial treatments consisting of QS inhibitors, antibiotics, and phage therapies could exhibit exceptional synergy in killing pathogens, including the notorious persister cells. Last, and in contrast, our findings offer simple conditions, namely decreasing growth rate and/or reducing temperature, that could be explored to increase CRISPR adaptation frequency for applications, such as the development of phage-resistant bacterial strains, possibly for use in industry or as probiotics.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4.1"><title>Bacterial strains, plasmids, and phage.</title><p>The strains and plasmids used in this study are listed in <xref ref-type="supplementary-material" rid="tabS1">Table&#x000a0;S1</xref>. To construct the chromosomal 3<italic>&#x000d7;flag</italic>-tagged <italic>csy4</italic> in PA14, DNA fragments flanking the 3&#x02032; terminus of <italic>csy4,</italic> including a 3<italic>&#x000d7;flag</italic> tag, were amplified, sewed together by overlap extension PCR, and cloned into pEXG2 (a generous gift from Joseph Mougous, University of Washington, Seattle, WA) using HindIII and XbaI restriction sites (<xref rid="B47" ref-type="bibr">47</xref>). The plasmid to make the &#x00394;CRISPR &#x00394;<italic>cas</italic> PA14 mutant was engineered using the identical strategy and DNA fragments surrounding the CRISPR <italic>cas</italic> locus, flanked by EcoRI and XbaI restriction sites. The resulting plasmids were used to transform <named-content content-type="genus-species">E. coli</named-content> SM10&#x003bb;<italic>pir</italic> and were subsequently mobilized into PA14 via mating. Exconjugants were selected on Luria-Bertani (LB) containing gentamicin (30&#x02009;&#x003bc;g/ml) and irgasan (100&#x02009;&#x003bc;g/ml), followed by recovery of mutants on M9 medium containing 5% (wt/vol) sucrose. Candidate mutants were confirmed by PCR and sequencing. A PA14 strain harboring a CRISPR spacer matching phage JBD44a was generated by cloning 1,581&#x02009;bp of JBD44a gene <italic>gp</italic>33 using native HindIII sites into the adaptation-promoting pCR2SP1 seed plasmid (<xref rid="B18" ref-type="bibr">18</xref>). The plasmid was propagated in PA14 on LB agar with 50&#x02009;&#x000b5;g/ml gentamicin, and single colonies were streaked repeatedly on LB agar and tested for plasmid loss. CRISPR-adapted clones were identified using PCR with primers that enabled an assessment of incorporation of spacers into either CRISPR1 or CRISPR2. Newly integrated spacers were identified and mapped using sequencing. A strain with the new spacer AGCCACAACANAGGCCAGAGAAGCTGCTGCGA in CRISPR2 that targeted gene <italic>gp33</italic> was selected and tested for resistance to JBD44a by a cross-streak assay. The primers used are listed in <xref ref-type="supplementary-material" rid="tabS2">Table&#x000a0;S2</xref>.</p><supplementary-material content-type="local-data" id="tabS1"><object-id pub-id-type="doi">10.1128/mBio.02184-18.8</object-id><label>TABLE&#x000a0;S1</label><p>Bacterial strains, phage, and plasmids. Download <inline-supplementary-material id="tS1" mimetype="application" mime-subtype="pdf" xlink:href="mbo006184172st1.pdf" content-type="local-data">Table&#x000a0;S1, PDF file, 0.05 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material><supplementary-material content-type="local-data" id="tabS2"><object-id pub-id-type="doi">10.1128/mBio.02184-18.9</object-id><label>TABLE&#x000a0;S2</label><p>Primers used in this study. Download <inline-supplementary-material id="tS2" mimetype="application" mime-subtype="pdf" xlink:href="mbo006184172st2.pdf" content-type="local-data">Table&#x000a0;S2, PDF file, 0.04 MB</inline-supplementary-material>.</p><permissions><copyright-statement>Copyright &#x000a9; 2018 H&#x000f8;yland-Kroghsbo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>H&#x000f8;yland-Kroghsbo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions></supplementary-material></sec><sec id="s4.2"><title>Growth conditions.</title><p>PA14 and mutants were grown at the indicated temperatures in LB broth or on LB solidified with 15&#x02009;g agar/liter. LB was supplemented with 50&#x02009;&#x003bc;g/ml gentamicin where appropriate. For AI supplementation assays, 3OC<sub>12</sub>-HSL and C<sub>4</sub>-HSL (Sigma) or the solvent dimethyl sulfoxide (DMSO) was used. Growth of bacterial cultures was measured by OD<sub>600</sub>, where 1 unit equals 10<sup>9</sup> CFU/ml.</p></sec><sec id="s4.3"><title>Adaptation assay.</title><p>WT PA14 and the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant were transformed with pCR2SP1 seed, as described previously (<xref rid="B18" ref-type="bibr">18</xref>), and plated on LB medium containing 50&#x02009;&#x003bc;g/ml gentamicin; in the case of the &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI</italic> mutant, either DMSO (control) or 2&#x02009;&#x003bc;M 3OC<sub>12</sub>-HSL plus 10&#x02009;&#x003bc;M C<sub>4</sub>-HSL (designated AI) was added. The plates were incubated at 37, 30, 23, and 15&#x000b0;C until the colonies were 1&#x02009;mm in diameter. Single colonies were tested for population-wide integration of new CRISPR spacers by PCR using DreamTaq Green PCR master mix (Thermo Fisher); primers used were designed to anneal upstream of the CRISPR2 array and inside the second spacer, which enabled the detection of expansion of this array. The PCR products were subjected to agarose gel electrophoresis, and band intensities were analyzed using the ImageQuant TL software (GE Healthcare).</p></sec><sec id="s4.4"><title>Relative plasmid copy number.</title><p>PA14 harboring pHERD30T, the empty vector backbone for the pCR2SP1 seed plasmid, was grown at 37, 30, 23, and 15&#x000b0;C on LB agar supplemented with gentamicin (50&#x02009;&#x003bc;g/ml). Total DNA was extracted from individual colonies that were 1&#x02009;mm in size using a DNeasy blood and tissue kit (Qiagen). qPCR was performed using PerfeCTa SYBR Green FastMix, Low ROX (Quantabio) with primers specific for pHERD30T and chromosomal <italic>rpoB</italic>.</p></sec><sec id="s4.5"><title>Western blot analysis.</title><p>The PA14 <italic>csy4</italic>-3<italic>&#x000d7;flag</italic> and &#x00394;<italic>lasI</italic> &#x00394;<italic>rhlI csy4</italic>-<italic>3&#x000d7;flag</italic> mutant strains were streaked onto LB medium and grown at 37, 30, 23, or 15&#x000b0;C until individual colonies reached 1&#x02009;mm in diameter. Single colonies were harvested and lysed with BugBuster protein extraction reagent (Millipore), following the manufacturer&#x02019;s instructions. Fifty micrograms of protein was separated by SDS-PAGE on a 4 to 20% Mini-PROTEAN TGX polyacrylamide gel (Bio-Rad) and blotted onto a polyvinylidene difluoride (PVDF) membrane (catalog no. 1620174; Bio-Rad). The membrane was incubated for 1&#x02009;h with monoclonal Anti-FLAG M2-peroxidase (HRP) antibody (catalog no. A8592; Sigma), monoclonal anti-RpoB antibody (catalog no. ab191598; Abcam), both at a 1:3,000 dilution, or polyclonal anti-GroEL antibody (catalog no. G6532; Sigma) at a 1:15,000 dilution in Tris-buffered saline with Tween 20 (TBST) and 5% skim milk. Anti-rabbit antibody (catalog no. W4011; Promega) was used as the secondary antibody for detection of the anti-RpoB and anti-GroEL antibodies. The membrane was washed in TBST and was developed using SuperSignal West Femto maximum sensitivity substrate (catalog no. 34095; Thermo Scientific).</p></sec></sec></body><back><fn-group><fn fn-type="other"><p><bold>Citation</bold> H&#x000f8;yland-Kroghsbo NM, Mu&#x000f1;oz KA, Bassler BL. 2018. Temperature, by controlling growth rate, regulates CRISPR-Cas activity in <italic>Pseudomonas aeruginosa</italic>. mBio 9:e02184-18. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mBio.02184-18">https://doi.org/10.1128/mBio.02184-18</ext-link>.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>We thank Jon E. Paczkowski and other members of the B.L.B. group for helpful suggestions. We thank George O&#x02019;Toole, Joseph Mougous, and Joseph Bondy-Denomy for providing bacterial strains and phage.</p><p>This work was supported by the Howard Hughes Medical Institute, NIH grant 2R37GM065859, National Science Foundation Grant MCB-1713731, an Alexander von Humboldt-Max Planck Society Award (to B.L.B.); the Danish Council for Independent Research Postdoctoral Fellowship DFF-4090-00265, administered by the University of Copenhagen, and Lundbeck Fellowship R220-2016-860 (to N.M.H.-K.).</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrangou</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fremaux</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Deveau</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boyaval</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Moineau</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Romero</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>P</given-names></name></person-group>
<year>2007</year>
<article-title>CRISPR provides acquired resistance against viruses in prokaryotes</article-title>. <source>Science</source>
<volume>315</volume>:<fpage>1709</fpage>&#x02013;<lpage>1712</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1138140</pub-id>.<pub-id pub-id-type="pmid">17379808</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marraffini</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Sontheimer</surname><given-names>EJ</given-names></name></person-group>
<year>2008</year>
<article-title>CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA</article-title>. <source>Science</source>
<volume>322</volume>:<fpage>1843</fpage>&#x02013;<lpage>1845</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1165771</pub-id>.<pub-id pub-id-type="pmid">19095942</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marraffini</surname><given-names>LA</given-names></name></person-group>
<year>2015</year>
<article-title>CRISPR-Cas immunity in prokaryotes</article-title>. <source>Nature</source>
<volume>526</volume>:<fpage>55</fpage>&#x02013;<lpage>61</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature15386</pub-id>.<pub-id pub-id-type="pmid">26432244</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nu&#x000f1;ez</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Engelman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Doudna</surname><given-names>JA</given-names></name></person-group>
<year>2015</year>
<article-title>Integrase-mediated spacer acquisition during CRISPR-Cas adaptive immunity</article-title>. <source>Nature</source>
<volume>519</volume>:<fpage>193</fpage>&#x02013;<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature14237</pub-id>.<pub-id pub-id-type="pmid">25707795</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Datsenko</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Pougach</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tikhonov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wanner</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Severinov</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Semenova</surname><given-names>E</given-names></name></person-group>
<year>2012</year>
<article-title>Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system</article-title>. <source>Nat Commun</source>
<volume>3</volume>:<fpage>945</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms1937</pub-id>.<pub-id pub-id-type="pmid">22781758</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brouns</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Jore</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Lundgren</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Westra</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Slijkhuis</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Snijders</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Dickman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Makarova</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Koonin</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>van der Oost</surname><given-names>J</given-names></name></person-group>
<year>2008</year>
<article-title>Small CRISPR RNAs guide antiviral defense in prokaryotes</article-title>. <source>Science</source>
<volume>321</volume>:<fpage>960</fpage>&#x02013;<lpage>964</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1159689</pub-id>.<pub-id pub-id-type="pmid">18703739</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mojica</surname><given-names>FJM</given-names></name>, <name name-style="western"><surname>D&#x000ed;ez-Villase&#x000f1;or</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Garc&#x000ed;a-Mart&#x000ed;nez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Almendros</surname><given-names>C</given-names></name></person-group>
<year>2009</year>
<article-title>Short motif sequences determine the targets of the prokaryotic CRISPR defence system</article-title>. <source>Microbiology</source>
<volume>155</volume>:<fpage>733</fpage>&#x02013;<lpage>740</lpage>. doi:<pub-id pub-id-type="doi">10.1099/mic.0.023960-0</pub-id>.<pub-id pub-id-type="pmid">19246744</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westra</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Semenova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Datsenko</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Wiedenheft</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Severinov</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Brouns</surname><given-names>SJ</given-names></name></person-group>
<year>2013</year>
<article-title>Type I-E CRISPR-cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition</article-title>. <source>PLoS Genet</source>
<volume>9</volume>:<elocation-id>e1003742</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1003742</pub-id>.<pub-id pub-id-type="pmid">24039596</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garneau</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Dupuis</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Villion</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Romero</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Barrangou</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Boyaval</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Fremaux</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Magadan</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Moineau</surname><given-names>S</given-names></name></person-group>
<year>2010</year>
<article-title>The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA</article-title>. <source>Nature</source>
<volume>468</volume>:<fpage>67</fpage>&#x02013;<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature09523</pub-id>.<pub-id pub-id-type="pmid">21048762</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGinn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Marraffini</surname><given-names>LA</given-names></name></person-group>
<year>2018</year>
<article-title>Molecular mechanisms of CRISPR-Cas spacer acquisition</article-title>. <source>Nat Rev Microbiol</source> doi:<pub-id pub-id-type="doi">10.1038/s41579-018-0071-7</pub-id>.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staals</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Biswas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brouns</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Fineran</surname><given-names>PC</given-names></name></person-group>
<year>2016</year>
<article-title>Interference-driven spacer acquisition is dominant over naive and primed adaptation in a native CRISPR-Cas system</article-title>. <source>Nat Commun</source>
<volume>7</volume>:<fpage>12853</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms12853</pub-id>.<pub-id pub-id-type="pmid">27694798</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Houte</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ekroth</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Broniewski</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Chabas</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ben</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bondy-Denomy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gandon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Boots</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Paterson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Buckling</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Westra</surname><given-names>ER</given-names></name></person-group>
<year>2016</year>
<article-title>The diversity-generating benefits of a prokaryotic adaptive immune system</article-title>. <source>Nature</source> doi:<pub-id pub-id-type="doi">10.1038/nature17436</pub-id>.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hynes</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Villion</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Moineau</surname><given-names>S</given-names></name></person-group>
<year>2014</year>
<article-title>Adaptation in bacterial CRISPR-Cas immunity can be driven by defective phages</article-title>. <source>Nat Commun</source>
<volume>5</volume>:<fpage>4399</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms5399</pub-id>.<pub-id pub-id-type="pmid">25056268</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agari</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sakamoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tamakoshi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Oshima</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kuramitsu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shinkai</surname><given-names>A</given-names></name></person-group>
<year>2010</year>
<article-title>Transcription profile of Thermus thermophilus CRISPR systems after phage infection</article-title>. <source>J Mol Biol</source>
<volume>395</volume>:<fpage>270</fpage>&#x02013;<lpage>281</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmb.2009.10.057</pub-id>.<pub-id pub-id-type="pmid">19891975</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fineran</surname><given-names>PC</given-names></name></person-group>
<year>2015</year>
<article-title>Regulation of the Type I-F CRISPR-Cas system by CRP-cAMP and GalM controls spacer acquisition and interference</article-title>. <source>Nucleic Acids Res</source>
<volume>43</volume>:<fpage>6038</fpage>&#x02013;<lpage>6048</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkv517</pub-id>.<pub-id pub-id-type="pmid">26007654</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Tseng</surname><given-names>CP</given-names></name></person-group>
<year>2014</year>
<article-title>CRP represses the CRISPR/Cas system in Escherichia coli: evidence that endogenous CRISPR spacers impede phage P1 replication</article-title>. <source>Mol Microbiol</source>
<volume>92</volume>:<fpage>1072</fpage>&#x02013;<lpage>1091</lpage>. doi:<pub-id pub-id-type="doi">10.1111/mmi.12614</pub-id>.<pub-id pub-id-type="pmid">24720807</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westra</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>van Houte</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Oyesiku-Blakemore</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Makin</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Broniewski</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Best</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bondy-Denomy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boots</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Buckling</surname><given-names>A</given-names></name></person-group>
<year>2015</year>
<article-title>Parasite exposure drives selective evolution of constitutive versus inducible defense</article-title>. <source>Curr Biol</source>
<volume>25</volume>:<fpage>1043</fpage>&#x02013;<lpage>1049</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cub.2015.01.065</pub-id>.<pub-id pub-id-type="pmid">25772450</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#x000f8;yland-Kroghsbo</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Paczkowski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Broniewski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Westra</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bondy-Denomy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bassler</surname><given-names>BL</given-names></name></person-group>
<year>2017</year>
<article-title>Quorum sensing controls the Pseudomonas aeruginosa CRISPR-Cas adaptive immune system</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>114</volume>:<fpage>131</fpage>&#x02013;<lpage>135</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1617415113</pub-id>.<pub-id pub-id-type="pmid">27849583</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Salmond</surname><given-names>GPC</given-names></name>, <name name-style="western"><surname>Przybilski</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Staals</surname><given-names>RHJ</given-names></name>, <name name-style="western"><surname>Fineran</surname><given-names>PC</given-names></name></person-group>
<year>2016</year>
<article-title>Quorum sensing controls adaptive immunity through the regulation of multiple CRISPR-Cas systems</article-title>. <source>Mol Cell</source>
<volume>64</volume>:<fpage>1102</fpage>&#x02013;<lpage>1108</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molcel.2016.11.012</pub-id>.<pub-id pub-id-type="pmid">27867010</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybtke</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hultqvist</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Givskov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tolker-Nielsen</surname><given-names>T</given-names></name></person-group>
<year>2015</year>
<article-title>Pseudomonas aeruginosa biofilm infections: community structure, antimicrobial tolerance and immune response</article-title>. <source>J Mol Biol</source>
<volume>427</volume>:<fpage>3628</fpage>&#x02013;<lpage>3645</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmb.2015.08.016</pub-id>.<pub-id pub-id-type="pmid">26319792</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahme</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Stevens</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Wolfort</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tompkins</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Ausubel</surname><given-names>FM</given-names></name></person-group>
<year>1995</year>
<article-title>Common virulence factors for bacterial pathogenicity in plants and animals</article-title>. <source>Science</source>
<volume>268</volume>:<fpage>1899</fpage>&#x02013;<lpage>1902</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.7604262</pub-id>.<pub-id pub-id-type="pmid">7604262</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiedenheft</surname><given-names>B</given-names></name>, <name name-style="western"><surname>van Duijn</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bultema</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Bultema</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Waghmare</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Waghmare</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Barendregt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Westphal</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Heck</surname><given-names>AJR</given-names></name>, <name name-style="western"><surname>Heck</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boekema</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Boekema</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Dickman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Dickman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Doudna</surname><given-names>JA</given-names></name></person-group>
<year>2011</year>
<article-title>RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>108</volume>:<fpage>10092</fpage>&#x02013;<lpage>10097</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1102716108</pub-id>.<pub-id pub-id-type="pmid">21536913</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cady</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Bondy-Denomy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Heussler</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>O'Toole</surname><given-names>GA</given-names></name></person-group>
<year>2012</year>
<article-title>The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages</article-title>. <source>J Bacteriol</source>
<volume>194</volume>:<fpage>5728</fpage>&#x02013;<lpage>5738</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.01184-12</pub-id>.<pub-id pub-id-type="pmid">22885297</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aziz</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Dwivedi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Akhter</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Breitbart</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>RA</given-names></name></person-group>
<year>2015</year>
<article-title>Multidimensional metrics for estimating phage abundance, distribution, gene density, and sequence coverage in metagenomes</article-title>. <source>Front Microbiol</source>
<volume>6</volume>:<fpage>381</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2015.00381</pub-id>.<pub-id pub-id-type="pmid">26005436</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Furlan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haynes</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schmieder</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Angly</surname><given-names>FE</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tammadoni</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nosrat</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Conrad</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rohwer</surname><given-names>F</given-names></name></person-group>
<year>2009</year>
<article-title>Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals</article-title>. <source>PLoS One</source>
<volume>4</volume>:<elocation-id>e7370</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0007370</pub-id>.<pub-id pub-id-type="pmid">19816605</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Xiang</surname><given-names>H</given-names></name></person-group>
<year>2014</year>
<article-title>Haloarcula hispanica CRISPR authenticates PAM of a target sequence to prime discriminative adaptation</article-title>. <source>Nucleic Acids Res</source>
<volume>42</volume>:<fpage>7226</fpage>&#x02013;<lpage>7235</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gku389</pub-id>.<pub-id pub-id-type="pmid">24803673</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Korbsrisate</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Withatanung</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Adler</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Clokie</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Galyov</surname><given-names>EE</given-names></name></person-group>
<year>2014</year>
<article-title>Temperature dependent bacteriophages of a tropical bacterial pathogen</article-title>. <source>Front Microbiol</source>
<volume>5</volume>:<fpage>599</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2014.00599</pub-id>.<pub-id pub-id-type="pmid">25452746</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Vega</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>LH</given-names></name></person-group>
<year>2011</year>
<article-title>Temperature-induced activation of freshwater Cyanophage AS-1 prophage</article-title>. <source>Acta Histochem</source>
<volume>113</volume>:<fpage>294</fpage>&#x02013;<lpage>299</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.acthis.2009.11.003</pub-id>.<pub-id pub-id-type="pmid">20138651</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Klaenhammer</surname><given-names>TR</given-names></name></person-group>
<year>1984</year>
<article-title>Phage resistance in a phage-insensitive strain of Streptococcus lactis: temperature-dependent phage development and host-controlled phage replication</article-title>. <source>Appl Environ Microbiol</source>
<volume>47</volume>:<fpage>979</fpage>&#x02013;<lpage>985</lpage>.<pub-id pub-id-type="pmid">16346553</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#x02019;Driscoll</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Glynn</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cahalane</surname><given-names>O</given-names></name>, <name name-style="western"><surname>O&#x02019;Connell-Motherway</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Van Sinderen</surname><given-names>D</given-names></name></person-group>
<year>2004</year>
<article-title>Lactococcal plasmid pNP40 encodes a novel, temperature-sensitive restriction-modification system</article-title>. <source>Appl Environ Microbiol</source>
<volume>70</volume>:<fpage>5546</fpage>&#x02013;<lpage>5556</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.70.9.5546-5556.2004</pub-id>.<pub-id pub-id-type="pmid">15345443</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kropinski</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Berry</surname><given-names>D</given-names></name></person-group>
<year>1987</year>
<article-title>Effect of growth temperature on the lipids, outer membrane proteins, and lipopolysaccharides of Pseudomonas aeruginosa PAO</article-title>. <source>J Bacteriol</source>
<volume>169</volume>:<fpage>1960</fpage>&#x02013;<lpage>1966</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jb.169.5.1960-1966.1987</pub-id>.<pub-id pub-id-type="pmid">3106325</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGroarty</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Rivera</surname><given-names>M</given-names></name></person-group>
<year>1990</year>
<article-title>Growth-dependent alterations in production of serotype-specific and common antigen lipopolysaccharides in Pseudomonas aeruginosa PAO1</article-title>. <source>Infect Immun</source>
<volume>58</volume>:<fpage>1030</fpage>&#x02013;<lpage>1037</lpage>.<pub-id pub-id-type="pmid">2108085</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinkai</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kira</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kashihara</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kuramitsu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yokoyama</surname><given-names>S</given-names></name></person-group>
<year>2007</year>
<article-title>Transcription activation mediated by a cyclic AMP receptor protein from Thermus thermophilus HB8</article-title>. <source>J Bacteriol</source>
<volume>189</volume>:<fpage>3891</fpage>&#x02013;<lpage>3901</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.01739-06</pub-id>.<pub-id pub-id-type="pmid">17369302</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papenfort</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bassler</surname><given-names>BL</given-names></name></person-group>
<year>2016</year>
<article-title>Quorum sensing signal-response systems in Gram-negative bacteria</article-title>. <source>Nat Rev Microbiol</source>
<volume>14</volume>:<fpage>576</fpage>&#x02013;<lpage>588</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro.2016.89</pub-id>.<pub-id pub-id-type="pmid">27510864</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pesci</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Pearson</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Seed</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Iglewski</surname><given-names>BH</given-names></name></person-group>
<year>1997</year>
<article-title>Regulation of las and rhl quorum sensing in Pseudomonas aeruginosa</article-title>. <source>J Bacteriol</source>
<volume>179</volume>:<fpage>3127</fpage>&#x02013;<lpage>3132</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jb.179.10.3127-3132.1997</pub-id>.<pub-id pub-id-type="pmid">9150205</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Passador</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Iglewski</surname><given-names>BH</given-names></name>, <name name-style="western"><surname>Greenberg</surname><given-names>EP</given-names></name></person-group>
<year>1995</year>
<article-title>A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>92</volume>:<fpage>1490</fpage>&#x02013;<lpage>1494</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.92.5.1490</pub-id>.<pub-id pub-id-type="pmid">7878006</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambello</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Kaye</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Iglewski</surname><given-names>BH</given-names></name></person-group>
<year>1993</year>
<article-title>LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression</article-title>. <source>Infect Immun</source>
<volume>61</volume>:<fpage>1180</fpage>&#x02013;<lpage>1184</lpage>.<pub-id pub-id-type="pmid">8454322</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seed</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Passador</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Iglewski</surname><given-names>BH</given-names></name></person-group>
<year>1995</year>
<article-title>Activation of the Pseudomonas aeruginosa lasI gene by LasR and the Pseudomonas autoinducer PAI: an autoinduction regulatory hierarchy</article-title>. <source>J Bacteriol</source>
<volume>177</volume>:<fpage>654</fpage>&#x02013;<lpage>659</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jb.177.3.654-659.1995</pub-id>.<pub-id pub-id-type="pmid">7836299</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>M</given-names></name></person-group>
<year>2016</year>
<article-title>Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade mammalian host immunity</article-title>. <source>Cell Res</source>
<volume>26</volume>:<fpage>1273</fpage>&#x02013;<lpage>1287</lpage>. doi:<pub-id pub-id-type="doi">10.1038/cr.2016.135</pub-id>.<pub-id pub-id-type="pmid">27857054</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werner</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Roe</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bugnicourt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Franklin</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Heydorn</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Molin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pitts</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>PS</given-names></name></person-group>
<year>2004</year>
<article-title>Stratified growth in Pseudomonas aeruginosa biofilms</article-title>. <source>Appl Environ Microbiol</source>
<volume>70</volume>:<fpage>6188</fpage>&#x02013;<lpage>6196</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AEM.70.10.6188-6196.2004</pub-id>.<pub-id pub-id-type="pmid">15466566</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grosso-Becerra</surname><given-names>MV</given-names></name>, <name name-style="western"><surname>Croda-Garc&#x000ed;a</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Merino</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Serv&#x000ed;n-Gonz&#x000e1;lez</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mojica-Espinosa</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sober&#x000f3;n-Ch&#x000e1;vez</surname><given-names>G</given-names></name></person-group>
<year>2014</year>
<article-title>Regulation of Pseudomonas aeruginosa virulence factors by two novel RNA thermometers</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>111</volume>:<fpage>15562</fpage>&#x02013;<lpage>15567</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1402536111</pub-id>.<pub-id pub-id-type="pmid">25313031</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amlinger</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hoekzema</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>EGH</given-names></name>, <name name-style="western"><surname>Koskiniemi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lundgren</surname><given-names>M</given-names></name></person-group>
<year>2017</year>
<article-title>Fluorescent CRISPR adaptation reporter for rapid quantification of spacer acquisition</article-title>. <source>Sci Rep</source>
<volume>7</volume>:<fpage>10392</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-017-10876-z</pub-id>.<pub-id pub-id-type="pmid">28871175</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wentland</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>McFeters</surname><given-names>GA</given-names></name></person-group>
<year>1996</year>
<article-title>Spatial variations in growth rate within Klebsiella pneumoniae colonies and biofilm</article-title>. <source>Biotechnol Prog</source>
<volume>12</volume>:<fpage>316</fpage>&#x02013;<lpage>321</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bp9600243</pub-id>.<pub-id pub-id-type="pmid">8652119</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harms</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Maisonneuve</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gerdes</surname><given-names>K</given-names></name></person-group>
<year>2016</year>
<article-title>Mechanisms of bacterial persistence during stress and antibiotic exposure</article-title>. <source>Science</source>
<volume>354</volume>:<fpage>aaf4268</fpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aaf4268</pub-id>.<pub-id pub-id-type="pmid">27980159</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearl</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gabay</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kishony</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Oppenheim</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Balaban</surname><given-names>NQ</given-names></name></person-group>
<year>2008</year>
<article-title>Nongenetic individuality in the host-phage interaction</article-title>. <source>PLoS Biol</source>
<volume>6</volume>:<elocation-id>e120</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pbio.0060120</pub-id>.<pub-id pub-id-type="pmid">18494559</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#x000f6;ker</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dean</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>J</given-names></name></person-group>
<year>2010</year>
<article-title>Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules</article-title>. <source>J Bacteriol</source>
<volume>192</volume>:<fpage>1946</fpage>&#x02013;<lpage>1955</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.01231-09</pub-id>.<pub-id pub-id-type="pmid">20097861</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rietsch</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vallet-Gely</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Dove</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Mekalanos</surname><given-names>JJ</given-names></name></person-group>
<year>2005</year>
<article-title>ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>102</volume>:<fpage>8006</fpage>&#x02013;<lpage>8011</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0503005102</pub-id>.<pub-id pub-id-type="pmid">15911752</pub-id></mixed-citation></ref></ref-list></back></article><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gut Pathog</journal-id><journal-id journal-id-type="iso-abbrev">Gut Pathog</journal-id><journal-title-group><journal-title>Gut Pathogens</journal-title></journal-title-group><issn pub-type="epub">1757-4749</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6233571</article-id><article-id pub-id-type="publisher-id">275</article-id><article-id pub-id-type="doi">10.1186/s13099-018-0275-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Characterization and CRISPR-based genotyping of clinical <italic>trh</italic>-positive <italic>Vibrio parahaemolyticus</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kongrueng</surname><given-names>Jetnapang</given-names></name><address><email>jetnapang.k31280@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Srinitiwarawong</surname><given-names>Kanchana</given-names></name><address><email>kanchana.w@psu.ac.th</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nishibuchi</surname><given-names>Mitsuaki</given-names></name><address><email>nisibuti@cseas.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2474-5229</contrib-id><name><surname>Mittraparp-arthorn</surname><given-names>Pimonsri</given-names></name><address><email>pimonsri.m@psu.ac.th</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vuddhakul</surname><given-names>Varaporn</given-names></name><address><email>varaporn.v@psu.ac.th</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 1162</institution-id><institution-id institution-id-type="GRID">grid.7130.5</institution-id><institution>Department of Microbiology, Faculty of Science, </institution><institution>Prince of Songkla University, </institution></institution-wrap>Hat Yai, Thailand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 2033</institution-id><institution-id institution-id-type="GRID">grid.258799.8</institution-id><institution>Center for Southeast Asian Studies, </institution><institution>Kyoto University, </institution></institution-wrap>Kyoto, Japan </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>10</volume><elocation-id>48</elocation-id><history><date date-type="received"><day>21</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>8</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1"><italic>Vibrio parahaemolyticus</italic> is a causative agent of gastroenteritis. Most of the clinical isolates carry either <italic>tdh</italic> and/or <italic>trh</italic> genes which are considered as the major virulence genes of this pathogen. In this study, the clinical isolates of <italic>V. parahaemolyticus</italic> carrying <italic>trh</italic> gene (<italic>n&#x02009;</italic>=&#x02009;73) obtained from 1886 to 2012 from various countries were investigated for the urease production, haemolytic activity, and biofilm formation. In addition, the potential of clustered regularly interspaced short palindromic repeats (CRISPR)-based genotyping among these isolates was investigated.</p></sec><sec><title>Results</title><p id="Par2">In this study, no significant differences were observed in the urease production between <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup> and <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup> isolates (<italic>p</italic>&#x02009;=&#x02009;0.063) and between the <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>1<sup>+</sup> and <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup> isolates (<italic>p</italic>&#x02009;=&#x02009;0.788). The isolates carrying only the <italic>trh</italic> gene showed variation&#x000a0;in their haemolytic activity. The ratio of urease production and haemolytic activity between the <italic>trh</italic>1<sup>+</sup> and <italic>trh</italic>2<sup>+</sup> isolates and biofilm formation of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates were not significantly different. Sixteen of thirty-four tested isolates (47.0%) of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> were positive for CRISPR detection. The discriminatory power index (DI) of CRISPR-virulence typing was higher than the DI obtained by CRISPR typing alone.</p></sec><sec><title>Conclusion</title><p id="Par3">The <italic>tdh</italic> and <italic>trh</italic> genes were not involved in urease production in the <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic>, and variation&#x000a0;of haemolytic activity detected in <italic>V. parahaemolyticus</italic> carrying only the <italic>trh</italic> gene might be correlated to the sequence&#x000a0;variation within <italic>trh</italic>1 and <italic>trh</italic>2 genes. Additionally, biofilm production of <italic>V. parahaemolyticus</italic> was not associated with harboring of virulence genes. For genotyping, CRISPR sequences combined with virulence genes can be used as genetic markers to differentiate <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> strains.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s13099-018-0275-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>CRISPR</kwd><kwd>CRISPR-virulence typing</kwd><kwd><italic>trh</italic> gene</kwd><kwd><italic>Vibrio parahaemolyticus</italic></kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004396</institution-id><institution>Thailand Research Fund</institution></institution-wrap></funding-source><award-id>PHD/0213/2556</award-id><principal-award-recipient><name><surname>Vuddhakul</surname><given-names>Varaporn</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005683</institution-id><institution>Kyoto University</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par4"><italic>Vibrio parahaemolyticus</italic> is a halophilic Gram-negative bacterium that occurs naturally in worldwide aquatic environments. The organism causes gastroenteritis in several countries due to consumption of raw or undercooked seafood [<xref ref-type="bibr" rid="CR1">1</xref>]. The pathogenicity of this bacterium in humans is associated to the production of thermostable direct hemolysin (TDH) encoded by <italic>tdh</italic> gene and/or TDH-related hemolysin (TRH) encoded by <italic>trh</italic> gene, which are considered to be the major virulence factors, however, not many isolates from the environment possess these genes [<xref ref-type="bibr" rid="CR2">2</xref>]. <italic>V. parahaemolyticus</italic> obtained the <italic>tdh</italic> and <italic>trh</italic> genes from other organisms and transmit them among <italic>V. parahaemolyticus</italic> strains via horizontal gene transfer [<xref ref-type="bibr" rid="CR3">3</xref>]. TDH and TRH are approximately 67% identity in their amino acid sequences and possess common biological activities including haemolytic activity, enterotoxicity, cytotoxicity, and cardiotoxicity [<xref ref-type="bibr" rid="CR4">4</xref>]. The <italic>trh</italic> gene possesses a significantly broader nucleotide sequence variation and can be subdivided into two main subtypes (<italic>trh</italic>1 and <italic>trh</italic>2) which share 84% identity in their sequences&#x000a0; [<xref ref-type="bibr" rid="CR5">5</xref>]. The presence of <italic>trh</italic> gene in <italic>V. parahaemolyticus</italic> isolates is associated with the urease production because of the genetic linkage between <italic>ure</italic> and <italic>trh</italic> genes on the chromosome of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> [<xref ref-type="bibr" rid="CR6">6</xref>]. Urease is an enzyme that catalyzes the hydrolysis of urea to ammonia, raising the pH of environment inside the host. It is possible that urease contributes to the pathogenicity of this bacterium by increasing its chance of survival after entering the human body, as has been previously demonstrated for <italic>Yersinia enterocolitica</italic> infections [<xref ref-type="bibr" rid="CR7">7</xref>]. Clustered regularly interspaced short palindromic repeats (CRISPR) and repetitive sequences such as tandem repeats are commonly detected in the genomes of bacteria. Their lengths and numbers are highly variable among bacterial strains and are useful for bacterial genotyping [<xref ref-type="bibr" rid="CR8">8</xref>]. CRISPR is a segment of&#x000a0;prokaryotic&#x000a0;DNA&#x000a0;containing direct repeats (DRs), typically 24&#x02013;47&#x000a0;bp nucleotides in length, and spacer (non-repetitive sequences obtained from foreign genetic elements). The polymorphism detected in CRISPR loci has been applied as a genetic marker for typing many bacteria, such as <italic>Campylobacter fetus</italic> and <italic>S. Typhimurium</italic> [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Association of CRISPR and virulence factors of bacteria has been demonstrated in <italic>Pseudomonas aeruginosa</italic>, <italic>Myxococcus xanthus</italic>, <italic>Francisella novicida</italic> and <italic>Listeria monocytogenes</italic> [<xref ref-type="bibr" rid="CR11">11</xref>]. In <italic>V. parahaemolyticus</italic>, correlation between CRISPR and virulence genes was determined in 208 isolates from clinical and food samples [<xref ref-type="bibr" rid="CR12">12</xref>]. CRISPR was detected in 149 of 153 (97.4%) of <italic>tdh</italic><sup>+</sup> isolates. In contrast, among the 6 <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> tested isolates, only 2 were positive for CRSIPR locus [<xref ref-type="bibr" rid="CR12">12</xref>]. Therefore, association of CRISPR and the <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> is not completely concluded.</p><p id="Par5">In this work, <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates from clinical samples were investigated for urease production, haemolytic activity and biofilm formation. In addition, molecular typing based on CRISPR was analyzed.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Bacterial strains</title><p id="Par6">A total of 73 clinical <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates were obtained from various countries between 1886 and 2012 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). They belonged to 28 different serotypes consisting of 10 O serogroups and 19&#x000a0;K antigens. All isolates were confirmed as <italic>V. parahaemolyticus</italic> using PCR targeted to the <italic>toxR</italic> gene [<xref ref-type="bibr" rid="CR13">13</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>A total of 73 isolates of <italic>trh</italic>-positives <italic>V. parahaemolyticus</italic> isolated from clinical samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Country</th><th align="left">Year</th><th align="left" colspan="3">Presence of gene <italic>tdh trh</italic>1 <italic>trh</italic>2</th><th align="left">No. of isolates</th><th align="left">O:K serotype (no. of isolates)</th></tr></thead><tbody><tr><td align="left">Thailand</td><td align="left">1991&#x02013;2012</td><td align="left">+</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">14</td><td align="left">O1:KUT (3), O3:K6 (5), O3:K72 (2), O4:K62 (2), O4:K63 (1), O12:KUT (1)</td></tr><tr><td align="left"/><td align="left">1987&#x02013;2006</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">10</td><td align="left">O1:K48 (1), O1:K56 (1), O1:K69 (1), O3:K6 (3), O3:KUT (2), O4:K53 (1), O5:KUT (1)</td></tr><tr><td align="left"/><td align="left">1886&#x02013;2012</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">9</td><td align="left">O1:K1 (1), O1:KUT (4), O1:K69 (1), O3:K72 (1), O3:KUT (1), O8:K56 (1)</td></tr><tr><td align="left"/><td align="left">1999&#x02013;2012</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">6</td><td align="left">O1:K25 (1), O1:K41 (2), O1:K69 (1), O1:KUT (2)</td></tr><tr><td align="left">USA</td><td align="left">1990&#x02013;1996</td><td align="left">+</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">5</td><td align="left">O1:K56 (1), O4:K12 (2), O4:K63 (1), O1:KUT (1)</td></tr><tr><td align="left"/><td align="left">1990</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">1</td><td align="left">O4:K12 (1)</td></tr><tr><td align="left"/><td align="left">1991&#x02013;1996</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">2</td><td align="left">O3:K59 (1), O11:K15 (1)</td></tr><tr><td align="left">Bangladesh</td><td align="left">1994</td><td align="left">+</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">1</td><td align="left">O4:K11 (1)</td></tr><tr><td align="left"/><td align="left">1981</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">1</td><td align="left">O4:K11 (1)</td></tr><tr><td align="left"/><td align="left">1977&#x02013;1986</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">11</td><td align="left">O1:K25 (1), O1:K56 (2), O1:KUT (3), O3:K7 (1), O3:KUT (2), O13:KUT (1), O5:KUT (1)</td></tr><tr><td align="left">Maldives</td><td align="left">1985</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">1</td><td align="left">O3:K6 (1)</td></tr><tr><td align="left">Singapore</td><td align="left">1985&#x02013;1992</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">2</td><td align="left">O1:K69 (1), O1:KUT (1)</td></tr><tr><td align="left"/><td align="left">1985</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">1</td><td align="left">O4:K11 (1)</td></tr><tr><td align="left">Vietnam</td><td align="left">2010</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td><td char="." align="char">1</td><td align="left">O1:K1 (1)</td></tr><tr><td align="left">India</td><td align="left">1994</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">1</td><td align="left">O1:KUT (1)</td></tr><tr><td align="left"/><td align="left">1994</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">1</td><td align="left">O1:KUT (1)</td></tr><tr><td align="left">Philippines</td><td align="left">1983&#x02013;1987</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">3</td><td align="left">O3:KUT (1), O10:K71 (1), O6:K46 (1)</td></tr><tr><td align="left">Hong Kong</td><td align="left">1983&#x02013;1993</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">2</td><td align="left">O1:K1 (1), O1:K69 (1)</td></tr><tr><td align="left">Malaysia</td><td align="left">1995</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">+</td><td char="." align="char">1</td><td align="left">O4:K12 (1)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec4"><title>Detection of virulence genes</title><p id="Par7">Genomic DNA of all <italic>V. parahaemolyticus</italic> isolates was extracted using boiling method [<xref ref-type="bibr" rid="CR14">14</xref>] and was used as templates to detect the virulence genes, <italic>tdh</italic>, <italic>trh</italic>1 and <italic>trh</italic>2. A 251-bp sequence of <italic>tdh</italic> gene was amplified by PCR [<xref ref-type="bibr" rid="CR15">15</xref>]. For detection of <italic>trh</italic> genes, PCR was performed using two primer sets based on&#x000a0;<italic>trh</italic>1&#x000a0;and&#x000a0;<italic>trh</italic>2&#x000a0;sequences available in the NCBI GenBank database. The <italic>trh</italic>1 primers: Trh1-F1 (5&#x002b9;-CTGAATCACCAGTTAACGC-3&#x002b9;) and Trh1-R1: (5&#x002b9;-GGCGTTTRATCCAAATAC-3&#x002b9;) generated a PCR product of 313-bp and <italic>trh</italic>2 primers: Trh2-F2 (5&#x002b9;-CAATCAAAACTGAATCCCC-3&#x002b9;) and Trh2-R3 (5&#x002b9;-CATCAACAAAAMATTTTACCGA-3&#x002b9;) provided an amplicon of 276-bp. The PCR reaction was carried out with a reaction mixture consisting of 1.5&#x000a0;mM MgCl<sub>2</sub>, 0.2&#x000a0;mM dNTPs, 0.2&#x000a0;&#x003bc;M of each primer, 0.025 U of <italic>GoTaq</italic> DNA polymerase and 2.0&#x000a0;&#x003bc;l DNA templates in a 20&#x000a0;&#x003bc;l volume. The reactions were performed with a Thermal Cycler Gene Atlas&#x000a0;(Astec, Fukuoka, Japan) as follows: 5&#x000a0;min for a hot start at 96&#x000a0;&#x000b0;C, followed by 35 cycles of amplification consisting of denaturation at 94&#x000a0;&#x000b0;C for 1&#x000a0;min, annealing at 53&#x000a0;&#x000b0;C for 1&#x000a0;min and extension at 72&#x000a0;&#x000b0;C for 1&#x000a0;min and final extension at 72&#x000a0;&#x000b0;C for 7&#x000a0;min. Electrophoresis was performed on a 1.5% agarose gel and the amplicons were detected using a UV transilluminator. In addition, the specificity of the <italic>trh</italic>1 and <italic>trh</italic>2 primers was also determined by purification of PCR products using ethanol/sodium acetate precipitation, and sequencing.</p></sec><sec id="Sec5"><title>Quantitative urease assay</title><p id="Par8">Urease was quantified using a colorimetric assay based on the reaction of ammonia (NH<sub>3</sub>) and phenol in the presence of hypochlorite which yields a blue product of indophenol [<xref ref-type="bibr" rid="CR16">16</xref>]. Briefly, bacteria were inoculated in LB broth supplemented with 3% sodium chloride (NaCl) and 0.1% urea and incubated at 37&#x000a0;&#x000b0;C. Overnight cultures were concentrated by centrifugation, washed twice with 50&#x000a0;mM HEPES buffer (pH 7.5) and resuspended in the same buffer. The cells were lysed by sonication, then, 50&#x000a0;&#x003bc;l of supernatant obtained after centrifugation was mixed with 25&#x000a0;mM of urea in HEPES buffer (pH 7.5). After incubation at 37&#x000a0;&#x000b0;C for 30&#x000a0;min, ammonia released from the lysate was determined by adding solution of 1% (w/v) phenol and 170&#x000a0;&#x003bc;M sodium nitroprusside followed by solution of 125&#x000a0;mM sodium hydroxide (NaOH) and 0.05% (w/v) sodium hypochlorite (NaOCl). Subsequently, the tubes were incubated at 37&#x000a0;&#x000b0;C for 30&#x000a0;min and the absorbance was determined on a&#x000a0;Hitachi U 2000 Double-Beam UV/VIS spectrophotometer&#x000a0;(Hitachi Instruments Inc., Danbury, CT) at a wavelength of 625&#x000a0;nm. Ammonium chloride (NH<sub>4</sub>Cl) was used to perform standard curve. The total protein concentration from the same lysate was determined by Lowry&#x02019;s method with Folin-Ciocalteu&#x02019;s reagent solution (Nacalai Tesque Inc., Kyoto, Japan) and bovine serum albumin (BSA) was used to set up standard curve [<xref ref-type="bibr" rid="CR17">17</xref>]. Urease activity was calculated as micromoles of NH<sub>3</sub> per minute per milligram of protein.</p></sec><sec id="Sec6"><title>Determination of haemolytic activity</title><p id="Par9"><italic>V. parahaemolyticus</italic> carrying either the <italic>trh</italic>1 or <italic>trh</italic>2 gene could lyse human erythrocyte [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In this study, haemolytic activity of 15 <italic>tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>1<sup>+</sup> and 20 <italic>tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>2<sup>+</sup> isolates of <italic>V. parahaemolyticus</italic> was evaluated using the blood agarose assay [<xref ref-type="bibr" rid="CR19">19</xref>] with some modification. Briefly, <italic>V. parahaemolyticus</italic> was grown in LB broth supplemented with 2% NaCl at 37&#x000a0;&#x000b0;C for 18&#x000a0;h, the pellet was harvested and resuspended in PBS (pH 7.0). Then, the cells were sonicated and the supernatant obtained by centrifugation was determined. The 50&#x000a0;&#x003bc;l of the supernatant was added into the agarose wells containing various concentration of human blood (1%, 0.5% and 0.25%). After incubation at 37&#x000a0;&#x000b0;C for 24&#x000a0;h, a clear zone&#x000a0;around the well was indicated as haemolytic activity. High haemolytic activity (+3) was defined as the isolates can lyse all three concentration of erythrocytes whereas medium (+2) and low (+1) haemolytic activities were defined as the isolates can haemolyse two (0.5% and 0.25%) and one (0.25%) blood concentrations, respectively.</p></sec><sec id="Sec7"><title>Quantitative biofilm assays</title><p id="Par10">Each 5 isolates of <italic>V. parahaemolyticus</italic> belonging to the <italic>tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>1<sup>+</sup>, <italic>tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>2<sup>+</sup>, <italic>tdh</italic><sup><bold>+</bold></sup>
<italic>trh</italic>1<sup>+</sup> and <italic>tdh</italic><sup><bold>+</bold></sup>
<italic>trh</italic>2<sup>+</sup> isolates was investigated for biofilm formation as previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. Biofilm formation was quantified by measuring the optical density (OD) at 570&#x000a0;nm using a LUMIstar Omega spectrophotometer (BMG LABTECH, Germany). LB broth supplemented with 2% NaCl was used as control. The experiment was performed in triplicate.</p></sec><sec id="Sec8"><title>Determination of CRISPR using PCR technique</title><p id="Par11">The primers for detection of CRISPR of <italic>V. parahaemolyticus</italic> were designed from the CRISPR sequences of <italic>V. parahaemolyticus</italic> serotype O3:K6 (strain RIMD2210633) obtained from the CRISPR database website (<ext-link ext-link-type="uri" xlink:href="http://crispr.u-psud.fr/">http://crispr.u-psud.fr/</ext-link>) [<xref ref-type="bibr" rid="CR21">21</xref>]. The forward primer: VpCRISPR_3-F (5&#x002b9;-ATGCATTCCAAAGCTACCACTC-3&#x002b9;) and the reverse primer: VpCRISPR_705-R (5&#x002b9;-GCCTACCAGATAGCAAGTGTCC-3&#x002b9;) generated a 592-bp product. The PCR reaction mixture consisted of 1&#x02009;&#x000d7;&#x02009;<italic>Ex Taq</italic> Buffer, 2&#x000a0;mM MgCl<sub>2</sub>, 1.25 U Takara <italic>Ex Taq</italic> DNA polymerase (Takara Biochemicals, Tokyo, Japan), 200&#x000a0;&#x003bc;M dNTPs, 0.2&#x000a0;&#x003bc;M of each primer, and 5&#x000a0;&#x003bc;l of DNA template in a total volume of 50&#x000a0;&#x003bc;l. The PCR reaction was performed using the following conditions: initial denaturation cycle for 1&#x000a0;min at 94&#x000a0;&#x000b0;C, followed by 30 cycles of amplification consisting of denaturation at 94&#x000a0;&#x000b0;C for 1&#x000a0;min, annealing at 50&#x000a0;&#x000b0;C for 1&#x000a0;min and extension at 72&#x000a0;&#x000b0;C for 1&#x000a0;min and final extension at 72&#x000a0;&#x000b0;C for 5&#x000a0;min. The PCR product was confirmed by sequencing using the forward primer: VpCRISPR_3-F.</p><p id="Par12">CRISPR&#x000a0;pattern including the DRs and spacers&#x000a0;was investigated using the CRISPRfinder&#x000a0;tool (<ext-link ext-link-type="uri" xlink:href="http://crispr.i2bc.paris-saclay.fr/Server/">http://crispr.i2bc.paris-saclay.fr/Server/</ext-link>). The DR sequences in each isolate were analyzed based on the similarity of consensus direct repeat sequences (CDRs). In addition, all spacer sequences were investigated using the CRISPRTarget tool (<ext-link ext-link-type="uri" xlink:href="http://bioanalysis.otago.ac.nz/CRISPRTarget/">http://bioanalysis.otago.ac.nz/CRISPRTarget/</ext-link>) and were used for phylogenetic tree construction.</p><p id="Par13">In this work, CRISPR-virulence typing was constructed and compared to profiles obtained by CRISPR typing alone. CRISPR-virulence typing was constructed based on the CRISPR spacer sequences and the presence of virulence genes that included the <italic>tdh</italic>, <italic>trh</italic>1 and <italic>trh</italic>2 genes. A profile of each isolate was created using a binary matrix of presence or absence of spacer sequences and virulence genes. The dendrogram was constructed using BioNumerics 7.0 software (Applied Maths, Saint-Martens-Latem, Belgium) with the UPGMA algorithm using the Dice similarity coefficient. The discriminatory power index (DI) of CRISPR typing alone and CRISPR-virulence typing were assessed by Simpson&#x02019;s diversity index [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par14">Urease activity and correlation between urease and haemolytic activities of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates were determined by the independent samples <italic>t</italic> test analysis using SPSS 11.5 software. The differences observed were considered statistically significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec10"><title>Results and discussion</title><sec id="Sec11"><title>Urease production in <italic>trh</italic><sup>+</sup><italic>V. parahaemolyticus</italic></title><p id="Par15">Urease is&#x000a0;detected&#x000a0;in&#x000a0;many pathogenic bacteria such as <italic>Proteus mirabilis</italic>, <italic>Helicobacter pylori</italic> and <italic>Yersinia enterocolitica</italic> [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. In <italic>V. parahaemolyticus</italic>, urease-positive phenotype strongly correlates with the possession of the <italic>trh</italic> gene making it as a marker of <italic>trh</italic><sup>+</sup> strains [<xref ref-type="bibr" rid="CR26">26</xref>]. In this work, urease production in <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates was evaluated. Previous results have suggested that the presence of urea is involved in the urease induction of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> TH3996 strain [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, in this work, all tested isolates were grown in the liquid medium supplemented with 0.1% urea before testing. Urease production of the <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup><italic>, tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup><italic>, tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>1<sup>+</sup>and <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates varied from 0.46 to 15.54, 1.75 to 21.05, 0.89 to 20.79 and 3.46 to 21.20&#x000a0;&#x003bc;mol NH<sub>3</sub>/min/mg protein, respectively. No significant differences were observed in the urease production between the <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup> and <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup> (<italic>p</italic>&#x02009;=&#x02009;0.063) as well as in the <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>1<sup>+</sup> and <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup> isolates (<italic>p</italic>&#x02009;=&#x02009;0.788) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). These indicated that&#x000a0;urease production among clinical <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates varied distinctively but it was not associated with either the <italic>trh</italic> or <italic>tdh</italic> genes. In addition, no correlation between urease production and serotypes of <italic>V. parahaemolyticus</italic> was observed in this study (Additional file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>: Table S1).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Comparison of urease production between <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates according to the presence or absence of <italic>tdh</italic>. Horizontal bar within box represents median values and vertical line out of the box indicates&#x000a0;minimum and maximum. The difference in urease production in each group was compared using the independent samples <italic>t</italic>-test analysis</p></caption><graphic xlink:href="13099_2018_275_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec12"><title>Haemolytic activity of <italic>trh</italic><sup>+</sup><italic>V. parahaemolyticus</italic></title><p id="Par16">A total of 15 <italic>trh</italic>1<sup>+</sup> isolates was determined, 13.3%, 53.3% and 33.3% of the total isolates exhibited high, medium and low haemolytic activity, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). For 20 isolates of <italic>V. parahaemolyticus</italic> carrying the <italic>trh</italic>2 gene, 5%, 35% and 60% of the total isolates displayed high, medium and low haemolytic activity. It has been demonstrated that the expression of <italic>trh</italic>2 was lower than the <italic>trh</italic>1 [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Therefore, the results obtained in this study might correlate to the expression of the genes and the sequences variation within the <italic>trh</italic>1 and <italic>trh</italic>2 genes [<xref ref-type="bibr" rid="CR5">5</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Haemolytic&#x000a0;activity of <italic>V. parahaemolyticus</italic> carrying only the <italic>trh</italic> gene isolated from clinical samples using blood agarose assay</p></caption><graphic xlink:href="13099_2018_275_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par17">In this work, correlation between urease production and haemolytic activity of <italic>trh</italic><sup>+</sup> isolates was evaluated. Although the urease production and haemolytic activity ratio of <italic>trh</italic>2<sup>+</sup> isolates was higher (1.65 to 21.20&#x000a0;&#x003bc;mol NH<sub>3</sub>/min/mg protein) than that of the <italic>trh</italic>1<sup>+</sup> isolates (0.56&#x02013;19.21&#x000a0;&#x003bc;mol NH<sub>3</sub>/min/mg protein), no significant difference was observed (<italic>p</italic>&#x02009;=&#x02009;0.683) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). This indicated the urease was not involved in the human erythrocyte lysis by TRH hemolysin of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> strains.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Correlation between urease production and haemolytic activity of <italic>V. parahaemolyticus</italic> isolates carrying only the <italic>trh</italic> gene. Horizontal bar within box represents median values and vertical lines out of the box indicate minimum and maximum. &#x025ef; indicates the outlier. No significant differences were observed in the urease production/haemolytic activity between the isolates carrying the <italic>trh</italic>1 and <italic>trh</italic>2 genes (<italic>p</italic>&#x000a0;=&#x000a0;0.683) using the independent samples <italic>t</italic>-test analysis</p></caption><graphic xlink:href="13099_2018_275_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec13"><title>Biofilm formation</title><p id="Par18">Most of human bacterial infections are associated with biofilms that contributed to their resistance and persistence in the host [<xref ref-type="bibr" rid="CR29">29</xref>]. Previous study demonstrated that biofilm formation of vibrios was a survival mechanism associated with their pathogenesis and stress tolerance [<xref ref-type="bibr" rid="CR30">30</xref>]. In order to investigate the involvement of the virulence genes and biofilm production, 4 categories of <italic>V. parahaemolyticus</italic> (<italic>tdh</italic><sup><bold>+</bold></sup>
<italic>trh</italic>1<sup>+</sup>, <italic>tdh</italic><sup><bold>+</bold></sup>
<italic>trh</italic>2<sup>+</sup><italic>, tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>1<sup>+</sup>, and <italic>tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>2<sup>+</sup>) were determined. There was no any difference in biofilm formation among 4 categories of <italic>V. parahaemolyticus</italic> because high variation of biofilm formation within the isolates in each category was observed (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Variation in biofilm formation among the bacterial isolates has been reported. High variability in biofilm formation of 34 strains of <italic>Acinetobacter baumannii</italic> isolated from hospitalized patients was observed without correlation to molecular types and antimicrobial resistance [<xref ref-type="bibr" rid="CR31">31</xref>]. Ninety-eight strains with the same serotype of <italic>Listeria monocytogenes</italic> displayed different&#x000a0;biofilm&#x000a0;formation [<xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, quantitative biofilm assay of <italic>Vibrio cholerae</italic> isolates in Thailand demonstrated&#x000a0;that those isolates possessed a wide range of biofilm production [<xref ref-type="bibr" rid="CR33">33</xref>].<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Biofilm formation of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolated from clinical samples. Symbols represent mean of biofilm formation of each isolates and horizontal bar indicate mean of biofilm formation of each category</p></caption><graphic xlink:href="13099_2018_275_Fig4_HTML" id="MO4"/></fig>
</p></sec><sec id="Sec14"><title>CRISPR sequences in <italic>trh</italic><sup>+</sup><italic>V. parahaemolyticus</italic></title><p id="Par19">In the present study, specific primer pairs for detecting CRISPR region were designed and compared to the previously reported by Sun and co-workers [<xref ref-type="bibr" rid="CR12">12</xref>]. No difference in the specificity detected in the 5 <italic>V. parahaemolyticus</italic> tested isolates after confirmation by sequencing (data not shown). Thirty-four isolates of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> including 10 isolates of <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup> and each 8 isolates of <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup><italic>, tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>1<sup>+</sup><italic>, tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup> were selected for CRISPR sequences analysis. Sixteen isolates (47.0%) were positive for CRISPR, they were 8, 5 and 3 from <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup>, <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup>, and <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup> isolates, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). None of the isolate carrying only the <italic>trh</italic>1 gene was positive for CRISPR. The&#x000a0;result indicated that the number of CRISPR-positive isolates of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> obtained in this study was higher than the 2 out of 6 (33.3%) isolates reported in a previous study [<xref ref-type="bibr" rid="CR12">12</xref>]. It is of interest that CRISPR was mostly detected in the isolates carrying the <italic>trh</italic> gene together with the <italic>tdh</italic> gene. Association of <italic>tdh</italic> and the presence of CRISPR was observed in 97.4% of <italic>V. parahaemolyticus</italic> isolates [<xref ref-type="bibr" rid="CR12">12</xref>]. Thus, horizontal gene transfer of virulence genes might have occurred among <italic>V. parahaemolyticus</italic> and close related species. The numbers of DRs were between 25 and 28&#x000a0;bp nucleotides in lengths and the DR unique sequences of all CRISPR-positive isolates were GTGAACTGCCGAATAGGTAGCTGAT (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). A total of 28 spacers were obtained and the number of spacer detected in each isolate was between 1 or 2 with 30 to 32&#x000a0;bp nucleotides in lengths (Additional file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Spacer analysis using the CRISPRTarget and the BLAST databases from NCBI revealed that most of them showed 87&#x02013;100% similarity to <italic>Vibrio alginolyticus</italic> plasmids except one spacer of PSU5256 suggesting the possibility of genetic transfer between <italic>V. alginolyticus</italic> and <italic>V. parahaemolyticus</italic> (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2). Phylogenetic tree of all 28 spacers were generated and 6 different spacer patterns designated as SP1 to SP6 were classified using maximum likelihood method (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Characteristics of CRISPR loci in all 16 CRISPR-positive <italic>V. parahaemolyticus</italic> isolates</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Isolate assigned</th><th align="left">Gene harboring</th><th align="left">Consensus direct repeats (CDRs) sequences<sup>a</sup></th><th align="left">No. of DRs</th><th align="left">No. of spacers</th><th align="left">CRISPR locus pattern (bp)<sup>b</sup></th></tr></thead><tbody><tr><td align="left">PSU4921</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>31</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5105</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>31</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5106</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>31</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5107</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>31</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5264</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">2</td><td char="." align="char">1</td><td align="left"><underline>28</underline>-<bold>33</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5296</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>31</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5322</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>30</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">1884</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>A</td><td char="." align="char">2</td><td char="." align="char">1</td><td align="left"><underline>26</underline>-<bold>31</bold>-<underline>26</underline></td></tr><tr><td align="left">1990</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">2</td><td char="." align="char">1</td><td align="left"><underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">2475</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">2</td><td char="." align="char">1</td><td align="left"><underline>28</underline>-<bold>32</bold>-<underline>28</underline></td></tr><tr><td align="left">2435</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>32</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">2443</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>31</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">2463</td><td align="left"><italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left">
<underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>
</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>25</underline>-<bold>31</bold>-<underline>25</underline>-<bold>31</bold>-<underline>25</underline></td></tr><tr><td align="left">PSU5256</td><td align="left"><italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>32</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5323</td><td align="left"><italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>30</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr><tr><td align="left">PSU5331</td><td align="left"><italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup></td><td align="left"><underline>GTGAACTGCCGAATAGGTAGCTGAT</underline>AAT</td><td char="." align="char">3</td><td char="." align="char">2</td><td align="left"><underline>28</underline>-<bold>30</bold>-<underline>28</underline>-<bold>31</bold>-<underline>28</underline></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Underline indicates the consensus sequence</p><p><sup>b</sup>Underline indicates the direct repeat length and bold indicates the spacer length</p></table-wrap-foot></table-wrap>
<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Phylogenetic relationship of all 28 spacer sequences detected in 16 CRISPR-positive <italic>V. parahaemolyticus</italic> isolates. The tree was constructed using maximum likelihood method. Numbers at branch-points represent confidence values obtained after bootstrap analysis of the maximum likelihood tree using 1000 replicates. The scale bar represents 0.1 substitutions per nucleotide position. PSU5256-s2, spacer no. 2 of <italic>V. parahaemolyticus</italic> PSU5256; C1, <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup>; C2<italic>, tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup>; C3, <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>1<sup>+</sup>; C4, <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup></p></caption><graphic xlink:href="13099_2018_275_Fig5_HTML" id="MO5"/></fig>
</p><p id="Par20">CRISPR analysis based on the CRISPR spacer sequences has been applied for bacterial subtyping such as <italic>Campylobacter jejuni</italic>, <italic>Mycobacterium tuberculosis</italic>, <italic>Salmonella enterica</italic> and <italic>Yersinia pestis</italic> [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. In this work, a total of 16 of 34 <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates were positive for CRISPR detection, and they were classified into 5 CRISPR types (CTs) based on CRISPR spacer patterns at 75% similarity level (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). All isolates in CT1 type were <italic>trh</italic>1<sup>+</sup> that contained spacers SP4 and SP6. CT2 of both the <italic>trh</italic>1<sup>+</sup> and <italic>trh</italic>2<sup>+</sup> isolates harbored spacers SP1 and SP6. One isolate of <italic>trh</italic>2<sup>+</sup>
<italic>V. parahaemolyticus</italic> containing spacers SP1 and SP5 was classified into CT3 type. However, CT4 and CT5 contained only one spacer (SP3 in CT4; SP2 in CT5) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Although the tested <italic>V. parahaemolyticus</italic> isolates were classified using CPISPR-based typing, they could not be grouped according to the <italic>trh</italic> gene harboring (<italic>trh</italic>1 or <italic>trh</italic>2) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>CRISPR&#x02013;based typing of 16 CRISPR-positive <italic>V. parahaemolyticus</italic> isolates. Dendrogram was constructed based on binary matrix using BioNumerrics 7.0. Similarity (%) between patterns was calculated using the Dice index. The data were sorted using the UPGMA method</p></caption><graphic xlink:href="13099_2018_275_Fig6_HTML" id="MO6"/></fig>
</p><p id="Par21">Previous study demonstrated that a combination of CRISPR and virulence genes significantly increased the discriminatory power and could be a useful subtyping method for investigation of <italic>Salmonella</italic> outbreaks [<xref ref-type="bibr" rid="CR37">37</xref>]. In this work, a combination of CRISPR spacer sequences with virulence genes (<italic>tdh</italic>, <italic>trh</italic>1 and <italic>trh</italic>2 genes) of <italic>V. parahaemolyticus</italic> isolates was investigated. CRISPR-virulence typing profiles obtained from 34 isolates of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> were organized into 7 clusters with 12 different profiles at 75% similarity level (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). The isolates within the same cluster possessed the identical subtype&#x000a0;of the <italic>trh</italic> gene (either&#x000a0;<italic>trh</italic>1 or <italic>trh</italic>2). All <italic>trh</italic>1<sup>+</sup> isolates were classified in the CV1, CV2 and CV3 clusters of CRISPR-virulence typing, while the remaining four clusters (CV4 to CV7) were <italic>trh</italic>2<sup>+</sup> isolates. The isolates in clusters CV1, CV2, CV4 and CV6 possessed the <italic>tdh</italic> gene, but not all of them gave positive results for CRISPR detection. The CV3 and CV5 clusters were negative for CRISPR (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). Identical CRISPR-virulence typing profiles were detected in clusters CV1 (PSU5105 and PSU5106; PSU4921, PSU5107, PSU5296 and PSU5322), CV2 (PSU5069 and PSU5305; PSU5264 and 1884) and CV6 (PSU5323 and PSU5331; 2435, 2443 and 2463) (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). It is postulated that these bacteria might obtain the plasmids or exogenous genetic elements derived&#x000a0;from the same origin. It was of interest that the spacers SP2 and SP5 were not detected in <italic>trh</italic>1<sup>+</sup> isolates, whereas <italic>trh</italic>2<sup>+</sup> isolates lacked spacer SP4 (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). The spacer SP2 and SP4 were homologous to <italic>V. alginolyticus</italic> plasmids, whereas spacer SP5 showed no sequence&#x000a0;homology with any bacteriophages or plasmids (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2). Self-derived spacers have been detected in some microbial genomes [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. It has been postulated that some bacterial spacers may be self-targeting spacers that are a form of autoimmunity [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>CRISPR-virulence analysis of 34 <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic>. Dendrogram was constructed based on binary matrix using BioNumerrics 7.0. Similarity (%) between patterns was calculated using the Dice index. The data were sorted using the UPGMA method</p></caption><graphic xlink:href="13099_2018_275_Fig7_HTML" id="MO7"/></fig></p><p id="Par22">The discriminatory power index (DI) of both CRISPR analysis and CRISPR-virulence typing were evaluated. DI of CRISPR-virulence typing (DI&#x02009;=&#x02009;0.90) was higher than that of CRISPR typing (DI&#x02009;=&#x02009;0.67). This was in agreement with a recent study that DI of CRISPR-virulence typing of <italic>Helicobacter pylori</italic> was higher than CRISPR typing alone [<xref ref-type="bibr" rid="CR42">42</xref>]. Although, pulse field gel electrophoresis (PFGE) is a good method for discrimination of <italic>V. parahaemolyticus</italic>, it is laborious, time consuming [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In this study, Analysis of CRISPR spacers and virulence genes were evaluated for typing <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic>. CRISPR-virulence gene typing is a method based on PCR detection that provided high DI (0.90). It is easy to perform which required only PCR machine, therefore, CRISPR-virulence gene typing could be a useful method for typing <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic>.</p></sec></sec><sec id="Sec15"><title>Conclusions</title><p id="Par23">A total of 73 isolates of <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> obtained from clinical samples were characterized. There was no significant difference in the urease production between the <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>1<sup>+</sup> and <italic>tdh</italic><sup>+</sup>
<italic>trh</italic>2<sup>+</sup> and between the <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>1<sup>+</sup> and <italic>tdh</italic><sup>&#x02212;</sup>
<italic>trh</italic>2<sup>+</sup> isolates indicating that&#x000a0;the <italic>tdh</italic> and <italic>trh</italic> genes were not involved in urease production in the <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates. The haemolytic activity of <italic>trh</italic>1<sup>+</sup> isolates was higher than the <italic>trh</italic>2<sup>+</sup> isolates. Variation&#x000a0;in biofilm production was detected in the isolates belonging to the <italic>tdh</italic><sup><bold>+</bold></sup>
<italic>trh</italic>1<sup>+</sup>, <italic>tdh</italic><sup><bold>+</bold></sup>
<italic>trh</italic>2<sup>+</sup><italic>, tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>1<sup>+</sup>, and <italic>tdh</italic><sup><bold>&#x02212;</bold></sup>
<italic>trh</italic>2<sup>+</sup> groups. For genotyping, combination of CRISPR spacers and virulence genes provide high discriminatory power than that of CRISPR typing alone and it was able to distinguish between <italic>trh</italic>1<sup>+</sup> and <italic>trh</italic>2<sup>+</sup>
<italic>V. parahaemolyticus</italic> isolates. Thus, CRISPR-virulence gene typing can be a useful method for typing <italic>trh</italic><sup>+</sup>
<italic>V. parahaemolyticus</italic> strains.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec16"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13099_2018_275_MOESM1_ESM.docx"><caption><p><bold>Additional file 1: Table S1.</bold> Urease production, haemolytic activity and the ratio of urease production to haemolytic activity of all 73 <italic>trh</italic><sup><italic>+</italic></sup>
<italic>V. parahaemolyticus</italic> isolates.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13099_2018_275_MOESM2_ESM.docx"><caption><p><bold>Additional file 2: Table S2.</bold> Foreign genetic element similar to spacers using CRISPR targets analysis.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><ack><title>Authors&#x02019; contributions</title><p>Conceptualization: VV, Formal analysis: PM, MN, KS. Investigation: JK, PM. Methodology: JK, PM, MN. Supervision: VV. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par24">Not applicable.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par25">The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par26">All data generated or analyzed during this study are included in this published article (and its additional files).</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par27">Not applicable.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par28">Not applicable.</p></sec><sec id="FPar6"><title>Funding</title><p id="Par29">This work was financially supported by the Thailand Research Fund (TRF) through the Royal Golden Jubilee Ph.D. Program (Grant No. PHD/0213/2556) and the Center for Southeast Asia Studies (CSEAS), Kyoto University.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par30">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiou</surname><given-names>CS</given-names></name><name><surname>Hsu</surname><given-names>SY</given-names></name><name><surname>Chiu</surname><given-names>SI</given-names></name><name><surname>Wang</surname><given-names>TK</given-names></name><name><surname>Chao</surname><given-names>CS</given-names></name></person-group><article-title><italic>Vibrio parahaemolyticus</italic> serovar O3:K6 as cause of unusually high incidence of food-borne disease outbreaks in Taiwan from 1996 to 1999</article-title><source>J Clin Microbiol</source><year>2000</year><volume>38</volume><fpage>4621</fpage><lpage>4625</lpage><?supplied-pmid 11101606?><pub-id pub-id-type="pmid">11101606</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuddhakul</surname><given-names>V</given-names></name><name><surname>Chowdhury</surname><given-names>A</given-names></name><name><surname>Laohaprertthisan</surname><given-names>V</given-names></name><name><surname>Pungrasamee</surname><given-names>P</given-names></name><name><surname>Patararungrong</surname><given-names>N</given-names></name><name><surname>Thianmontri</surname><given-names>P</given-names></name><name><surname>Ishibashi</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>C</given-names></name><name><surname>Nishibuchi</surname><given-names>M</given-names></name></person-group><article-title>Isolation of a pandemic O3:K6 clone of a <italic>Vibrio parahaemolyticus</italic> strain from environmental and clinical sources in Thailand</article-title><source>Appl Environ Microbiol</source><year>2000</year><volume>66</volume><fpage>2685</fpage><lpage>2689</lpage><pub-id pub-id-type="doi">10.1128/AEM.66.6.2685-2689.2000</pub-id><pub-id pub-id-type="pmid">10831459</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terai</surname><given-names>A</given-names></name><name><surname>Baba</surname><given-names>K</given-names></name><name><surname>Shirai</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>O</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Nishibuchi</surname><given-names>M</given-names></name></person-group><article-title>Evidence for insertion sequence-mediated spread of the thermostable direct hemolysin gene among <italic>Vibrio</italic> species</article-title><source>J Bacteriol</source><year>1991</year><volume>173</volume><fpage>5036</fpage><lpage>5046</lpage><pub-id pub-id-type="doi">10.1128/jb.173.16.5036-5046.1991</pub-id><pub-id pub-id-type="pmid">1650342</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishibuchi</surname><given-names>M</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>RG</given-names></name><name><surname>Kaper</surname><given-names>JB</given-names></name></person-group><article-title>Enterotoxigenicity of <italic>Vibrio parahaemolyticus</italic> with and without genes encoding thermostable direct hemolysin</article-title><source>Infect Immun</source><year>1992</year><volume>60</volume><fpage>3539</fpage><lpage>3545</lpage><?supplied-pmid 1500161?><pub-id pub-id-type="pmid">1500161</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishishita</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>N</given-names></name><name><surname>Kumagai</surname><given-names>K</given-names></name><name><surname>Yamasaki</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Nishibuchi</surname><given-names>M</given-names></name></person-group><article-title>Sequence variation in the thermostable direct hemolysin-related hemolysin (<italic>trh</italic>) gene of <italic>Vibrio parahaemolyticus</italic></article-title><source>Appl Environ Microbiol</source><year>1992</year><volume>58</volume><fpage>2449</fpage><lpage>2457</lpage><?supplied-pmid 1514791?><pub-id pub-id-type="pmid">1514791</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Suthienkul</surname><given-names>O</given-names></name><name><surname>Kozawa</surname><given-names>J</given-names></name><name><surname>Yamaichi</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name></person-group><article-title>Close proximity of the <italic>tdh</italic>, <italic>trh</italic>, and <italic>ure</italic> genes on the chromosome of <italic>Vibrio parahaemolyticus</italic></article-title><source>Microbiology</source><year>1998</year><volume>144</volume><fpage>2517</fpage><lpage>2523</lpage><pub-id pub-id-type="doi">10.1099/00221287-144-9-2517</pub-id><pub-id pub-id-type="pmid">9782499</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Koning-Ward</surname><given-names>TF</given-names></name><name><surname>Robins-Browne</surname><given-names>RM</given-names></name></person-group><article-title>Contribution of urease to acid tolerance in <italic>Yersinia enterocolitica</italic></article-title><source>Infect Immun</source><year>1995</year><volume>3</volume><fpage>3790</fpage><lpage>3795</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupski</surname><given-names>JR</given-names></name><name><surname>Roth</surname><given-names>JR</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name></person-group><article-title>Chromosomal duplications in bacteria, fruit flies, and humans</article-title><source>Am J Hum Genet</source><year>1996</year><volume>58</volume><fpage>21</fpage><lpage>27</lpage><?supplied-pmid 8554058?><pub-id pub-id-type="pmid">8554058</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calleros</surname><given-names>L</given-names></name><name><surname>Betancor</surname><given-names>L</given-names></name><name><surname>Iraola</surname><given-names>G</given-names></name><name><surname>M&#x000e9;ndez</surname><given-names>A</given-names></name><name><surname>Morsella</surname><given-names>C</given-names></name><name><surname>Paolicchi</surname><given-names>F</given-names></name><name><surname>Silveyra</surname><given-names>S</given-names></name><name><surname>Velilla</surname><given-names>A</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>R</given-names></name></person-group><article-title>Assessing the intra&#x02013;species genetic variability in the clonal pathogen <italic>Campylobacter fetus</italic>: CRISPRs are highly polymorphic DNA markers</article-title><source>J Microbiol Methods</source><year>2017</year><volume>132</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.mimet.2016.11.012</pub-id><pub-id pub-id-type="pmid">27867047</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>F</given-names></name><name><surname>Medeiros</surname><given-names>MI</given-names></name><name><surname>Rodrigues</surname><given-names>DD</given-names></name><name><surname>Allard</surname><given-names>MW</given-names></name><name><surname>Falcao</surname><given-names>JP</given-names></name></person-group><article-title>Molecular characterization of <italic>Salmonella typhimurium</italic> isolated in Brazil by CRISPR-MVLST</article-title><source>J Microbiol Methods</source><year>2017</year><volume>133</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.mimet.2016.12.020</pub-id><pub-id pub-id-type="pmid">28034696</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westra</surname><given-names>ER</given-names></name><name><surname>Buckling</surname><given-names>A</given-names></name><name><surname>Fineran</surname><given-names>PC</given-names></name></person-group><article-title>CRISPR-Cas systems: beyond adaptive immunity</article-title><source>Nat Rev Microbiol</source><year>2014</year><volume>12</volume><fpage>317</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3241</pub-id><pub-id pub-id-type="pmid">24704746</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name></person-group><article-title>Association of CRISPR/Cas evolution with <italic>Vibrio parahaemolyticus</italic> virulence factors and genotypes</article-title><source>Foodborne Pathog Dis.</source><year>2015</year><volume>12</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1089/fpd.2014.1792</pub-id><pub-id pub-id-type="pmid">25455966</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Okuda</surname><given-names>J</given-names></name><name><surname>Matsumoto</surname><given-names>C</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Nishibuchi</surname><given-names>M</given-names></name></person-group><article-title>Identification of <italic>Vibrio parahaemolyticus</italic> strains at the species level by PCR targeted to the <italic>toxR</italic> gene</article-title><source>J Clin Microbiol</source><year>1999</year><volume>37</volume><fpage>1173</fpage><lpage>1177</lpage><?supplied-pmid 10074546?><pub-id pub-id-type="pmid">10074546</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theron</surname><given-names>J</given-names></name><name><surname>Cilliers</surname><given-names>J</given-names></name></person-group><article-title>Du Preez M, Bro &#x000c8; zel1 VS, Venter1 SN. Detection of toxigenic <italic>Vibrio cholerae</italic> from environmental water samples by an enrichment broth cultivation-pit-stop semi-nested PCR procedure</article-title><source>J Appl Microbiol</source><year>2000</year><volume>89</volume><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2672.2000.01140.x</pub-id><pub-id pub-id-type="pmid">11021588</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tada</surname><given-names>J</given-names></name><name><surname>Ohashi</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>N</given-names></name><name><surname>Shirasaki</surname><given-names>Y</given-names></name><name><surname>Ozaki</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>S</given-names></name><name><surname>Takano</surname><given-names>J</given-names></name><name><surname>Nishibuchi</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name></person-group><article-title>Detection of thermostable direct hemolysin gene (<italic>tdh</italic>) and the thermostable direct hemolysin-related hemolysin gene (<italic>trh</italic>) of <italic>Vibrio parahaemolyticus</italic> by polymerase chain reaction</article-title><source>Mol Cell Probes</source><year>1992</year><volume>6</volume><fpage>477</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/0890-8508(92)90044-X</pub-id><pub-id pub-id-type="pmid">1480187</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weatherburn</surname><given-names>MW</given-names></name></person-group><article-title>Phenol-hypochlorite reaction for determination of ammonia</article-title><source>Anal Chem</source><year>1967</year><volume>39</volume><fpage>971</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1021/ac60252a045</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>OH</given-names></name><name><surname>Rosebrough</surname><given-names>NJ</given-names></name><name><surname>Farr</surname><given-names>AL</given-names></name><name><surname>Randall</surname><given-names>RJ</given-names></name></person-group><article-title>Protein measurement with the Folin phenol reagent</article-title><source>J Biol Chem</source><year>1951</year><volume>193</volume><fpage>265</fpage><lpage>275</lpage><?supplied-pmid 14907713?><pub-id pub-id-type="pmid">14907713</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>T</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Miwatani</surname><given-names>T</given-names></name></person-group><article-title>Purification and characterization of a hemolysin produced by a clinical isolate of Kanagawa phenomenon-negative <italic>Vibrio parahaemolyticus</italic> and related to the thermostable direct hemolysin</article-title><source>Infect Immun</source><year>1988</year><volume>56</volume><fpage>961</fpage><lpage>965</lpage><?supplied-pmid 3126151?><pub-id pub-id-type="pmid">3126151</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishibuchi</surname><given-names>M</given-names></name><name><surname>Kaper</surname><given-names>JB</given-names></name></person-group><article-title>Nucleotide sequence of the thermostable direct hemolysin gene of <italic>Vibrio parahaemolyticus</italic></article-title><source>J Bacteriol</source><year>1985</year><volume>162</volume><fpage>558</fpage><lpage>564</lpage><?supplied-pmid 3988703?><pub-id pub-id-type="pmid">3988703</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kongrueng</surname><given-names>J</given-names></name><name><surname>Mitraparp-Arthorn</surname><given-names>P</given-names></name><name><surname>Bangpanwimon</surname><given-names>K</given-names></name><name><surname>Robins</surname><given-names>W</given-names></name><name><surname>Vuddhakul</surname><given-names>V</given-names></name><name><surname>Mekalanos</surname><given-names>J</given-names></name></person-group><article-title>Isolation of <italic>Bdellovibrio</italic> and like organisms and potential to reduce acute hepatopancreatic necrosis disease caused by <italic>Vibrio parahaemolyticus</italic></article-title><source>Dis Aquat Org.</source><year>2017</year><volume>124</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.3354/dao03120</pub-id><pub-id pub-id-type="pmid">28492178</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grissa</surname><given-names>I</given-names></name><name><surname>Vergnaud</surname><given-names>G</given-names></name><name><surname>Pourcel</surname><given-names>C</given-names></name></person-group><article-title>The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats</article-title><source>BMC Bioinform</source><year>2007</year><volume>8</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-172</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>PR</given-names></name><name><surname>Gaston</surname><given-names>MA</given-names></name></person-group><article-title>Numerical index of the discriminatory ability of typing systems: an application of Simpson&#x02019;s index of diversity</article-title><source>J Clin Microbiol</source><year>1988</year><volume>26</volume><fpage>2465</fpage><lpage>2466</lpage><?supplied-pmid 3069867?><pub-id pub-id-type="pmid">3069867</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Probst</surname><given-names>P</given-names></name><name><surname>Hermann</surname><given-names>E</given-names></name><name><surname>zum B&#x000fc;schenfelde</surname><given-names>KM</given-names></name><name><surname>Fleischer</surname><given-names>B</given-names></name></person-group><article-title>Zum Buschenfelde KH, Fleischer B. Identification of the <italic>Yersinia enterocolitica</italic> urease subunit as a target antigen for human synovial T lymphocytes in reactive arthritis</article-title><source>Infect Immun</source><year>1993</year><volume>61</volume><fpage>4507</fpage><lpage>4509</lpage><?supplied-pmid 8406844?><pub-id pub-id-type="pmid">8406844</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriwanthana</surname><given-names>B</given-names></name><name><surname>Island</surname><given-names>MD</given-names></name><name><surname>Mobley</surname><given-names>HLT</given-names></name></person-group><article-title>Sequence of the <italic>Proteus mirabilis</italic> urease accessory gene <italic>ureG</italic></article-title><source>Gene</source><year>1993</year><volume>129</volume><fpage>103</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(93)90703-6</pub-id><pub-id pub-id-type="pmid">8335248</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voland</surname><given-names>P</given-names></name><name><surname>Weeks</surname><given-names>DL</given-names></name><name><surname>Marcus</surname><given-names>EA</given-names></name><name><surname>Prinz</surname><given-names>C</given-names></name><name><surname>Sachs</surname><given-names>G</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name></person-group><article-title>Interactions among the seven <italic>Helicobacter pylori</italic> proteins encoded by the urease gene cluster</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2003</year><volume>284</volume><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00160.2002</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suthienkul</surname><given-names>O</given-names></name><name><surname>Ihibashi</surname><given-names>M</given-names></name><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Nettip</surname><given-names>N</given-names></name><name><surname>Supavej</surname><given-names>S</given-names></name><name><surname>Eampokalap</surname><given-names>B</given-names></name><name><surname>Makino</surname><given-names>M</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name></person-group><article-title>Urease production correlates with possession of the <italic>trh</italic> gene in <italic>Vibrio parahaemolyticus</italic> strains isolated in Thailand</article-title><source>J Infect Dis</source><year>1995</year><volume>172</volume><fpage>1405</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1093/infdis/172.5.1405</pub-id><pub-id pub-id-type="pmid">7594689</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Yamaichi</surname><given-names>Y</given-names></name><name><surname>Oyagi</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name></person-group><article-title>Genetic characterization of DNA region containing the <italic>trh</italic> and <italic>ure</italic> genes of <italic>Vibrio parahaemolyticus</italic></article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>5742</fpage><lpage>5748</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.10.5742-5748.2000</pub-id><pub-id pub-id-type="pmid">10992480</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>J</given-names></name><name><surname>Nishibuch</surname><given-names>M</given-names></name></person-group><article-title>Manifestation of the Kanagawa phenomenon, the virulence-associated phenotype, of <italic>Vibrio parahaemolyticus</italic> depend on a particular single base change in the promoter of the thermostable direct hemolysin</article-title><source>Mol Microbiol</source><year>1998</year><volume>39</volume><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1998.01072.x</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Aziz</surname><given-names>SM</given-names></name><name><surname>Aeron</surname><given-names>A</given-names></name></person-group><article-title>Bacterial biofilm: dispersal and inhibition strategies</article-title><source>SAJ Biotechnol.</source><year>2014</year><volume>1</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yildiz</surname><given-names>FH</given-names></name><name><surname>Visic</surname><given-names>KV</given-names></name></person-group><article-title><italic>Vibrio</italic> biofilms: so much the same yet so different</article-title><source>Trends Microbiol</source><year>2009</year><volume>17</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2008.12.004</pub-id><pub-id pub-id-type="pmid">19231189</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wroblewska</surname><given-names>MM</given-names></name><name><surname>Sawicka-Grzelak</surname><given-names>A</given-names></name><name><surname>Marchel</surname><given-names>H</given-names></name><name><surname>Luczak</surname><given-names>M</given-names></name><name><surname>Sivan</surname><given-names>A</given-names></name></person-group><article-title>Biofilm production by clinical strains of <italic>Acinetobacter baumannii</italic> isolated from patients hospitalized in two tertiary care hospitals</article-title><source>FEMS Immunol Med Microbiol</source><year>2008</year><volume>53</volume><fpage>140</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2008.00403.x</pub-id><pub-id pub-id-type="pmid">18400015</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doijad</surname><given-names>SP</given-names></name><name><surname>Barbuddhe</surname><given-names>SB</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Poharkar</surname><given-names>KV</given-names></name><name><surname>Kalorey</surname><given-names>DR</given-names></name><name><surname>Kurkure</surname><given-names>NV</given-names></name><name><surname>Rawool</surname><given-names>DB</given-names></name><name><surname>Chakraborty</surname><given-names>T</given-names></name></person-group><article-title>Biofilm-forming abilities of <italic>Listeria monocytogenes</italic> serotypes isolated from different sources</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0137046</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0137046</pub-id><pub-id pub-id-type="pmid">26360831</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preeprem</surname><given-names>S</given-names></name><name><surname>Mittraparp-arthorn</surname><given-names>P</given-names></name><name><surname>Bhoopong</surname><given-names>P</given-names></name><name><surname>Vuddhakul</surname><given-names>V</given-names></name></person-group><article-title>Isolation and characterization of <italic>Vibrio cholerae</italic> isolates from seafood in Hat Yai City, Songkhla, Thailand</article-title><source>Foodborne Pathog Dis.</source><year>2014</year><volume>11</volume><fpage>881</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1089/fpd.2014.1772</pub-id><pub-id pub-id-type="pmid">25188839</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fricke</surname><given-names>W</given-names></name><name><surname>Mammel</surname><given-names>M</given-names></name><name><surname>McDermott</surname><given-names>P</given-names></name><name><surname>Tartera</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>D</given-names></name><name><surname>Leclerc</surname><given-names>J</given-names></name><name><surname>Ravel</surname><given-names>J</given-names></name><name><surname>Cebula</surname><given-names>T</given-names></name></person-group><article-title>Comparative genomics of 28 <italic>Salmonella enteric</italic> isolates: evidence for CRISPR-mediated adaptive sublineage evolution</article-title><source>J Bacteriol</source><year>2011</year><volume>193</volume><fpage>3556</fpage><lpage>3568</lpage><pub-id pub-id-type="doi">10.1128/JB.00297-11</pub-id><pub-id pub-id-type="pmid">21602358</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourcel</surname><given-names>C</given-names></name><name><surname>Salvignol</surname><given-names>G</given-names></name><name><surname>Vergnaud</surname><given-names>G</given-names></name></person-group><article-title>CRISPR elements in <italic>Yersinia pestis</italic> acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies</article-title><source>Microbiology</source><year>2005</year><volume>151</volume><fpage>653</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1099/mic.0.27437-0</pub-id><pub-id pub-id-type="pmid">15758212</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shariat</surname><given-names>N</given-names></name><name><surname>Dudley</surname><given-names>EG</given-names></name></person-group><article-title>CRISPRs: molecular signatures used for pathogen subtyping</article-title><source>Appl Environ Microbiol</source><year>2014</year><volume>80</volume><fpage>430</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1128/AEM.02790-13</pub-id><pub-id pub-id-type="pmid">24162568</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Kariyawasam</surname><given-names>S</given-names></name><name><surname>Jayarao</surname><given-names>BM</given-names></name><name><surname>Barrangou</surname><given-names>R</given-names></name><name><surname>GernerSmidt</surname><given-names>P</given-names></name><name><surname>Ribot</surname><given-names>EM</given-names></name><name><surname>Knabel</surname><given-names>SJ</given-names></name><name><surname>Dudley</surname><given-names>EG</given-names></name></person-group><article-title>Subtyping <italic>Salmonella enterica</italic> serovar enteritidis isolates from different sources by using sequence typing based on virulence genes and clustered regularly interspaced short palindromic repeats (CRISPRs)</article-title><source>Appl Environ Microbiol</source><year>2011</year><volume>7</volume><fpage>4520</fpage><lpage>4526</lpage><pub-id pub-id-type="doi">10.1128/AEM.00468-11</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooton</surname><given-names>SP</given-names></name><name><surname>Brathwaite</surname><given-names>KJ</given-names></name><name><surname>Connerton</surname><given-names>IF</given-names></name></person-group><article-title>The bacteriophage carrier state <italic>of Campylobacter jejuni</italic> features changes in host non-coding RNAs and the acquisition of new host-derived CRISPR spacer sequences</article-title><source>Front Microbiol</source><year>2016</year><volume>7</volume><fpage>355</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2016.00355</pub-id><pub-id pub-id-type="pmid">27047470</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooton</surname><given-names>SP</given-names></name><name><surname>Connerton</surname><given-names>IF</given-names></name></person-group><article-title><italic>Campylobacter jejuni</italic> acquire new host-derived CRISPR spacers when in association with bacteriophages harboring a CRISPR-like Cas4 protein</article-title><source>Front Microbiol</source><year>2014</year><volume>5</volume><fpage>744</fpage><?supplied-pmid 25601859?><pub-id pub-id-type="pmid">25601859</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>L</given-names></name><name><surname>Wurtzel</surname><given-names>O</given-names></name><name><surname>Amitai</surname><given-names>G</given-names></name><name><surname>Sorek</surname><given-names>R</given-names></name></person-group><article-title>Self-targeting by CRISPR: gene regulation or autoimmunity?</article-title><source>Trends Genet</source><year>2010</year><volume>26</volume><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2010.05.008</pub-id><pub-id pub-id-type="pmid">20598393</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shmakov</surname><given-names>S</given-names></name><name><surname>Smargon</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Pyzocha</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Wolf</surname><given-names>YI</given-names></name><name><surname>Severinov</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name></person-group><article-title>Diversity and evolution of class 2 CRISPR-Cas systems</article-title><source>Nat Rev Microbiol</source><year>2017</year><volume>15</volume><fpage>169</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.184</pub-id><pub-id pub-id-type="pmid">28111461</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangpanwimon</surname><given-names>K</given-names></name><name><surname>Sottisuporn</surname><given-names>J</given-names></name><name><surname>Mittraparp-arthorn</surname><given-names>P</given-names></name><name><surname>Ueaphatthanaphanich</surname><given-names>W</given-names></name><name><surname>Rattanasupar</surname><given-names>A</given-names></name><name><surname>Pourcel</surname><given-names>C</given-names></name><name><surname>Vuddhakul</surname><given-names>C</given-names></name></person-group><article-title>CRISPR-like sequences in <italic>Helicobacter pylori</italic> and application in genotyping</article-title><source>Gut Pathog.</source><year>2017</year><volume>9</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s13099-017-0215-8</pub-id><pub-id pub-id-type="pmid">29177012</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>KM</given-names></name><name><surname>Luey</surname><given-names>CKY</given-names></name><name><surname>Parsons</surname><given-names>MB</given-names></name><name><surname>Cooper</surname><given-names>KLF</given-names></name><name><surname>Nair</surname><given-names>GB</given-names></name><name><surname>Alam</surname><given-names>M</given-names></name><name><surname>Islam</surname><given-names>MA</given-names></name><name><surname>Cheung</surname><given-names>DTL</given-names></name><name><surname>Chu</surname><given-names>YW</given-names></name><name><surname>Ramamurthy</surname><given-names>T</given-names></name><name><surname>Pazhani</surname><given-names>GP</given-names></name><name><surname>Bhattacharya</surname><given-names>SK</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Terajima</surname><given-names>J</given-names></name><name><surname>Arakawa</surname><given-names>E</given-names></name><name><surname>Ratchtrachenchai</surname><given-names>OA</given-names></name><name><surname>Huttayananont</surname><given-names>S</given-names></name><name><surname>Ribot</surname><given-names>EM</given-names></name><name><surname>Gerner-Smidt</surname><given-names>P</given-names></name><name><surname>Swaminathan</surname><given-names>B</given-names></name></person-group><article-title>Evaluation and validation of a PulseNet standardized pulsed-field gel electrophoresis protocol for subtyping <italic>Vibrio parahaemolyticus</italic>: an international multicenter collaborative study</article-title><source>J Clin Microbiol</source><year>2008</year><volume>46</volume><fpage>2766</fpage><lpage>2773</lpage><pub-id pub-id-type="doi">10.1128/JCM.00424-08</pub-id><pub-id pub-id-type="pmid">18579720</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Urtaza</surname><given-names>J</given-names></name><name><surname>Lozano-Leon</surname><given-names>A</given-names></name><name><surname>DePaola</surname><given-names>A</given-names></name><name><surname>Ishibashi</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Nishibuchi</surname><given-names>M</given-names></name><name><surname>Liebana</surname><given-names>E</given-names></name></person-group><article-title>Characterization of pathogenic <italic>Vibrio parahaemolyticus</italic> isolates from clinical sources in Spain and comparison with Asian and North American pandemic isolates</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><fpage>4672</fpage><lpage>4678</lpage><pub-id pub-id-type="doi">10.1128/JCM.42.10.4672-4678.2004</pub-id><pub-id pub-id-type="pmid">15472326</pub-id></element-citation></ref></ref-list></back></article>